netFormulary
 Report : A-Z of formulary items 20/05/2024 01:34:07
[Back]
 
Section Name Details
06.04.01.01 Continuous combined HRT patch Evorel® Conti
13.05.02 5-Methoxypsoralen 20mg tablets 
13.05.02 8-Methoxypsoralen 10mg tablets 
05.03.01 Abacavir 
05.03.01 Abacavir & Lamivudine 
05.03.01 Abacavir & Lamivudine & Dolutegravir 
05.03.01 Abacavir & Lamivudine & Zidovudine 
10.01.03 Abatacept Orencia®
  • Abatacept 250mg injection is approved for:
    • Juvenile idiopathic arthritis in patients aged six years and above (licensed) and under six years. It should only be prescribed with informed consent.
    • People aged 6 years and older to treat polyarticular juvenile idiopathic arthritis (JIA) whose diease has responded inadequately to other DMARDs, including at least one tumour necrosis factor (TNF) inhibitor in accordance with NICE.
    • Rheumatoid arthritis after the failure of a TNF inhibitor in line with NICE.
    • Treatment in adults with severe rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed in accordance with NICE.
    • Treatment of severe treatment-resistant morphoea in line with NHS England Clinical Commissioning Policy
    • Treating modertae rheumatoid arthritis after conventional DMARDs have failed in line with NICE
    • Treating idiopathic inflammatory myopathies in adults and children aged 2 and over in line with NHS England Commissioning Policy
  • Abatacept 125mg SC injection (prefilled syringe) is approved for moderate to severe rheumatoid arthritis in accordance with NICE.
02.09 Abciximab 
08.03.04.01 Abemaciclib Verzenios®

  • 50mg, 100mg and 150mg tablets

  • Approved as an options for treating locally advanced or metastatic, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer as first endocrine-based therapy in adults in line with NICE

  • Approved with fulvestrant for treating hormone receptor-positive, HER2 negative advanced breast cancer after endocrine therapy in line with NICE 


 

09.06.07 Abidec® 
  • Drops containing in each 0.6ml dose ascorbic acid 50mg, ergocalciferol
    400 units, nicotinamide 5mg, pyridoxine HCL 500micrograms, riboflavin
    400 micrograms, thiamine 1mg & vitamin A 1,333 units.
    To be used in children and adults.
08.03.04.02 Abiraterone 
  • Approved for castration-resistant metastatic prostate cancer in line with NICE.
  • Approved for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in line with NICE and NHS England Commissioning Policy.
13.05.03 Abrocitinib Cibinqo®
  • Approved for the treatment of moderate to severe atopic dermatitis in line with NICE



14.04 Absorbed Diptheria Low Dose, Tetanus, and Poliomyelitis vaccine 
14.04 Absorbed Diptheria Low Dose, Tetanus, Pertussis and Poliomyelitis vaccine 
14.04 Absorbed Diptheria, Tetanus, Pertussis and Poliomyelitis vaccine 
08.01.05 Acalabrutinib Calquence®
  • 100mg capsules
  • Approved for treating chronic lymphocytic leukaemia in adults in line with NICE
04.10.01 Acamprosate 
  • COUNTY DURHAM Red acamprosate, chlordioazepoxide, disulfiram & nalmefene prescribing should be retained within the commissioned service within County Durham.
06.01.02.03 Acarbose 
02.08.02 Acenocoumarol Sinthrome®
  • 1mg tablets
04.08.01 Acetazolamide 
11.06 Acetazolamide 
  • second line carbonic anhydrase inhibitor for glaucoma
12.01.01 Acetic Acid 2% spray Earcalm ®
19 Acetic acid 5% 
  • T o be diluted to 2.5%
    - approved for the use in the detection of dysplasia/ neoplasia
    in Barrett’s oesophagus
11.08.02 Acetylcholine Chloride 
  • 20mg in 2ml injection.
03.07 Acetylcysteine 
  • 600mg effervescent tablets.
  • Green Green for licensed indications.
  • Green plus For use on specialist advice in the treatment of idiopathic pulmonary fibrosis.
  • For the prevention of x-ray contrast media induced renal damage Red Traffic Light.

 

16 Acetylcysteine 2gram in 10ml injection 

Paracetamol overdose


11.08.01 Acetylcysteine 5% eye drops and preservative free eye drops 
11.08.01 Acetylcysteine 5% with Hypromellose 0.35% Ilube

Eye drops: acetylcysteine 5%, hypromellose 0.35% (Ilube®)

05.03.02.01 Aciclovir 
  • Tablets: 200mg, 400mg, 800mg
  • Dispersible tablets: 200mg, 400mg, 800mg
  • Oral suspension (sugar-free available): 200mg/5ml, 400mg/5ml
11.03.03 Aciclovir  
  • 3% eye ointment 
11.03.03 Aciclovir 
  • 800mg Tablets
  • For the treatment of ophthalmic zoster.
13.10.03 Aciclovir 5% cream 
05.03.02.01 Aciclovir Injection 
  • Injection (for IV infusion): 250mg, 500mg
12.03.02 Aciclovir tablets and suspension 

see section 05.03.02

13.05.02 Acitretin Neotigason®
  • 10mg and 25mg capsules 
03.01.02 Aclidinium Eklira Genuair®

 

    • 322 microgram/dose (equivalent to aclidinium bromide 375 microgram/dose) inhalation powder (DPI)



 

03.01.04 Aclidinium & formoterol  Duaklir Genuair®

 

    • Aclidinium 340 microgram/dose & formoterol 12 microgram/dose (equivalent to aclidinium bromide 396 microgram/dose, formoterol fumarate dihydrate 11.8 microgram/dose) inhalation powder (DPI)



 

18.03.03 Acticoat® Flex 3 

Conformable antimicrobial barrier dressing consisting of polyester core between low adherent silver-coated high density polyethylene mesh.

  • Specialist initiation only 
18.03.03 Acticoat® Flex 7 

Conformable antimicrobial barrier dressing consisting of polyester core between low adherent silver-coated high density polyethylene mesh.

  • Specialist initiation only
18.10 Acti-glide® 
13.08.01 Actikerall® 
18.09.01 Actilymph® 
18.03.03 Actisorb Silver 220 

Knitted fabric of activated charcoal with one-way stretch, with silver residues, within spun-bound nylon sleeve

18.06.01 ActiV.A.C.® 
18.09.01 Activa® hosiery 
16 Activated charcoal Actidose Aqua Advance®, Carbomix®
  • Actidose Aqua Advance® – 50g in 240ml suspension
  • Carbomix® - 50g powder supplied in a bottle to which
    water is added to prepare a suspension
18.02.05 ActivHeal Foam 

Polyurethane Foam Film Dressing without Adhesive Border

18.02.06 ActivHeal® Alginate  

Calcium sodium alginate dressing

18.02.06 ActivHeal® Aquafiber 

Non-woven, calcium sodium alginate dressing

18.02.01 ActivHeal® Hydrogel 
  • 8g only
18.08.02 Actiwrap® Latex-free Bandage 

Polyamide and Cellulose Contour Bandage, BP 1988

 

01.05.03 Adalimumab 

  • Only approved for use in accordance with NICE guidance. 

10.01.03 Adalimumab 
  • Adalimumab is approved for:
    • The treatment of adults with severe rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed in accordance with NICE 
    • Rheumatoid arthritis after the failure of a TNF inhibitor in accordance with NICE.
    • Treatment of severe active ankylosing spondylitis in adults whose disease has responded inadequately to, or who cannot tolerate, non-steroidal anti-inflammatory drugs in accordance with NICE.
    • Psoriatic arthritis in accordance with NICE.
    • As a second-line anti-TNF therapy in children with juvenile idiopathic arthritis and uveitis.
    • Children and adults aged 2 years and older to treat polyarticular juvenile idiopathic arthritis (JIA) whose disease has responded inadequately to 1 or more DMARD in accordance with NICE.
    • Treating moderate rheumatoid arhritis after conventional DMARDs have failed in line with NICE

 

11.04.02 Adalimumab  
  • 40mg Injection
  • Approved for the treatment of children with Severe Refractory Uveitis in line with interim NHS England Clinical Commissioning Policy.
  • Approved for the treatment of non-infectious uveitis in line with NICE and NHS England Commissioning Policy (replaces interim policy for adalimumab for adults with severe refractory uveitis from 24th October 2017)
13.05.03 Adalimumab 
  • Approved for psoriasis in line with NICE.
  • Approved for the treatment of moderate to severe hidradenitis suppurativa in line with NICE and NHS England Commissioning Policy
  • Approved for the treatment of plaque psoriasis in children and young people in line with NICE 

Biosimilars are available – note that indications can differ between different products – prescribe by brand. Consult with individual trust pharmacy department for details of
preferred biosimilar brand.

13.06.01 Adapalene 0.1% gel and cream Differin®
13.06.01 Adapalene and benzoyl peroxide Epiduo® Gel
  • adapalene 0.1%/benzoyl peroxide 2.5% & adapelene 0.3%/benzoyl peroxide 2.5%
18.02.03 Adaptic® Touch 

Non-adherent soft silicone wound Contact Dressing

16 Adder Snakebite Antiserum 
05.03.03.01 Adefovir Dipivoxil Hepsera®
  • 10 mg tablets
02.03.02 Adenosine 
  • 6mg in 2ml injection
  • 25mg in 5ml injection unlicensedunlicensed
  • 30mg in 10ml injection for infusion - NHCT only
  • 130mg in 130ml IV infusion unlicensedunlicensed
24.01 Adenosine injection 1 mg/1 mL, 100 mL, 120 mL, 130 mL 
02.07.03 Adrenaline (epinephrine) 
  • 1 in 1,000 injections in 1ml syringes and 1ml & 10ml ampoules.
  • 1 in 10,000 injections in 1ml & 10ml ampoules & syringes.
03.04.03 Adrenaline / Epinephrine Emerade®
  • Approved for use in the emergency treatment of anaphylaxis for patients with a BMI of >40 or who have required more than one auto-injector previously to control symptoms. Specialist immunologist initiation only Green Traffic Light.
  • Approved for use by NUTH Community Dental Team in anaphylaxis boxes Red Traffic Light.
03.04.03 Adrenaline / Epinephrine Jext® & Jext Junior®
03.01.05 AeroChamber Plus® 
03.01.05 AeroChamber® Flow-Vu 
08.01.05 Afatinib  

  • Approved as a possible treatment for adults with locally advanced or metastatic non-small-cell lung cancer if their cancer tests positive for the epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation and they have not had an EGFR-TK inhibitor before NICE and additional NHS England criteria.

08.01.05 Aflibercept Zaltrap®
11.08.02 Aflibercept 4mg/0.1ml injection Eylea®
  • Approved for wet age related macular degeneration in line with NICE.
  • Approved for macular oedema – central retinal vein occlusion in line with NICE.
  • Approved for diabetic macular oedema in line with NICE.
  • Approved for treating visual impairment caused by macular oedema after branch retinal vein occlusion in line with NICE.
  • Approved as an option for treating visual impairment because of myopic choroidal neovascularisation in adults in line with NICE

 

09.08.01 Agalsidase Alfa  
09.08.01 Agalsidase Beta 
04.03.04 Agomelatine 
  • NETAG approved for the treatment of depression only following an adequate trial of at least three alternative antidepressant drugs at maximally tolerated doses (as described by NICE and as stated in the BNF).
  • Prescribing and monitoring should be initiated by specialist mental health physicians. After a minimum of 12 weeks, prescribing may be transferred to primary care. 
02.03.02 Ajmaline 
  • For use as a diagnostic test of Brugada syndrome.
05.05.01 Albendazole 
16 Alcohol (Ethanol) 
13.11.01 Alcohol hand rub gel 
13.11.01 Alcohol impregnated wipes 

Containing 70% isopropyl alcohol or methylated spirit (e.g. Clini-wipes®, Alcowipes®)

11.09 Alcon Optifree® Express System 
08.01.05 Alectinib Alecensa®
  • 150mg capsules
  • Approved as an option for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults in line with NICE 
08.02.03 Alemtuzumab 
  • Alemtuzumab 30mg in 1ml concentrate for IV infusion is approved for use in, lymphocytic leukaemia & prevention of graft vs. host disease in bone marrow transplant patients, and high-risk kidney and pancreas transplantation.
  • Alemtuzumab 12mg in 1.2ml concentrate for IV infusion is approved for treating adults with active relapsing– remitting multiple sclerosis in line with NICE and NHS England commissioning policy. 

 

06.06.02 Alendronic Acid 
  • Approved alendronic acid formulations include:
    • 10mg tablets (taken daily)
    • 70mg tablets (taken once weekly) – preferred
    • 70mg effervescent tablets (Binosto®) - for use only in patients with documented swallowing difficulties

  • Alendronic acid is approved for the primary prevention of osteoporosis in postmenopausal women in line with NICE
  • Approved for the secondary prevention of osteoporotic fragility fractures in postmenopausal women who are confirmed to have osteoporosis primary in line with NICE.
  • Approved for the treatment of osteoporosis in line with NICE
09.06.04 Alfacalcidol 
  • 250 nanogram & 1 microgram capsules
  • 2 microgram/ml sugar-free oral drops – one drop containing approx. 100 nanograms of alfacalcidol 
  • 1 microgram in 0.5ml & 2 micrograms in 1ml injections
04.07.02 Alfentanil 
  • Palliative care use Green plus 
  • 500micrograms in 1ml [ST&S], 1mg in 2ml, 5mg in 10ml & 5mg in 1ml injection ampouless - approved for initiation by specialists in palliative care Green plus 
  • All non-palliative care indications Red
15.01.04.03 Alfentanil 
  • 500micrograms in 1ml [ST&S], 1mg in 2ml, 5mg in 10ml & 5mg in 1ml injection ampouless - approved for initiation by specialists in palliative care
15.01.04.03 Alfentanil 
  • All non-palliative care indications
07.04.01 Alfuzosin 2.5mg tablets and 10mg XL tablets 
18.03.01 Algivon® 

Absorbent, non-adherent calcium alginate dressing impregnated with medical grade manuka honey

  • Specialist use only
09.08.01 Alglucosidase Alfa Myozyme®
03.04.01 Alimemazine 
  • Hospital only for the following indications
    • Enteral sedation in paediatric ITU setting
    • Use in patients where promethazine has failed

  • Existing patients can continue to be prescribed in primary care until a treatment review has taken place  
15.01.04.01 Alimemazine 
  • 30mg/5ml syrup.
    • see section 03.04.01 for other formulations.
02.12 Alirocumab 
  • Only approved for use in accordance with NICE guidance.
13.05.01 Alitretinoin Toctino®
  • Approved for adults with severe chronic hand eczema that have not responded to potent topical corticosteroids in line with NICE.
19 Alkaline Nasal Douche 
18.02.05 Allevyn® Adhesive  

Polyurethane Foam Film Dressing with Adhesive Border

 

18.02.03 Allevyn® Gentle 

Soft Polymer Wound Contact Dressing with Polyurethane Foam Film Backing

18.02.03 Allevyn® Gentle Border  

Silicone gel wound contact dressing, with polyurethane foam film backing

18.02.03 Allevyn® Gentle Border Lite 

Silicone gel wound contact dressing, with polyurethane foam film backing

  • Podiatry only
18.02.03 Allevyn® Life 

Soft silicone wound contact dressing, with central mesh screen, polyurethane foam film backing and adhesive border

10.01.04 Allopurinol 
  • An allopurinol 100mg in 5ml suspension (unlicensedunlicensed) is also approved for use. 
10.01.04 Allopurinol 
  • An allopurinol 100mg in 5ml suspension (unlicensedunlicensed) is also approved for use. 
06.01.02.03 Alogliptin  
08.03.04.01 Alpelisib Piqray®
  • 50mg, 150mg and 200mg tablets
  • Approved with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults in line with NICE
09.06.05 Alpha Tocopherol Vedrop®
  • 50mg in 1ml oral solution - approved for the treatrment of children with vitamin E deficiency due to fat malabsorption syndromes.
09.06.05 Alpha Tocopheryl Acetate 
  • 500mg in 5ml suspension
  • 134mg (200 unit) capsules
09.06.05 Alpha Tocopheryl Acetate Injection 

Injection: 100mg/2ml

07.04.05 Alprostadil Vitaros® & Muse®
  • Vitaros® 3mg/g cream
  • Muse® 500microgram, and 1mg.

Treatment with alprostadil cream (Vitaros®) is NOT approved for use in County Durham and Tees Valley

07.04.05 Alprostadil Caverject® & Viridal Duo®
  • Approved as the second choice intracavernosal injection option.
  • Caverject® 10 & 20 microgram injections (Caverject® dual chamber injections are easier to use and less expensive than the vials).
  • Viridal Duo® 10, 20 and 40 microg starter pack and dual chamber injection (approved for use whilst supply issues surrounding Caverject® are ongoing).
02.10.02 Alteplase 
  • 10mg, 20mg, and 50mg injections.
  • Also approved for stoke in accordance with NICE guidance. 
  • 2mg in 2ml injection - approved for unblocking intravenous lines, mainly in paediatric dialysis patients.

 

11.08.02.04 Alteplase intravitreal injection 
18.09.01 Altiform® Hosiery 
18.09.01 Altipress® 
13.12 Aluminimum Chloride  Driclor®, Anhydrol Forte®
  • Aluminium chloride hexahydrate 20% solution in an alcoholic basis
04.09.01 Amantadine 
  • For use on the advice of neurologists.
02.05.01 Ambrisentan 
  • Approved for pulmonary hypertension - in accordance with NHS England Commissioning policy. 
05.01.04 Amikacin 
  • Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
  • Approved for the treatment of non-tuberculous mycobacterial pulmonary diseases caused by Mycobacterium Avium Complex (MAC) that is refractory to current treatment options (adults and post pubescent children) in line with NHSE Specialised Commissioning Policy 
02.02.03 Amiloride Hydrochloride 
02.11 Aminocaproic acid 
  • Approved for the use in paediatric patients undergoing extracorporeal membrane oxygenation (ECMO).
03.01.03 Aminophylline Injection 
  • 250mg/10ml injection
  • COPD: intravenous aminophylline of limited benefit.
  • Injection used in hospital for acute asthma not responding to steroids and continuous inhaled bronchodilators.
  • Plasma levels need to be checked before administration if patient has previously taken theophylline/ aminophylline.
02.03.02 Amiodarone 
  • 100mg & 200mg tablets Amber
  • 50mg in 5ml suspension is also approved Amber unlicensedunlicensed
  • 150mg/3ml & 300mg/10ml injection Red Traffic Light

NHS England (June 2019) advises that prescribers should not initiate amiodarone in primary care for any new patient.

in exceptional circumstances, where there is a clinical need for amiodarone to be prescribed, this should be undertaken in a cooperation arrangement with a multi-disciplinary team and/or other healthcare professional. Amiodarone has an important place in the treatment of severe cardiac rhythm disorders where other treatments either cannot be used or have failed. It has potential major toxicity and its use requires monitoring both clinically and via laboratory testing. 

MHRA Drug Safety Update (Mar 2022): Amiodarone (Cordarone X): reminder of risks of treatment and need for patient monitoring and supervision

04.02.01 Amisulpride 
04.03.01 Amitriptyline 
04.07.03 Amitriptyline 
04.07.04.02 Amitriptyline 
06.01.05 Amitriptyline 
07.04.02 Amitriptyline  
  • 10mg, 25mg and 50mg tablets
  • 25mg in 5ml sugar-free oral solution is also approved for use.
  • Green plus Green plus for the treatment of nocturnal enuresis in children aged 6 years and above when organic pathology, including spina bifida and related disorders, have been excluded and no response has been achieved to all other non-drug and drug treatments, including antispasmodics and vasopressin-related products.Should only be prescribed by a healthcare professional with expertise in the management of persistent enuresis
02.06.02 Amlodipine 
  • Preferred calcium channel blocker for treating hypertension.
    • If a 10mg dose is not tolerated e.g. due to leg/ankle
      oedema, consider reducing dose before changing to an
      alternative such as lercanidipine.

05.01.01.03 Amoxicillin 
  • 250mg, 500mg & 1g injections Red
05.02.03 Amphotericin 
  • 50mg injection (Fungizone®)
  • 50mg liposomal injection (Ambisome®)
11.03.02 Amphotericin B Preservative-free 
  • 0.1% and 0.3% eye drops.
08.01.05 Amsacrine  
09.01.04 Anagrelide 
  • For the treatment of thrombocythemiaas a 2nd line agent in patients poorly/non-responsive tohydroxycarbamide therapy.
10.01.03 Anakinra Kineret®
  • Approved for:
    • Juvenile Idiopathic Arthritis (JIA) in line with NICE and NHS England Clinical Commissioning Policy: E03/P/d
    • Periodic Fevers and Autoinflammatory conditions in line with NHS England Clinical Commissioning Policy: 170062P
    • Adult‑onset Still’s disease and systemic juvenile idiopathic arthritis in people 8 months and older in line with NICE
    • Cryopyrin Associated Periodic Syndrome in line with NHSE Service Specification
    • The treatment of severe gout in patients who have not responded to other treatment and for patients with pseudogout who have failed to respond to conventional treatment or unable to tolerate conventional treatment.
    • Chronic Infantile Neurocutaneous Arthritis (CINCA) and Muckle-Wells Syndrome (unlicensedunlicensed indications).
    • Islet cell transplantation as part of a protocol including alemtuzumab and etanercept to improve outcomes (i.e. insulin dependance)
    • Haemophagocytic Lymphohistiocytosis (HLH) for adults and children in all ages

 

08.03.04.01 Anastrozole 
02.08.02 Andexanet alfa Ondexxya®

 

    • 200mg powder for solution for infusion

 

    • Approved for reversing anticoagulation from apixaban and rivaroxaban in adults with life-threatening or uncontrolled bleeding in line with NICE

 

18.08.08 AndoFlex® TLC  
  • Specialist use only
18.08.08 AndoFlex® UBZ 
  • Specialist use only
05.02.04 Anidulafungin 
01.01.02 Antacid with oxetacaine 
  • Used to relieve symptoms in patients who have had radiotherapy and may be of value in some patients with acute oesophagitis. Not for routine use as an antacid.
11.04.02 Antazoline 0.5% with Xylometazoline 0.05% Otrivine-Antistin®
13.08.01 Anthelios Sunscreen Lotion 
  •  ACBS
14.05.03 Anti-D (Rh0) Immunoglobulin Rhophylac®
  • Approved for the prevention of RhoD sensitisation in
    women in line NICE.
  • Approved for use by haematologists in appropriate patients with immune thrombo-cytopenia. The 1,500 and 5,000 unit vials (WinRho) are much more expensive than the other formulations and should only be used on advice from haematologists. It is the only formulation licensed for use in immune thrombocytopaenia.
14.05.03 Anti-D (Rh0) Immunoglobulin WinRho SDF®
  • Approved for the prevention of RhoD sensitisation in
    women in line NICE.
  • Approved for use by haematologists in appropriate patients with immune thrombo-cytopenia. The 1,500 and 5,000 unit vials (WinRho) are much more expensive than the other formulations and should only be used on advice from haematologists. It is the only formulation licensed for use in immune thrombocytopaenia.
02.11 Antithrombin III Kybernin®
08.02.02 Antithymocyte immunoglobulin (horse)  Thymoglobuline®
  • NETAG approved for aplastic anaemia in adults (unlicensedunlicensed).
08.02.02 Antithymocyte immunoglobulin (rabbit)  Thymoglobuline®
  • Used in the management of transplant rejection.
01.07.01 Anusol ® 
  • Cream and Suppositories
  • Self Care Self Care Medicine: Advise that a prescription for treatment of haemorrhoids should not routinely be offered in primary care as the condition is self-limiting and will clear up on its own without the need for treatment.
01.07.02 Anusol®HC 
  • Self Care Self Care Medicine: Advise CCGs that a prescription for treatment of haemorrhoids should not routinely be offered in primary care as the condition is self-limiting and will clear up on its own without the need for treatment.
  • Topical corticosteroids are suitable for occasional short-term use (no more than 7 days) after exclusion of infections
08.03.04.02 Apalutamide  Erleada®
  • 60mg tablets
  • Approved for treating hormone‑relapsed non‑metastatic prostate cancer that is at high risk of metastasising in adults in line with NICE
  • Approved for treating hormone-sensitive metastatic prostate cancer in adults in line with NICE, only if:
    • docetaxel is not suitable

 

02.08.02 Apixaban 
  • Only approved for use in accordance with NICE guidance. 
04.09.01 Apomorphine 
  • 5mg/1ml (20ml) solution for infusion for infusion pumps & 10mg/1ml (3ml) solution for injection cartridges (Dacepton®) - NEW PATIENTS
  • 30mg/3ml solution for injection (APO-go®) - Patients commenced on treatment prior to July 2022 can continue on APO-go® (including 50mg/10ml solution for infusion pre-filled syringes for infusion pumps)
  • Apomorphine 10mg lozenges are also approved (RVI) unlicensedUnlicensed
18.07.02 Appeel® Single Use Wipes 
  • Specialist use only 
11.08.02 Apraclonidine 
  • 0.5% and 1% ophthalmic solution.
10.01.03 Apremilast Otezla®
  • Approved for the treatment of psoriatic arthritis in line with NICE
13.05.03 Apremilast Otezla®
  • 10mg, 20mg & 30mg tablets
  • To be used in accordance with NICE guidance
04.06 Aprepitant 
  • For the prevention of chemotherapy induced nausea and vomiting (CINV) in high risk patients in accordance with North of England Cancer Network: CINV Guidelines in adult oncology and haematology patients
02.11 Aprotinin 
  • For limited use in cardiothoracic surgery.
A2.03.01 Aptamil 
18.03.03 Aquacel® Ag Extra 
18.02.04 Aquacel® Extra 

Soft sterile non-woven pad containing hydrocolloid fibres.

  • Provides greater tensile strength compared to aquacel 
18.02.04 Aquacel® Foam 

Soft non-woven pad containing hydrocolloid-fibres with foam layer, without adhesive border

18.02.04 Aquacel® Foam Border 

Soft non-woven pad containing hydrocolloid-fibres with foam layer, with adhesive border

18.02.04 Aquacel® Surgical cover dressing 
  • Not to be prescribed on FP10
13.02.01 AquaGel lubricating jelly 
  • Approved for the relief of dryness of the nose, lips and face when a patient is using oxygen via nasal prongs, CPAP masks etc
13.02.01 Aqueous Cream BP 
  • Due to the SLS content to be used as a soap substitute only.
01.06.03 Arachis Oil 
02.08.01 Argatroban 
  • For use on advice of haematologists in patients with heparin induced thrombocytopenia.
09.08.01 Arginine  
06.05.02 Argipressin 20units in 1ml injection 
04.02.01 Aripiprazole 

  • Approved for schizophrenia in people aged 15 to 17 years in line with NICE.

  • Approved for moderate to severe manic episodes in young people aged 13 and older with bipolar I disorder NICE.

  • Aripriprazole 10mg & 15mg orodispersible tablets are approved for doses over 5mg for those patients who have difficulty swallowing.

  • Aripiprazole 1mg in 1ml oral solution is only for doses of 5mg or less, or when titrating patients on doses of increments of less than 5mg, in patients who have difficulty swallowing tablets.

  • To be used in accordance with NICE criteria.

  • Note: Aripiprazole 7.5mg/ml IM Injection is approved for use in rapid tranquilisation in patients with acute psychosis. Red Traffic Light NTW use only.


 

04.02.02 Aripiprazole Abilify Maintena®
  • Green plus CNTW
  • Amber TEWV
  • NTAG approved for the treatment of schizophrenia as per its licensed indication and as outlined in the Guidance on the Use of Antipsychotic Long-acting Injections in the North of England.
08.01.05 Arsenic Trioxide  
  • NECDAG approved relapsed or refractory acute promyelocytic leukaemia (APL).
05.04.01 Artesunate 
  • Approved for severe malaria in in line WHO guidance.
15.02 Articaine Hydrochloride with Adrenaline 
  • Articaine 4% & adrenaline 1 in 100,000 injection
    • approved for mandibular procedures in patients in whom nerve blocks are contraindicated.

12.03.05 Artificial Saliva 
  • Use cheapest
  • Available products include
    • AS Saliva Orthana®
    • Biotene Oralbalance® gel
    • BioXtra® Glandosane® spray
    • Malic acid Salivix®
    • Oralieve® Moisturising Spray & Gel 
  • Patients should be advised of self-care measures and signposted to purchase over the counter remedies where appropriate.
11.08.01 Artificial Tears Minims 

Hydroxyethylcellulose Artifical Tears Minims 4.4mg per mL Minims Eye Drops

08.01.05 Asciminib Scemblix®
  • 20mg and 40mg tablets
  • Approved as an option for treating chronic-phase Philadelphia chromosome-positive chronic myeloid leukaemia without a T315I mutation after 2 or more tyrosine kinase inhibitors in adults, in line with NICE
09.06.03 Ascorbic Acid Vitamin C
  • 50mg, 100mg, 200mg & 500mg tabs
  • 500mg in 5ml injection unlicensedunlicensed
11.08.02.04 Ascorbic acid 10% Preservative-free eye drops 
09.08.01 Asfotase alfa Strensiq®
  • 40mg/ml & 100mg/ml solution for injection
  • Approved for the treatment of paediatric-onset and juvenile-onset hypophosphatasia in line with NICE and NHS England Commissioning Policy
18.03.03 Askina® Calgitrol 15g Paste 
  • Specialist use only
02.09 Aspirin 
  • 75mg dispersible tablets
  • Note: 75mg e/c tablets – no longer recommended for use.
04.07.01 Aspirin 
04.07.04.01 Aspirin 
07.01.04 Aspirin 
  • Dispersible tablets: 75mg
02.09 Aspirin 500mg in 5ml injection 
  • For specialist use in the endovascular treatment of cerebral
    aneurysms
10.02.01 Ataluren Translarna®
  • Approved as an option for treating Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene in people 2 years and over who can walk - in line with NICE HST22.
05.03.01 Atazanavir 
  • For limited use as part of triple therapy where other protease inhibitors are unsuitable
05.03.01 Atazanavir sulfate and cobicistat 

To be used in accordance with NHS England Clinical Commissioning Policy (SSC1614).

02.03.02 Atenolol 
02.04 Atenolol 
02.04 Atenolol Injection 
  • 5mg/10ml injection
08.01.05 Atezolizumab 
  • 840mg/14ml & 1200mg/20m concentrate for solution for infusion (IV)
  • 1875mg/15ml solution for injection (S/C)
  • Approved for treating locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults who have had chemotherapy (and targeted treatment if they have an EGFR- or ALK‑positive tumour).  
  • Approved in combination with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (HCC) in adults who have not had previous systemic treatment in line with NICE
  • Approved for the treatment of advanced non-small-cell lung cancer in line with NICE
  • Approved for untreated PD-L1-positive locally advanced or metastatic urothelial cancer in adults when cisplatin-containing chemotherapy is unsuitable in line with NICE
  • Approved for for adjuvant treatment of resected non-small-cell lung cancer in adults in line with NICE
  • Approved with carboplatin and etoposide is recommended as an option for untreated extensive-stage small-cell lung cancer in adults in line with NICE
  • Approved with nab‑paclitaxel for triple-negative, unresectable, PD‑L1‑positive, locally advanced or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease in line with NICE
  • Approved for untreated PD-L1-positive locally advanced or metastatic urothelial cancer in adults when cisplatin-containing chemotherapy is unsuitable in line with NICE
19 Atidarsagene autotemcel Libmeldy®
  • Atidarsagene autotemcel is recommended, within its marketing authorisation, as an option for treating metachromatic leukodystrophy with mutations in the arylsulphatase A (ARSA) gene:
    • for children who have late infantile or early juvenile types, with no clinical signs or symptoms
    • for children who have the early juvenile type, with early clinical signs or symptoms, and who can still walk independently and have no cognitive decline.
 
04.04 Atomoxetine 
  • 10mg, 18mg, 25mg, 40mg, 60mg, 80mg & 100mg capsules
  • 4mg/1ml oral solution - approved for patients with more complex needs e.g. younger patients and those with swallowing difficulties.

 

02.12 Atorvastatin 
  • 10mg, 20mg, 40mg & 80mg tablets
02.12 Atorvastatin Chewable 
  • 10mg and 20mg chewable tablets
  • Note: atorvastatin 10mg and 20mg chewable tablets should be used instead of simvastatin suspension where solid dosage forms cannot be used. 

 

07.01.03 Atosiban 
  • Approved formulations include:
    • 6.75mg in 0.9ml injection
    • 37.5mg in 5ml (7.5mg/ml) concentrate for IV infusion.

05.04.08 Atovaquone 
  • Approved for use in patients intolerant of co-trimoxazole
15.01.05 Atracurium 
  • 25mg in 2.5ml
  • 50mg in 5ml  
  • 250mg in 25ml injection
18.01.01 Atrauman  
01.02 Atropine  
  • 500microgram in 5ml mixture (unlicensedunlicensed).
15.01.03 Atropine 600microgram injection 
15.01.03 Atropine pre-filled syringes minijet®
  • 1mg in 5ml and 3mg in 30ml injections in prefilled syringes used in cardiac resuscitation.
16 Atropine sulphate 
11.05 Atropine Sulphate Single Use Minims® 
10.01.05 Autologous chondrocyte implantation 

Commissioning: NHS England 

Overview | Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee | Guidance | NICE

10.01.05 Avacopan Tavneos®
  • an option for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis in adults - in line with NICE TA825
09.08.01 Avalglucosidase alfa Nexviadyme®
  • 100mg powder for concentrate for solution for infusion
  • Approved for treating Pompe disease in line with NICE
09.01.04 Avatrombopag Doptelet®
  • Approved for the treatment of severe thrombocytopenia in people with chronic liver disease needing a planned invasive procedure in line with NICE
  • Approved for treating primary chronic immune thrombocytopenia in adults in line with NICE

 

13.02.01 Aveeno® Cream
08.02.03 Avelumab Bavencio®
  • Approved for  for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults in line with NICE
  • as an option for treating metastatic Merkel cell carcinoma in adults who have not had chemotherapy for metastatic disease in line with NICE
07.04.05 Aviptadil 25microgram/phentolamine 2mg solution for injection Invicorp®
  • 25microgram/phentolamine 2mg solution for injection. 
  • Approved as first choice intracavernosal injection option.

 

 

08.01.05 Axicabtagene ciloleucel 
  • 0.4 – 2 × 108 cells dispersion for infusion
08.01.05 Axitinib  Inlyta®
  • Approved as treatment for adults with advanced renal cell carcinoma when tyrosine kinase inhibitors or cytokines have not worked in line with NICE.

 

08.01.03 Azacitidine  
  • Approved for myelodysplastic syndromes, CLL and AML - in line with NICE guidance.
01.05.03 Azathioprine 
08.02.01 Azathioprine 
  • For Transplant indications Red unless from a Trust/speciality that hasn't formaly repatriated it's patients or for patients who require weekly scripts for MDS boxes Amber.            
  • An azathioprine 50mg in 5ml suspension (unlicensedunlicensed) is also available.
10.01.03 Azathioprine 
  • See section 8.2.1
13.06.01 Azelaic Acid  
  • 15% (Finacea®) and 20% (Skinoren®) gel 
12.02.01 Azelastine and fluticasone  Dymista®
12.02.01 Azelastine Hydrochloride 140microgram nasal spray Rhinolast®
11.03.01 Azithromycin Azyter®
05.01.05 Azithromycin Injection 
  • 500mg powder vial for infusion
05.01.05 Azithromycin Oral Preparations 
  • Tablets: 250mg, 500mg
  • Capsules: 250mg
  • Oral suspension: 200mg/5ml
05.01.02.03 Aztreonam 
  • Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
05.01.02.03 Aztreonam nebuliser solution Cayston®
  • To be used in accordance with NHS England Commissioning Policy   
10.02.02 Baclofen 
  • The following baclofen intrachecal injections (unlicensedunlicensed) are also approved; 36mg in 12ml, and 72mg in 12ml intrathecal injections.Red Traffic Light
19 Baclofen Intrathecal 
11.08.01 Balanced Salt Solution 
  • Sterile solution containing sodium chloride 0.64%, sodium acetate 0.39%, sodium citrate 0.17%, calcium chloride 0.048%, magnesium chloride 0.03%, potassium chloride 0.075% in 15ml bottles and 500ml bags.
  • For intra-ocular or topical irrigation during surgical procedures.
13.02.01 Balneum® Plus cream 
01.05.01 Balsalazide Sodium 

Alternatives

10.01.03 Baricitinib Olumiant®
  • Approved for the treatment of moderate to severe rheumatoid arthritis in adults in line with NICE.
  • Approved for use in monogenic interferonopathis in adults and children 2 years and over in line with NHS England Clinical Commissioning Policy.

 

13.05.03 Baricitinib Olumiant®
  • Approved for treating moderate to severe atopic dermatitis in adults in line with NICE.
17 Barium sulfate  E-Z-HD® 
17 Barium sulfate  Polibar® 
13.02.02 Barrier preparation Cavilon®Film
08.02.02 Basiliximab 
  • Approved for limited use in adult renal transplant patients with high risk of acute organ rejection.
  • Approved for severe graft versus host disease post haematopoietic stem cell transplantation.
  • Approved for induction therapy in renal transplantation in children and adolescents in with combinations that include ciclosporin in line with NICE.
11.09 Bausch & Lomb contact lens solution Boston®
11.09 Bausch & Lomb saline Salette®
08.02.04 BCG 81mg vial (connaught) 
14.04 BCG vaccine  

(BCG Vaccine, Dried/Tub/BCG) 1ml multidose vials containing freeze dried powder for preparing intradermal injections

03.02 Beclometasone Qvar®
  • QVAR® CFC-free MDI: 50mcg, 100mcg per puff
  • QVAR® breath-actuated MDI: 50mcg, 100mcg per puff

 

  • N.B. CFC-free beclometasone must be prescribed by brand name.
  • 50mcg QVAR is equivalent to 100mcg for a conventional beclometasone inhaler and 100mcg is equivalent to 250mcg conventional beclometasone. 

 

 

03.02.03 Beclometasone and formoterol Fostair®
  • Beclomethasone dipropionate 100 microgram/dose & formoterol 6 microgram/dose pressurised metered dose inhaler (pMDI)
  • Beclomethasone dipropionate 200 microgram/dose & formoterol 6 microgram/dose pressurised metered dose inhaler (pMDI)

 

03.02.03 Beclometasone and formoterol Fostair NEXThaler®
  • Beclomethasone 100 microgram/dose & formoterol 6 microgram/dose dry powder inhaler (DPI)
  • Beclomethasone 200 microgram/dose & formoterol 6 microgram/dose dry powder inhaler (DPI)

 

03.02.03 Beclometasone and formoterol Luforbec®
  • Beclomethasone dipropionate 100 microgram/dose & formoterol 6 microgram/dose pressurised metered dose inhaler (pMDI)
    • Additional treatment option


 

03.02 Beclometasone dipropionate Clenil Modulite®
  • 50 / 100 / 200 / 250 microgram/dose pressurised metered dose inhaler (pMDI) - Clenil Modulite®



 

12.02.01 Beclometasone Dipropionate 50 microgram nasal spray 
03.02.03 Beclometasone, formoterol & glycopyrronium Trimbow®
  • Beclometasone 87 microgram/dose, formoterol 5 microgram/dose & glycopyrronium 9 microgram/dose pressurised metered dose inhaler (pMDI)
  • Beclometasone 172 microgram/dose, formoterol 5 microgram/dose & glycopyrronium 9 microgram/dose pressurised metered dose inhaler (pMDI)

 

03.02.03 Beclomethasone, formoterol & glycopyrronium Trimbow NEXThaler®
  • Beclomethasone 88 microgram/dose, formoterol 5 microgram/dose & glycopyrronium 9 microgram/dose dry powder inhaler (DPI)

 

05.01.09 Bedaquiline 
  • To be used in accordance with NHS England Commissioning Policy 
03.04.02 Bee and Wasp Allergen Extracts Pharmalgen®
  • For use in adults and children by adult and paediatric immunologists only. Only approved for use in accordance with NICE guidance. 
10.01 Belimumab 

Approved for the treatment of active autoantibody-positive systemic lupus erythematosus in line with NICE.

10.01.03 Belimumab Benlysta®

  • Approved for treating active autoantibody-positive systemic lupus erythematosus in line with NICE

02.12 Bempedoic acid Nilemdo®
  • 180mg tablets
  • Approved for the treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia in adults in line with NICE and following the statin intensification pathway outlined in NEELI

 

02.12 Bempedoic acid with ezetimibe  Nustendi®
  • Bempedoic acid 180mg & ezetimibe 10mg tablets
  • Approved for the treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia in adults in line with NICE and following the statin intensification pathway outlined in NEELI

 

08.01.01 Bendamustine  
  • Approved for the first line treatment of CLL (Binet stage B or C) in, patients for whom fludarabine combination chemotherapy is not appropriate in line with NICE. 
  • NECDAG approved for use in combination with rituximab for patients with CLL not fit for FCR chemotherapy and not fit for alemtuzumab. 
  • Approved for Low Grade Non-Hodgkins Lymphoma in line with NICE - not recommended for (low grade) non-Hodgkin's lymphoma that is refractory to rituximab or a rituximab-containing regimen NICE.
02.02.01 Bendroflumethiazide 2.5mg tablets 
  • Current patients should continue on bendroflumethiazide
  • Bendroflumethiazide 5mg tablets are available but not recommended for general use.
04.02.01 Benperidol 
  • Approved for the control of deviant antisocial sexual behaviour
03.04.02 Benralizumab Fasenra®
  • 30mg/1ml solution for injection (pre-filled devices)
  • Approved for treating severe eosinophilic asthma in adults in line with NICE and NHS England Commissioning Policy.

 

10.01.04 Benzbromarone 

Tablets: 100mg

Special order product

13.06.01 Benzoyl Peroxide 5% Gel Acnecide®
13.06.01 Benzoyl Peroxide 5% with Clindamycin 1% Duac®
12.03.01 Benzydamine Mouthwash & Spray Difflam®
05.01.01.01 Benzylpenicillin 
11.03.01 Benzylpenicillin 0.3% Eye drops 
05.01.01.01 Benzylpenicillin Benzathine 
03.05.02 Beractant Survanta®
  • 25mg/ml suspension for intratracheal administration
02.11 Beriplex - P/N® 
  • Approved for reversing the effects of oral anticoagulants in patients with life or limb threatening bleeding in accordance with a regional protocol.
03.04.03 Berotralstat Orladeyo®

  • 150mg capsule

  • Approved for preventing recurrent attacks of hereditary angioedema in people 12 years and older in line with NICE

04.06 Betahistine Dihydrochloride 
09.08.01 Betaine 
07.01.04 Betamethasone 
  • Injection: 4mg/ml
12.03.01 Betamethasone 
  • Soluble tablets 500 micrograms
  • Used as mouth gargle
13.04.01 Betamethasone (as Dipropionate) 0.05% with Salicylic Acid 2% Diprosalic®
  • Scalp application
13.04 Betamethasone (as Dipropionate) 0.05% with Salicylic Acid 3% Diprosalic®
  • Ointment
13.04 Betamethasone (as Valerate) 0.025% Betnovate-RD®
  • Cream and ointment
13.04 Betamethasone (as Valerate) 0.1% 
  • Cream, ointment & scalp application
13.04 Betamethasone (as Valerate) 0.1% with Clioquinol 3% Betnovate C®
  • Cream and ointment
13.04 Betamethasone (as Valerate) 0.1% with Fucidic Acid 2% Fucibet®
13.04 Betamethasone (as valerate) medicated plasters Betesil®
  • 2.25mg medicated plasters

 

13.09 Betamethasone 0.05%, salicylic acid 2% Diprosalic ®
12.01.01 Betamethasone 0.1% Betnovate® Scalp Application
  • unlicensed unlicensed
13.09 Betamethasone 0.1% 
12.01.01 Betamethasone 0.1% ear/eye/nose drops 
  • First choice corticosteroid ear drops.
11.04.01 Betamethasone 0.1% eye drops 
12.02.01 Betamethasone 0.1% eye/ear/nose drops 
12.01.01 Betamethasone 0.1% with neomycin 0.5% ear drops Betnesol N®
  • Alternative choice compound antibacterial/corticosteroid ear drop.
11.04.01 Betamethasone 0.1% with Neomycin 0.5% eye drops 
06.03.02 Betamethasone 4mg in 1ml 
12.02.01 Betamethasone Sodium Phosphate 0.1% eye/ear/nose drops 
08.01.05 Bevacizumab Avastin®
11.08.02 Bevacizumab 1.25mg/0.5ml intravitreal injection 
  • NETAG approved for use in the management of macular oedema
    secondary to retinal vein occlusion. This is considered a more cost
    effective treatment option in RVO compared with ranibizumab.
  • NTAG approved for age related macular degeneration.

 

08.01.05 Bexarotene Targretin®
02.12 Bezafibrate 
18.02.03 Biatain® Silicone 

Silicone gel wound contact dressing, with polyurethane foam film backing

18.02.03 Biatain® Silicone Lite 

Silicone gel wound contact dressing, with polyurethane foam film backing

08.03.04.02 Bicalutamide 

Initiate with specialist advice.

11.06 Bimatoprost eye drops 
11.06 Bimatoprost with Timolol eye drops 
  • For use as a second/third-line agent in patients insufficiently responsive
    to monotherapy with a prostaglandin analogue or beta blocker
10.01.03 Bimekizumab  Bimzelx®
  • 160mg/1ml solution for injection - pre-filled pen and syringes
  • Approved for the treatment of active psoriatic arthritis in line with NICE
  • Approved fofr the treatment of axial spondyloartritis in line with NICE



13.05.03 Bimekizumab  Bimzelx®
  • 160mg/ml solution pre-filled pen/syringe
  • Approved for the treatment of moderate to severe plaque psoriasis in line with NICE

 

19 BioGaia® 
19 Biotin 5mg tablets 
06.01.01.02 Biphasic Insulin Aspart NovoMix® 30
  • Approved NovoMix® 30 formulations include:
    • 5x3ml cartridges (for use with Novopen® and Novopen® Penmate injection devices)
    • 5x3ml Flexpen® pens. 

06.01.01.02 Biphasic Insulin Lispro Humalog® Mix 25 amd Mix 50
  • Approved formulations of Humalog® Mix 25 and Mix 50 include:
    • 5x3ml cartridges
    • 5x3ml Kwikpen®
06.01.01.02 Biphasic Isophane Insulin Humulin® M3
  • Approved Humulin®M3 formulations include:
    • 10ml vials;
    • 5x3ml cartridges;
    • 5x3ml pens. 

01.06.02 Bisacodyl 
19 Bisacodyl 0.274% rectal soln 
12.02.03 Bismuth Subnitrate and Iodoform (B.I.P.P.)  1.25cm x 100cm & 2.5cm x 100cm impregnated gauze
13.10.05 Bismuth Subnitrate and Iodoform (B.I.P.P.) Paste 
  • For use in ENT surgery & epistaxis
    1.25cm x 100cm & 2.5cm x 100cm impregnated gauze
02.04 Bisoprolol 
  • 5mg & 10mg tablets.
  • 1.25mg, 2.5mg, 3.75mg & 7.5mg tablets - for use in the treatment of heart failure only. The 5mg and 10mg tablets should be used where possible - cheaper than other strengths.
02.08.01 Bivalirudin 
  • Approved for preventing thrombosis in patients undergoing percutaneous coronary artery interventions.
  • For use instead of abciximab in some low risk patients.
  • Approved in combination with aspirin and clopidogrel for the treatment of adults with ST segment elevation MI undergoing percutaneous coronary intervention, in accordance with NICE guidance. 
08.01.02 Bleomycin  
  • Also approved for use in intralesional sclerotherapy in the treatment of low-flow vascular lesions. unlicensedunlicensed indication
08.02 Blinatumomab Blincyto®
  • Approved for use in previously treated Philadelphia-chromosome-negative acute lymphosblastic leukaemia in line with NICE and NHS England Commissioning Policy.
  • Approved for the treatment of acute lymphoblastic leukaemia in remission with minimal residual disease activity in line with NICE
  • Only to be used in line with a current chemotherapy protocol from the North of England Cancer Alliance in line with the appropriate Network Site Specific Group’s clinical guidelines or chemotherapy algorithm

 

13.11.06 Bonney's Blue Paint 
  • For limited use in some operating theatres only.
12.02.03 Boric Acid & Povidone Iodine 
12.01.01 Boric acid (insufflation)  
08.01.05 Bortezomib  
  • Approved for:
    • Relapsed multiple myeloma in line with in line with NICE.
    • Combination with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma in line with NICE. 
    • Induction therapy for multiple myeloma in line with NICE.
    • Treatment of adults with mantle cell lymphoma that has not been treated before, if haemotopoietic stem cell transplantation is not suitable, in line with NICE.
02.05.01 Bosentan 
  • Approved for pulmonary hypertension - in accordance with NHS England Commissioning policy.
  • Approved for systemic sclerosis with ongoing digital ulcer disease (to reduce number of new digital ulcers) - in accordance with NHS England Commissioning policy.
08.01.05 Bosutinib Bosulif®
  • Approved as an option for the treatment of chronic, accelerated blast phase Philidephia chromosome positive chronic myeloid leukaemia in adults when they have previously had 1 or more tyrosine kinase inhibitor and imatinib, nilotinib and dasatanib are not appropriate in line with NICE.
01.10 Botulinum A toxin 
  • Approved for use in the repair of complex hernia
01.07.04 Botulinum toxin type A 
  • Approved for use by specialists as an alternative to surgery in patients failing other treatments. Also approved for use in paediatrics but there must be documented informed consent from patients/carers.
04.07.04.02 Botulinum Toxin Type A 
  • Only approved for use in accordance with NICE guidance. 
04.09.03 Botulinum Toxin Type A Botox®
  • Botox also approved for use in paediatric patients with severe bladder over- activity and neuropathic bladder who have not responded to other treatment.
  • Prescribe by brand name.

 

04.09.03 Botulinum Toxin Type A Vistabel®
  • Restricted to use in private patients receiving aesthetic treatment.
  • Prescribe by brand name.

 

04.09.03 Botulinum Toxin Type A Dysport®

  • Prescribe by brand name.

13.12 Botulinum toxin type A  
04.09.03 Botulinum Toxin Type A injection Xeomin ®
  •  50, 100 & 200 unit powder for solution for injection
    • Approved for the treatment of chronic sialorrhoea in line with NICE
    • Similar potency to Botox®, and may be less expensive (depending on price agreements/ contracts), but not licensed for the full range of indications.
    • Prescribe by brand name.



 

04.09.03 Botulinum Toxin Type B NeuroBloc®

  • Prescribe by brand name

14.04 Botulism antitoxin 

1 vial of Botulism antitoxin trivalent (equine) A B& E 5000 units injection

08.01.05 Brentuximab vedotin Adcetris®
  • 50mg powder for concentrate for solution for infusion
  • Approved for the treatment of relapsed or refractory systemic anaplastic large cell lymphoma in line with NICE and NHS England Commissioning Policy.
  • Approved for the treatment of CD30-positive Hodgkin lymphoma in patients:
    • if they have already had autologous stem cell transplant
    • if they have already had at least 2 previous therapies when autologous stem cell transplant or multi-agent chemotherapy are not suitable. CDF
  • Approved for the treatment of CD30-positive cutaneous T-cell lymphoma in line with NICE
  • Approved in combination with cyclophosphamide, doxorubicin and prednisone for untreated systmic anaplastic large cell lymphoma in adults in line with NICE

 

08.01.05 Brexucabtagene autoleucel Tecartus®
  • 0.4 – 2 × 108 cells dispersion for infusion
08.01.05 Brigatinib Alunbrig®
  • Approved for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults who have already had crizotinib in line with NICE.
  • Approved for treating ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor in line with NICE
13.06.01 Brimonidine Tartate 0.33% gel Mirvaso®
  • For specialist initiation for the treatment of severe rosacea. Following specialist review of effectiveness, primary care can continue supply.
11.06 Brimonidine Tartrate 0.2% eye drops 
11.06 Brinzolamide 
  • 1% eye drops.
11.06 Brinzolamide 1% with Timolol 0.5%  Azarga®
11.06 Brinzolamide 10mg/ml & brimonidine 2mg/ml Simbrinza®
  • Approved as a third line agent as an “add-on” in patients at the very end of medical management.
04.08.01 Brivaracetam 
  • Approved for use as adjunctive therapy in patients with severe/intractable partial onset seizures e.g. a sezuire frequency of 1 per week following failure of first-line adjunctive therapy. Response must be assessed within 3-6 months before transferring prescribing to primary or stopping treatment, as appropriate.
13.05.03 Brodalumab Kyntheum®
  • 210mg/1.5ml solution for injection in pre-filled syringes.
  • Approved for the treatment of moderate to severe plaque psoriasis in line with NICE 



 

11.08.02 Brolucizumab Beovu®
  • 19.8mg/0.165mL solution for injection (pre-filled syringes)
    • Approved for treating wet age-related macular degeneration in adults in line with NICE
04.09.01 Bromocriptine 
06.07.01 Bromocriptine 2.5mg tablets 
01.05.02 Budesonide 
  • Alternative
    • Budenofalk® (3mg capsules enclosing e/c pellets)
    • Entocort® (3mg capsules enclosing e/c m/r pellets)
    • For use on consultant gastroenterologist advice only
  • Oral Viscous Budesonide unlicensed unlicensed Red
    • For the treatment of eosinophilic oesophagitis.
    • 0.5mg or 1mg nebule is added to 13ml of syrup and this is then mixed and swallowed. 
  • Orodispersible tablet (Jorveza®) 
    • For the treatment of eosinophilic oesophagitis in adults in line with NICE Red
    • Approved for the maintenance of eosinophilic oesophagitis in line with NTAG Green plus 
  • 9mg MR tablet (Cortiment®) Red
    • For induction of remission in patients with mild to moderate active ulcerative colitis (UC) where 5-ASA treatment is not sufficient.
    • 8 week course to be provided by secondary care.
  •  4mg modified-release capsules (Kinpeygo®) Red 
    • Approved for treating primary IgA nephropathy in line with NICE
01.05.02 Budesonide 

  • 2mg foam enema

  • Equal first choice with hydrocortisone foam enema  

03.02 Budesonide 
  • 100 microgram/dose dry powder inhaler - Easyhaler® (DPI) 
  • 100 microgram/dose dry powder inhaler - Turbohaler® (DPI) 
  • 500 microgram/2ml & 1mg/2ml nebuliser liquid

 

03.02.03 Budesonide and formoterol DuoResp Spiromax®
  • Budesonide 160 microgram/dose & formoterol 4.5 microgram/dose (equivalent to budesonide 200 microgram/dose & formoterol fumarate dihydrate 6 microgram/dose) dry powder inhaler (DPI)
  • Budesonide 320 microgram/dose & formoterol 9 microgram/dose (equivalent to budesonide 400 microgram/dose & formoterol fumarate dihydrate 12 microgram/dose) dry powder inhaler (DPI)

 

03.02.03 Budesonide and formoterol Symbicort Turbohaler®
  • Budesonide 200 microgram/dose & formoterol 6 microgram/dose inhalation powder (DPI)
  • Budesonide 400 microgram/dose & formoterol 12 microgram/dose inhalation powder (DPI)

 

03.02.03 Budesonide and formoterol Fobumix®
  • Budesonide 80 microgram/dose & formoterol 4.5 microgram/dose (equivalent to budesonide 100 microgram/dose & formoterol fumarate dihydrate 6 microgram/dose) dry powder inhaler - Easyhaler (DPI)
  • Budesonide 160 microgram/dose & formoterol 4.5 microgram/dose (equivalent to budesonide 200 microgram/dose & formoterol fumarate dihydrate 6 microgram/dose) dry powder inhaler - Easyhaler (DPI) 
  • Budesonide 320 microgram/dose & formoterol 9 microgram/dose (equivalent to budesonide 400 microgram/dose & formoterol fumarate dihydrate 12 microgram/dose) dry powder inhaler - Easyhaler (DPI)

 

03.02.03 Budesonide, formoterol & glycopyrronium Trixeo Aerosphere®
  • Formoterol 5 microgram/dose, glycopyrronium 7.2 microgram/dose & budesonide 160 microgram/dose pressurised metered dose inhaler (pMDI)

 

05.03.03.02 Bulevirtide Hepcludex®
  • 2mg powder for solution for injection
  • Approved as an option for treating chronic hepatitis D in adults with compensated liver disease in line with NICE and NHSE Specialised Commissioning Policy only if:
    • there is evidence of significant fibrosis (METAVIR stage F2 or above or Ishak stage 3 or above) and
    • their hepatitis has not responded to peginterferon alfa‑2a (PEG‑IFN) or they cannot have interferon-based therapy
  • Only available from:
    • The Newcastle Upon Tyne Hospitals NHS Foundation trust
02.02.02 Bumetanide 
15.02 Bupivacaine Hydrochloride 
  • 0.25% & 0.5% injection 10ml
  • 0.25% & 0.5% + adrenaline 1 in 200,000 inj. 10ml
  • 0.5% in glucose 8% injection (Marcain Heavy)
  • 0.1% & 0.125% unlicensedunlicensed in sodium chloride 0.9% infusions
04.07.02 Buprenorphine 
  • 200microgram sublingual tablets
  • 300microgram in 1ml injection
  • Buprenorphine patches (Preferred brand - Butec®) are approved for use in palliative care when fentanyl 12 microgram/hr transdermal patches exceed the patient’s analgesic requirements.
04.10.03 Buprenorphine Buvidal®
  • 8mg/0.16ml 16mg/0.32ml, 24mg/0.48ml, 32mg/0.64ml, 64mg/0.18ml, 96mg/0.27ml, 128mg/0.36ml 160mg/0.45ml prolonged-release solution for injection (pre-filled syringes).
    • Approved for the treatment of opioid dependance  in adults and adolescents aged 16 years and over, by substance misuse service providers, in line with NTAG and RMOC guidance.


 

04.10.03 Buprenorphine 400 microgram, 2mg, and 4mg sublingual tablets 

  • Only approved for use in accordance with NICE guidance. 

  • In the treatment of substance misuse the 400microgram strength should be prescribed as Subutex® to avoid a product licensed for pain relief being supplied

04.10.03 Buprenorphine and Naloxone Suboxone®
04.10.02 Bupropion Hydrochloride 
  • RAG status as per local commissioning arrangements
  • MHRA Drug Safety Update (Nov 2020): Bupropion (Zyban): risk of serotonin syndrome with use with other serotonergic drugs
  • Resistant depression Red
06.06.02 Burosumab  Crysvita®

  • 10mg, 20mg & 30mg solution for injection

  • Approved for treating X-linked hypophosphataemia in children and young people in accordance with NICE

08.03.04.02 Buserelin 
  • Approved formulations include:
    • 5mg in 5ml injection;
    • 150 microgram metered dose nasal spray.

06.04.04 Buserelin 150microgram Nasal Spray Suprecur®
  • 150 micrograms per spray; 268 dose spray
06.07.02 Buserelin 150microgram nasal spray 
04.01.02 Buspirone Hydrochloride 
08.01.01 Busulfan 
  • Approved formulations include:
    • 2mg tablets;
    • 25mg capsules (unlicensedunlicensed);
    • 60mg in 10ml injection.

03.04.03 C1 Esterase Inhibitor 

  • Approvded for the treatment and pre-procedure prevention of angioedema attacks in patients with hereditary angioedema (HAE).

  • Approvded for the routine prevention of angioedema attacks in adults and adolescents years old with severe and recurrent attacks of HAE.


 


 

08.01.05 Cabazitaxel  
  • Approved for the treatment of hormone relapsed metastatic prostate cancer treated with with docetaxel in line with NICE.
04.09.01 Cabergoline 
06.07.01 Cabergoline 500microgram and 1mg tablets 
05.03.01 Cabotegravir Vocabria®

  • 30mg tablet

  • 600mg/3ml prolonged-release suspension for injection

  • Approved in combination with rilpivirine (Rekambys) for treating HIV-1 in adults in line with NICE

08.01.05 Cabozantinib Cometriq®
  • Approved for use in the treatment of renal cell carcinoma in line with NICE and NHS England Commissioning Policy
  • Approved for the treatment of medullary thyroid cancer in line with NICE and NHS England Commissioning Policy
  • Approved for use in untreated advanced renal cell carcinoma in line with NICE and NHS England Commissioning Policy
03.05.01 Caffeine Citrate 
  • 50mg in 5ml injection (equivalent to 25mg caffeine base in 5ml).
  • 50mg in 5ml oral solution.
13.05.02 Calcipotriol 50mcg/g  Dovonex®
  • 0.005% Cream and ointment
  • 0.005% scalp application

13.09 Calcipotriol 50micrograms in 1ml 
13.05.02 Calcipotriol with Betamethasone  
  • Calcipotriol 50mcg/1g and betamethasone (as betamethasone dipropionate) 500mcg/1g
    • Gel and ointment (Dovobet®)
      • approved for the treatment of scalp and mild to moderate non scalp plaque psoriasis vulgaris in adults.
    • 60g cutaneous spray (Enstilar®)
      • Approved for the treatment of plaque psoriasis
    • Cream (Wynzora®)
09.05.01.02 Calcitonin Salmon®
  • 400 units in 2ml injection
06.06.01 Calcitonin 400units in 2ml  
09.06.04 Calcitriol  

Capsules: 0.25 micrograms, 0.5 micrograms

16 Calcium chloride 
09.05.02.02 Calcium Acetate Phosex®, Renacet®
  • Phosex® 1g tablets (containing 250mg, 6.2mmol of calcium) 
  • Renacet® 475mg (containing 120.25mg, 3mmol of calcium) &
    950mg tablets (containing 240.5mg, 6mmol of calcium)
09.06.04 Calcium and Ergocalciferol Tablets 
  • Calcium lactate 300mg, calcium phosphate 150mg (Ca 97mg, 2.4 mmol) & ergocalciferol 10 micrograms (400 units).
09.05.01.01 Calcium Carbonate 
  • 1.25g chewable tablets (500mg, 12.6 mmol calcium).
  • 2.5g chewable tablets (1g, 25 mmol calcium).
  • 500mg in 5ml suspension unlicensedunlicensed.
09.05.02.02 Calcium Carbonate 
  • 1.25g & 2.5g chewable tablets (Calcichew)
    (Other formulations e.g. Remegel, Rennies, Rennie Soft gel and Settler’s.
    Tums are also stocked at the RVI for use in paediatric renal patients)
09.06.04 Calcium Carbonate and Colecalciferol 
  • Accrete®
    • Film coated tablet containing calcium carbonate 1.5g and colecalciferol 10 micrograms (400 units)
  • Adcal D3®
    • Chewable tablet containing calcium carbonate 1.5g and colecalciferol 400 units (contains soya and sucrose)
    • Effervescent tablet containing calcium carbonate 1.5g and colecalciferol 400 units
  • Cacit D3®
    • Effervescent granule sachet containing calcium carbonate 1.25g and colecalciferol 440 units
  • Calcichew D3 Forte®
    • Chewable table containing calcium carbonate 1.25g and colecalciferol 400 units
  • Evacal®
    • Chewable tablet containing calcium carbonate 1.5g and colecalciferol 400 units
      • approved as chewable option and also to be used in patients with peanut and soya allergy 
09.05.01.01 Calcium Chloride 
  • Injection:10% equivalent to calcium 6.8 mmol/10 mL
08.01 Calcium Folinate 
  • Approved for methotrexate-induced mucositis and myelosuppression. The following formulations are approved:
    • 15mg tablets.
    • 3mg, 15mg, 30mg, and 300mg injections
    • A calcium folinate 1mg per ml mouthwash can be prepared if needed.unlicensedunlicensed

16 Calcium folinate (Folinic Acid) 
09.05.01.01 Calcium Gluconate 
  • Injection: 10%, equivalent to calcium 2.25 mmol/10 mL
16 Calcium gluconate  
16 Calcium gluconate gel 
09.08.01 Calcium Levomefolate Prefolic
09.02.01.01 Calcium Resonium® 
  • Powder (Calcium polystyrene sulphonate)
13.02.01 Calmurid® emollient 
A2.04.01.02 Calogen®  
09.05.01.01 Calvive 1000® 
  • Calvive 1000 tablets [2263 mg of calcium lactate gluconate and 1750 mg of calcium carbonate (equivalent to 1000 mg or 25 mmol of calcium)]
06.01.02.03 Canagliflozin 
  • Only approved for use in accordance with NICE guidance. 
02.05.05.02 Candesartan 
02.09 Cangrelor Kengrexal®
  • 50mg powder for concentrate for solution for injection/infusion
    • Approved for bridging therapy in patients who have recently had a coronary stent but require urgent elective surgery


04.06 Cannabidiol  Epidyolex®

  • 100mg/1mL oral solution

    • Approved for use in combination with clobazam for treating seizuires associated with Dravet syndrome in people aged 2 years and older

    • Approved for use in combination with clobazam for treating seizures associated with Lennox-Gastaut syndrome



04.08.01 Cannabidiol Epidyolex®
  • 100mg/1mL oral solution
    • Approved for use in combination with clobazam for treating seizuires associated with Dravet syndrome in people aged 2 years and older
    • Approved for use in combination with clobazam for treating seizures associated with Lennox-Gastaut syndrome
    • Approved as an add-on treatment option for seizures caused by tuberous sclerosis complex in people aged 2 years and over - in line with NICE TA873.
10.02.02 Cannabis extract Sativex®
  • cannabidiol 2.5mg/dronabinol 2.7mg per dose oromucosal spray
  • approved to treat moderate to severe spasticity in adults with multiple sclerosis in line with NICE Amber
13.09 Capasal® 
08.01.03 Capecitabine  
  • Only approved for use in accordance with NICE guidance.
  • Approved in combination with gemcitabine following surgery for pancreatic cancer in line with NHS England Clinical Commissioning Policy
12.03.01 Caphosol® 
  • For limited use in patients having chemo-radiotherapy or radiotherapy to malignancies of the oral cavity, hypopharynx and oro-pharynx.
  • Trusts encouraged to prescribe enough between chemotherapy and radiotherapy appointments in secondary care in anticipation of mucositis developing.
09.01.04 Caplacizumab Cablivi ®

  • 10mg solution for injection

    • Approved with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura in adults, and in young people aged 12 years and over who weigh at least 40 kg in line with NICE



05.01.09 Capreomycin 
  • 1g injection

 

  • Infectious diseases, microbiology or respiratory advice only Only in patients with MDR-TB intolerant of other medication
04.07.03 Capsaicin 

  • Qutenza® cutaneous patch approved for the treatment of neuropathic pain as fourth line agent for neuropathic pain and in line with the attached regionally agreed pathway. Red

  • 0.075% cream (Axsain®) approved for post hepatic neuralgia and peripheral diabetic neuropathy Green plus

10.03.02 Capsaicin 
  • 0.025% cream
    • approved for use as an adjunct to core treatment for knee and hand osteoarthritis as per NICE


02.05.05.01 Captopril  
  • Treatment should only be on the advice of a hospital paediatrician.
  • 5mg in 5ml suspension are also approved for use.
  • 2mg capsules are also approved for use unlicensedunlicensed.
04.02.03 Carbamazepine 
04.07.03 Carbamazepine 
  • Restricted use in treatment of trigeminal neuralgia only.
04.08.01 Carbamazepine 
  • Carbamazepine 200mg and 400mg MR tablets (Tegretol® retard) are available on consultant request for those in whom conventional carbamazepine has been shown to be unsuitable Green Traffic Light
04.08.01 Carbamazepine Suppositories 
17 Carbex® granules   
06.02.02 Carbimazole 
03.07 Carbocisteine 
  • 375mg capsules.
  • 750mg/10ml oral solution in sachets: first choice liquid preparation for adult patients.
  • 250mg in 5ml syrup.
11.08.01 Carbomer 980 eye drops 
  • Viscotears® eye drops
  • GelTears® single unit dose eye drops
08.01.05 Carboplatin  
07.01.01 Carboprost 250microgram in 1ml  
08.01.05 Carfilzomib Kyprolis®
  • Approved for use in previously treated multiple myeloma in line with NICE and NHSE Commissioning Policy
  • Approved in combination with dexamethasone and lenalidomide for previously treated multiple myeloma in line with NICE

 

09.08.01 Carglumic Acid Carbaglu®
11.08.01 Carmellose sodium  
  • 0.5% and 1% eye drops.
08.01.01 Carmustine 
  • Approved formualtions include 100mg injection and 7.7mg implants.
  • Approved for newly diagnosed glioblastoma multiforme (GBM) in line with NICE.
09.08.01 Carnitine  
  • 30% oral solution
  • 1g in 5ml injection
12.04 Carnoy’s solution 
  • Unlicensed Drug Unlicensed
  • 10ml bottle
A2.05.02 Carobel, Instant®  
02.04 Carvedilol 
  • For use in the treatment of heart failure only.
05.02.04 Caspofungin 
07.05 Catheter Care Products 
07.04.04 Catheter Patency Solutions 
  • Chlorhexidine 0.02% (1 in 5,000) solution in 100ml sachets.
07.04.04 Catheter Patency Solutions 
  • Sodium chloride 0.9% solution in 100ml sachets.
07.04.04 Catheter Patency Solutions Urotainer Twin Suby G®
  • Solution G 2 x 30ml sachets (citric acid 3.23%, magnesium oxide 0.38%,
    sodium bicarbonate 0.7%, disodium edetate 0.01%)
07.04.04 Catheter Patency Solutions Urotainer Twin Solution R®
  • Solution R 2 x 30ml sachets (citric acid 6%, gluconolactone 0.6%, magnesium carbonate 2.8%, disodium edetate 0.01%)
05.01.02.01 Cefalexin 
05.01.02.01 Cefazolin 

  • 1g and 2g vials

    • Approved as an alternative to flucloxacillin in patients with non-immediate penicillin allergy or in those who cannot tolerate flucloxacillin or alternatives

    • To be used on the advice of microbiology and ID physicians only.



05.01.02.01 Cefiderocol Fetcroja®

  • 1g powder for concentrate for solution for infusion

    • approved for the treatment of infections with gram negative aerobic bacteria in patients with limited treatment options. Only to be used on the advice of mricbiology and ID physicians



05.01.02.01 Cefixime 
  • Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
  • 200mg tablets
  • 100mg in 5ml paediatric suspension: also approved for the prevention of irinotecan induced diarrhoea, specialist use only Red Traffic Light.
05.01.02.01 Cefotaxime 
  • Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
05.01.02.01 Ceftaroline 
  • Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
05.01.02.01 Ceftazadime / avibactam Zavicefta ®
  • 2.5g injection
  • Approved for use only on the advice of Microbiology/Infectious Diseases for the treatment of infections with carbapenemase-producing organisms for which treatment options are very limited, toxic and not particularly effective.
05.01.02.01 Ceftazidime 
05.01.02.01 Ceftobiprole 
  • Approved for the treatment of hospital acquired pneumonia and other infections on the advice of microbiology/infectious disease physicans.
05.01.02.01 Ceftolozane & tazobactam 
  • Approved for use in multiple antibiotic resistant strains of enterobacteriaceae, pseudomonas and acinetobacters on the advice of microbiology/infectious disease physicians.
05.01.02.01 Ceftriaxone 
  • Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines. Red Traffic Light
  • Approved for use in primary care (i.e. care homes) to treat patients with conditions such as UTIs and pneumonia, at risk of sepsis in line with local guidance and microbiology input Green Traffic Light
05.01.02.01 Cefuroxime 
11.03.01 Cefuroxime 5% eye drops 
10.01.01 Celecoxib 
  • Capsules: 100mg, 200mg
02.04 Celiprolol Hydrochloride 
  • For specialist use in the treatment of patients who cannot tolerate other beta-blockers. Treatment should only be intiated on the advice of a cardiologist. 
08.01.05 Cemiplimab Libtayo®
  • Approved for treating metastatic or locally advanced cutaneous squamous cell carcinoma in adults in line with NICE
04.08.01 Cenobamate Ontozry®

  • 12.5mg, 25mg, 50mg, 100mg, 150mg and 200mg tablets

  • Approved for treating focal onset seizure in epilepsy in line with NICE

    • Patients will be stabilised by the epilepsy specialist prior to transfer to the GP for continuation. This will usually be after 3 months of treatment.



08.01.05 Ceritinib  
  • Approved for use in previously treated anaplastic lymphoma kinase positive non-small-cell-lung cancer in line with NICE and NHS England Commissioning Policy.
  • Approved for untreated ALK-positive non-small-cell lung cancer in line with NICE and NHS England Commissioning Policy
10.01.03 Certolizumab Pegol Cimzia®
  • Approved for:
    • Adults with severe rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed in accordance with NICE.
    • Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor in accordance with NICE.
    • Severe active ankylosing spondylitis in adults whose disease has responded inadequately to, or who cannot tolerate, non-steroidal anti-inflammatory drugs in accordance with NICE.
    • Psoriatic arthritis in accordance with NICE.

13.05.03 Certolizumab pegol  
03.04.01 Cetirizine 
13.02.01 Cetraben® 
06.07.02 Cetrorelix 
08.01.05 Cetuximab  
  • Approved for the first-line treatment of metastatic colorectal cancer in combination with FOLFOX in line with NICE (monotherapy or combination chemotherapy is not recommended for the treatment of people with metastatic colorectal cancer that has progressed after first-line chemotherapy -  as per NICE). 
  • NECDAG approved for K-RAS wild type metastatic colorectal cancer; second line use in combination with chemotherapy in patients that have progressed on previous chemotherapy; third line use as a single agent in patients who have failed oxaliplatin- and irinotecan based therapy and who are intolerant to irinotecan. 
  • Approved for locally advanced squamous cell carcinoma of the head and neck in line with NICE. 
  • Approved for previously untreated metastatic colorectal cancer in line with NICE.
  • Approved for the treatment of metastatic and/or recurrent squamous cell carcinoma of the head and neck (oral cavity only) in line with NICE and NHS England Commissioning Policy
  • Note: cetuximab is not approved in combination with platinum-based chemotherapy for recurrent and/or metastatic squamous cell cancer of the head and neck as per NICE.
09.08.01 Chenodexoycholic acid Xenbilox®
  • 250mg capsules
  • Approved for the treatment of inborn errors of bile acid synthesis (all ages) in line with NHS England Commissioning Policy
  • Approved for the treatment of Cerebrotendinous Xanthomatosis in line with NHS Commissioning Policy. NHS England will commission this drug for patients who are currently being treated (April 2017)
04.01.01 Chloral Hydrate 
04.01.01 Chloral Hydrate 500mg in 5ml mixture 
08.01.01 Chlorambucil  
05.01.07 Chloramphenicol 
  • Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
12.01.01 Chloramphenicol 
11.03.01 Chloramphenicol 0.5% eye drops & ointment 
  • Preservative-free eye drops are also approved for use:
    • 0.5% preservative-free Minims® - first choice.
    • 0.5% preservative-free eye drops unlicensedunlicensed - approved only for patients who are unable to use Minims®due to dexterity problems

12.01.01 Chloramphenicol 5% and 10% ear drops 
04.01.02 Chlordiazepoxide 
04.10.01 Chlordiazepoxide 
  • COUNTY DURHAM Red acamprosate, chlordioazepoxide, disulfiram & nalmefene prescribing should be retained within the commissioned service within County Durham.
11.03.02 Chlorhexidine 
12.03.04 Chlorhexidine  
  • 0.2% mouthwash.
  • 0.2% mint flavoured spray.
  • 1% dental gel.
  • Dental products should only be prescribed by dentists and GPs should not accept requests to prescribe medicines that the dentist could reasonably prescribe themselves, nor accept requests from patients to issue FP10 prescriptions for items prescribed on a private prescription by their dentist.
  • 2% oral gel unlicensedunlicensed Red
    • For hospital use in the prevention of ventilator-associated pneumonia in adult patients who are ventilated (for >48 hours).
13.11.02 Chlorhexidine 0.015% with Cetrimide 0.15% 
13.11.02 Chlorhexidine Gluconate 
  • 0.05% solutions, 25ml & 100ml sachets 
  • 0.5% solution in 70% methylated spirit (pink, colourless & red staining)
  • 2.5% in 70% methylated spirit wipes
  • 0.5% hand rub (contains 70% isopropyl alcohol + emollients)
  • 4% surgical scrub
  • 2% in 70% isopropyl alcohol wipes (Clinell®)
  • Skin swabs & skin cleanser
  • 3ml & 10.5ml applicators (Chloraprep®)
  • 1% Obstetric cream
12.02.03 Chlorhexidine Hydrochloride 0.1%, Neomycin Suphate 0.5% Naseptin®
19 Chlorhexidine impregnated sponge Biopatch®
08.01.05 Chlormethine Gel 

160 micrograms/g gel

Approved for use in accordance with the following NICE TAs or if the indication is funded from the Cancer Drugs Fund:

Overview | Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma | Guidance | NICE

Commissioner: NHS England

Only to be used in line with a current chemotherapy protocol from the North of England Cancer Alliance in line with the appropriate Network Site Specific Group’s clinical guidelines or chemotherapy algorithm.

08.01.01 Chlormethine hydrochloride Ledaga®
  • 160micrograms/g gel 
  • Approved for the treatment of mycosis fungoides-type cutaneous T-cell lymphoma in line with NICE
15.02 Chloroprocaine hydrochloride  Ampres®

  • 50mg/5ml ampoules & 400mg/20ml vials.

    • Approved for spinal nerve and peripheral blocks. To be reviewed in April 2022.



05.04.01 Chloroquine 
  • 200mg tablets (=150mg chloroquine base) Green Traffic Light Not NHS Not NHS. 
  • 68mg in 5ml syrup (=50mg in 5ml chloroquine) Green Traffic Light Not NHS Not NHS
    272.5mg in 5ml injection (=200mg in 5ml chloroquine) unlicensedunlicensed Red Traffic Light.
02.02.01 Chlorothiazide 250mg in 5ml suspension 
  • Treatment should only be on advice from paediatric cardiology or nephrology specialists
03.04.01 Chlorphenamine 
04.02.01 Chlorpromazine 
01.09.01 Cholic acid 

  • Approved for the treatment of inborn errors of bile acid synthesis (all ages) in line with NHS England Commissioning Policy

12.03.01 Choline Salicylate Bonjela® Adult
07.04.04 Chondroitin sulfate Gepan Instill®

  • Approved the treatment of:

    • Interstitial cystitis/painful bladder syndrome

    • Radiation cystitis

    • Recurring bacterial cystitis

    • Overactive bladder



06.05.01 Choriogonadotropin Alfa Ovitrelle®

  •   Fertility treatment Red Traffic Light

  •   Hypogonadism Green Traffic Light

01.05.03 Ciclosporin 
  • Capsules: 10mg, 25mg, 50mg, 100mg
  • Oral solution: 100mg/ml
    • Must be prescribed by brand name
    • Brands include Capimune, Capsorin, Deximune, Neoral, Sandimmun, Vanquoral 
  • 50mg/1ml continuous infusion Red
08.02.02 Ciclosporin Sandimmun®
08.02.02 Ciclosporin 
  • Approved formulations include:
    • 10mg, 25mg, 50mg, and 100mg capsules;
    • 100mg in 1ml sugar free oral solution (oily).
    • Should be prescribed by brand for transplant indications   
  • For Transplant indications Red unless from a Trust/speciality that hasn't formally repatriated its patients or for patients who require weekly scripts for MDS boxes Amber

 

10.01.03 Ciclosporin 
  • See section 8.2.2
13.05.03 Ciclosporin 
  • Capsules & SF Solution 
    See section 8.2.2
11.04.02 Ciclosporin 0.1% (1mg/1ml) Eye Drops 
  • Ikervis® - Approved for the treatment of dry eye disease in adults that has not improved despite treatment with artificial tears in line with NICE
  • Verkazia® - Approved for the treatment of severe vernal keratoconjunctivitis in children from 4 years of age and adolescents
05.03.02.02 Cidofovir infusion 
  • For use in the prevention and treatment of cytomegalovirus infection. 
  • For limited use by ENT Surgeons in the treatment of selected
    patients with respiratory papillomatosis (unlicensedunlicensed)
01.03.01 Cimetidine 
09.05.01.02 Cinacalcet 

  • Approved for the treatment of secondary hyperparathyroidism in patients with end stage renal disease on maintenance haemodialysis where parathyroid gland surgery has failed or is inappropriate. Red Traffic Light

  • Also for short term use to control symptoms prior to a second attempt at more definitive surgery. Red Traffic Light

  • Approved for patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated based on serum calcium levels, symptoms and end organ damage, but in whom parathyroidectomy is either not clinically appropriate or is contraindicated. It is not normally commissioned if serum calcium concentration is <2.85mmol/L Amber

04.06 Cinnarizine 
09.08.01 Cipaglucosidase alfa (CIPA) Pombiliti®
  • 105mg powder for concentrate for solution for infusion vials
  • Approved with with miglustat (Opfolda) for treating late-onset Pompe disease in adults in line with NICE and NHSE Specialised Commissioning guidance


For information only - as there are no providers within the North East & Cumbria area that are commissioned to provide this service

11.03.01 Ciprofloxacin 

Eye drops: 0.3%
Eye ointment (preservative-free): 0.3%

12.01.01 Ciprofloxacin & dexamethasone Ciprodex®
  •  Ciprofloxacin 0.3% and dexamethasone 0.1% ear drops
12.01.01 Ciprofloxacin 0.2% ear drops 
  •  2mg/ml (0.2%) ear drops (0.25ml unit dose)
05.01.12 Ciprofloxacin Infusion 
  • 100mg & 200mg, 400mg intravenous infusions 
05.01.12 Ciprofloxacin Oral Preparations 
  • 250mg, 500mg & 750mg tablets
  • 250mg in 5ml suspension
15.01.05 Cisatracurium Nimbex®
  • 20mg in 10ml (2mg/ml) injection
  • 150mg in 30ml (5mg/ml) injection
08.01.05 Cisplatin  
04.03.03 Citalopram 
  • Please note maximum doses
    • Adults = 40mg
    • Elderly = 20mg
19 Citrasate® 
19 Citric Acid  

  • 0.6mmol/L solution

    • Approved for use to assist in the identification of silent aspiration in stroke patients.

    • Temporary approval subject to evaluation being carried out after 6 months 




08.01.03 Cladribine 
  • 10mg in 10ml solution for preparing infusions; 2mg in 1ml subcutaneous injection 
  • Approved for Hairy cell leukaemia only.

  • 10mg tablets
  • Approved for treating highly active multiple sclerosis in adults in line with NICE
05.01.05 Clarithromycin Injection 
  • Injection (for IV infusion): 500mg
05.01.05 Clarithromycin Oral Preparations 
  • Tablets: 250mg, 500mg
  • Oral suspension: 125/5ml, 250mg/5ml
11.09 Clens 100® 
13.06.01 Clindamycin  Dalacin T®
  • 1% topical solution (alcohol – water basis)
  • 1% lotion (aqueous)
07.02.02 Clindamycin 2% vaginal cream 
05.01.06 Clindamycin Injection 
  • Injection: 300mg/2ml, 600mg/4ml
05.01.06 Clindamycin Oral Preparations 
  • 150mg capsules.
  • 75mg in 5ml suspension unlicensedunlicensed
04.08.01 Clobazam 
13.09 Clobetasol 0.05% 
13.04 Clobetasol Propionate 0.05% Dermovate®
  • Cream, ointment & scalp application
13.04 Clobetasol Propionate with neomycin and nystatin Dermovate-NN®
  • Ointment
13.04 Clobetasone Butyrate 0.05% Eumovate®
  • Cream, ointment & scalp application
13.04 Clobetasone butyrate with nystatin and oxytetracycline Trimovate®
  • Clobetasone butyrate 500mcg/1g, nystatin 100000iu/1g, oxytetracycline (as oxytetracycline calcium) 30mg/1g
08.01.03 Clofarabine Evoltra®
05.01.10 Clofazimine 
  • 50mg and 100mg capsules
    • Approved for the treatment of non-tuberculous mycobacterial (NTM) infections, on the advice of microbiology and Infectious Diseases (ID) physicians
04.01.01 Clomethiazole 

  • Alcohol withdrawal - chlordiazepoxide is preferred in the management of alcohol withdrawal.

06.05.01 Clomifene Citrate 
07.05.01.01 Clomiphene 
  • Tablets: 50mg
04.03.01 Clomipramine 
04.08.01 Clonazepam 
  • Clonazepam 500microgram in 5ml sugar-free oral solution is also approved unlicensedunlicensed
04.08.02 Clonazepam 

  • For initiation by neurologists only.

04.07.04.02 Clonidine 
  • Clonidine is not generally recommended for migraine prophylaxis; may aggravate depression/cause insomnia.
02.05.02 Clonidine 100 microgram tablets 
  • Treatment should be on the advice of a cardiologist/nephrologist.
02.05.02 Clonidine 150 microgram in 1ml injection 
  • For use in paediatric cardiac ITU and in adult ITU patients with delerium and agitation, often around extubation unlicensedunlicensed.
19 Clonidine Intrathecal Injection 
02.09 Clopidogrel 
  • Approved for use in cardiac patients being fitted with stents/acute coronary syndromes and where aspirin is contraindicated/not tolerated, despite its use in combination with acid suppressants e.g. omeprazole.
  • Approved ischaemic stroke; in peripheral arterial/multivascular disease; or after MI only if aspirin not suitable in line with NICE.
  • The North of Tyne APC recommends the use of generic 75mg clopidogrel tablets in all the approved indications for clopidogrel.
  • Care should be taken to ensure that the brand supplied is suitable if it is to be packed into monitored dosage systems.
02.09 Clopidogrel 75mg in 5ml suspension 
  • Approved for use in paediatric patients with Berlin Heart devices.
07.02.02 Clotrimazole 
13.10.02 Clotrimazole 1% cream 
12.01.01 Clotrimazole 1% solution 
04.02.01 Clozapine 
  • First choice in patients with treatment-resistant schizophrenia. 
13.05.02 Coal tar 2% and salicylic acid 2% ointment 
13.09 Coal Tar Extract 5% shampoo Alphosyl 2 in 1®
13.05.02 Coal tar in emulsifying ointment solution 
  • 1% unlicensedunlicensed
  • 2% unlicensedunlicensed
  • 5% unlicensedunlicensed
13.05.02 Coal tar lotion 1% Exorex®
05.01.01.03 Co-Amoxiclav Injection 
  • Injection: 500/100 (600mg), 1000/200 (1.2g)
05.01.01.03 Co-Amoxiclav Oral Preparations 
  • Tablets: 250/125, 500/125
  • Oral suspension (sugar-free available): 125/31, 250/62, 400/57
18.08.07 Coban® 2 Comfort Foam Layer 
  • Used in lymphoedema
  • Specialist use 
18.08.07 Coban® 2 Compression Layer 
  • Used in lymphoedema
  • Specialist use 
18.08.08 Coban® 2 Layer 
  • Specialist use only
18.08.08 Coban® 2 Layer Lite 
  • Specialist use only
04.09.01 Co-Beneldopa 
05.03.01 Cobicistat Tybost®
11.07 Cocaine 

unlicensed P/F eye drops: 4%

15.02 Cocaine 
  • 4% nasal solution (drops) unlicensedunlicensed
    25% paste (1g syringe pack) unlicensedunlicensed
12.04 Cocaine 5% Nasal Spray 
15.02 Cocaine with Adrenaline 
  • 4% solution with adrenaline unlicensedunlicensed
04.09.01 Co-Careldopa 
04.09.01 Co-Careldopa and Entacapone 
19 Co-Careldopa liquid 
13.05.02 Cocois® 
07.03.01 Co-Cyprindiol 2000/35 - cyproterone Acetate 2mg with ethinylestradiol 35micrograms 
  • Co-cyprindiol should be reserved for those women requiring treatment for the androgenic conditions such as severe acne or moderately severe hirsutism. It is recommended that treatment be withdrawn 3 to 4 cycles after the androgenic condition(s) has/have completely resolved and that it is not continued solely to provide oral contraception. Venous thromboembolism occurs more frequently in women taking co-cyprindiol than those taking a low-dose combined oral contraceptive. Repeat courses may be given if the androgen-dependent condition(s) recur.
  • Note: generic co-cyprindiol is much cheaper than Dianette®
13.06.02 Co-Cyprindiol 2000/35
(Cyproterone Acetate 2mg with Ethinylestradiol 35micrograms)
 

  • Tablets containing cyproterone acetate 2mg & ethinylestradiol 35 micrograms
    generic co-cyprindiol is much cheaper than Dianette®

13.06.02 Co-Cyprindiol 2000/35
(Cyproterone Acetate 2mg with Ethinylestradiol 35micrograms)
 
  • Tablets containing cyproterone acetate 2mg & ethinylestradiol 35 micrograms.
  • Note: generic co-cyprindiol is much cheaper than Dianette®
13.09 Co-Cyprindiol 2000/35
(Cyproterone Acetate 2mg with Ethinylestradiol 35micrograms)
 
  • Tablets containing cyproterone acetate 2mg & ethinylestradiol 35 micrograms.
  • Note: generic co-cyprindiol is much cheaper than Dianette®
01.06.02 Co-danthramer 
  • Note: Co-danthramer and Co-danthrusate are generally restricted to use in the treatment of constipation in terminally ill patients. A combination of Senna and Docusate is normally preferred.
01.06.02 Co-danthrusate 
  • Note: Co-danthramer and Co-danthrusate are generally restricted to use in the treatment of constipation in terminally ill patients. A combination of Senna and Docusate is normally preferred.
01.04.02 Codeine 
04.07.02 Codeine 

First line

  • 15mg tablets

Second line

  • 30mg tablets

The following codeine preparations are unlicensedunlicensed and approved for use:

  • 30 mg suppositories.
  • codeine 2mg, 3mg, 6mg, 15mg;
  • codeine 30mg in 1ml injection CD
19 Codeine Phosphate Suppositories 
10.01.04 Colchicine 
09.06.04 Colecalciferol 
  • 20 microgram (800 units) capsules or tablets
    • For first line use in the long term maintenance treatment of patients with documented vitamin D deficiency following high strength therapy and also for use in patients with symptoms and insufficient levels. 
  • 80 microgram (3,200 units) capsules
    • For use in patients with malabsorption such as patients who have had bariatric surgery and require higher maintenance doses 
  • 500 microgram (20,000 units) capsules.
    • For use in patients requiring high strength therapy for vitamin D deficiency. 
  • 2740iu/ml oral solution (Fultium®-D3 Drops) 
  • 1000iu and 3000iu buccal spray (DLux®) unlicensedunlicensed Red Traffic Light
    • Approved for use in paediatric parenteral nutrition patients with short bowel syndrome and adults with metabolic bone disease who have vitamin D deficiency despite previous treatment.
09.06.04 Colecalciferol 25,000 unit liquid Invita D3®
01.09.02 Colesevelam 
  • Approved for second line use (after Colestyramine) for the treatment of bile malabsorption that results in diarrhoea.
02.12 Colesevelam 
  • For initiation in lipid clinic only in patients with familial hypercholesterolaemia and/or those with substantial cardiovascular risk and who are unable to tolerate existing treatments.
01.09.02 Colestyramine 
  • Also approved for the treatment for leflunomide toxicity Red Traffic Light
02.12 Colestyramine 
  • For initiation in lipid clinic only in patients with familial hypercholesterolaemia and/or those with substantial cardiovascular risk and who are unable to tolerate existing treatments.
  • Also approved for the treatment of leflunomide toxicity Red Traffic Light.
05.01.07 Colistimethate 
  • 1 million-unit & 2 million-unit vial for nebulisation/intravenous injection
    • Nebulised therapy for bronchiectasis Green Traffic Light
    • Nebulised therapy for patients on assisted ventilation, patients with tracheostomies and those with persistant bacterial bronchitis Green plus
    • To be used for treatment of Cystic Fibrosis in accordance with NHS England Commissioning Policy/NICE Guidance.
    • Nebulised therapy for CF Red Traffic Light.
    • Intravenous therapy Red Traffic Light.
    • Dry powder for inhalation (Colobreath®) Red Traffic Light.

13.10.05 Collodion Flexible BP 
  • 2.5% castor oil & colophony 2.5% in a collodion base.
01.01.01 Co-magaldrox Maalox®
  • Mucogel is first choice in the community due to cost.   
01.01.01 Co-magaldrox Mucogel®
  • First choice in the community due to cost.
06.04.01.01 Combined cyclical HRT tablet Elleste Duet®
  • Pack of 16 x 1mg estradiol tablets + 12 x 1mg estradiol and 1mg norethisterone tablets
06.04.01.01 Combined cyclical HRT tablet Femoston®
  • Femoston® 1/10 Tablets:
    • Pack of 14 x 1mg estradiol tablets + 14 tablets containing estradiol 1mg and dydrogesterone 10mg

 

  • Femoston® 2/10 Tablets:
    • Pack of 14 x 2mg estradiol tablets + 14 tablets containing estradiol 2mg and dydrogesterone 10mg
07.03.01 Combined Hormonal Contraceptive - patch Evra

  • Evra® are self-adhesive patches releasing approximately 20 micrograms ethinylestradiol and 150 micrograms norelgestromin/24 hours.

    • Approved for use by a small number of women with gastrointestinal absorption problems or with compliance issues.



07.03.01 Combined Hormonal Contraceptives - oral 
  • Logynon®
  • Logynon® ED
  • Tri-Regol®
07.03.01 Combined Hormonal Contraceptives - oral 

First Choice

  • Rigevidon® (ethinylestradiol 30 microgram/levonorgestrel 150microgram)

Alternatives

  • Cilique® (ethinylestradiol 35 microgram/norgestimate 250microgram)
  • Femodene® (ethinylestradiol 30 microgram/gestodene 75 microgram)
  • Femodene® ED (ethinylestradiol 30 microgram/gestodene 75 microgram)
  • Gedarel 30/150® (ethinylestradiol 30 microgram/desogestrel 150 microgram)
  • Levest® (ethinylestradiol 35 microgram/norgestimate 250microgram)
  • Lizinna® (ethinylestradiol 35 microgram/norgestimate 250 microgram)
  • Loestrin 30® (ethinylestradiol 30 microgram/ norethisterone 1.5mg)
  • Lucette® (ethinylestradiol 30 microgram/drospirenone 3mg)
  • Marvelon® (ethinylestradiol 30 microgram/desogestrel 150 microgram)
  • Microgynon® 30 (ethinylestradiol 30 microgram/levonorgestrel 150 microgram)
  • Microgynon® ED (ethinylestradiol 30 microgram/levonorgestrel 150 microgram)
  • Millinette 30/75® (ethinylestradiol 30 microgram/ gestodene 75 microgram)
  • Ovranette® (ethinylestradiol 30 microgram/levonorgestrel 150microgram)
  • Ovysmen® (ethinylestradiol 35 microgram/norethisterone 500 microgram
03.04.03 Conestat Alfa Ruconest®
  • Vials: 2,100 units (as dry powder)
06.04.01.01 Continuous combined HRT tablets Elleste-duet Conti, Kliofem, Kliovance, Femosten Conti, Premique-low dose
09.08.01 Copper histidinate 
  • Subcutaneous copper histidinate injections
  • Approved for presymptomatic neonates with classical Menkes disease in line with NHSE Specialised Commissioning Policy
  • The following providers are commissioned to provide this service within North East:
    • The Newcastle upon Tyne Hospitals NHS Trust
01.01.01 Co-simalcite Altacite plus®

 

18.01.02 Cosmopor E® 

Absorbent Perforated Dressing with Adhesive Border

05.04.08 Co-trimoxazole 
  • See section 05.01.08
05.01.08 Co-trimoxazole Infusion 
  • 480mg in 5ml ampoules for IV infusion
05.04.08 Co-trimoxazole Infusion 
  • 480mg/5ml injection
05.01.08 Co-trimoxazole Oral Preparations 
  • 480mg tablets, 960mg tablets
  • 240mg in 5ml & 480mg in 5ml suspensions.
18.08.03 Cotton Stockinette Bleached BP 1988 Comfi-gauz®
14.04 COVID-19 vaccines 
  • Comirnaty® Original / Omicron BA.4-5
  • Comirnaty® 10 Concentrate for children
  • Comirnaty® 3 (THREE) Concentrate
  • VidPrevtyn Beta®
  • Spikevax® Original/Omicron BA.4-5
08.01.05 Crisantaspase Erwinase
08.01.05 Crizotinib  
  • Approved in accordance with NICE and NHS England Commissioning Policy.
13.03 Crotamiton Eurax®
13.11.06 Crystal Violet 0.5% Paint 
  • For limited use in some operating theatres/critical care areas only.
04.06 Cyclizine 
11.05 Cyclopentolate Eye drops 
  • 0.5% and 1%.
11.05 Cyclopentolate Single Use Minims® 
  • 0.5% and 1%.
11.05 Cyclopentolate with phenylephrine 
08.01.01 Cyclophosphamide 
05.01.09 Cycloserine 
  • 250mg capsules Infectious diseases
  • microbiology or respiratory advice only
16 Cyproheptadine hydrochloride Periactin®
08.03.04.02 Cyproterone 
06.04.04 Cyproterone Acetate 
  • Tablets: 50mg & 100mg
06.04.02 Cyproterone Acetate 50mg and 100mg tablets 
  • Approved for use on the advice of a urologist.
08.01.03 Cytarabine  
  • A cytarabine 50mg vial - intrathecal injection (cytarabine encapsulated in liposomes) is also approved for use. 
02.08.02 Dabigatran 
  • Only approved for use in accordance with NICE guidance. 
08.01.05 Dabrafenib  Tafinlar®
  • Approved for the treatment of unresectable or metastatic BRAF V600 mutation-positive melanoma in line with NICE 
  • Approved for the treatment of BRAF-mutated anaplastic thyroid cancer (ATC) in line with NHSE Specialised Commissioning Policy
  • Approved with trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults in line with NICE

 

08.01.05 Dacarbazine  
05.03.03.02 Daclatasvir  

  • Approved for the treatment of chronic hepatitis C in line with NICE and NHS England Commissioning Policy.  

08.02.04 Daclizumab Zinbryta®
  • 150mg subcutaneous injection
    • Approved for the treatment of highly active relapsing-remitting mutiple sclerosis that has failed to respond to other treatment in adults in line with NICE and NHS England Commissioning Policy. 
    • Subject to restricted use by EMA
08.01.05 Dacomitinib Vizimpro®
  • Approved as an option for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in adults in line with NICE

 

08.01.02 Dactinomycin  
05.01.07 Dalbavancin Xydalba ®
  • 500mg injection
    • approved for the treatment of significant deep soft tissue infections such as joint, discitis and spinal infection, on the advice of infectious disease physicians or microbiology.

09.06.07 Dalivit® 
  • Drops containing in each 0.6ml dose ascorbic acid 50mg, ergocalciferol
    400 units, nicotinamide 5mg, pyridoxine HCl 500 micrograms, riboflavin
    400 micrograms, thiamine 1mg & vitamin A 5,000 units)
    • Dalivit drops are to be retained for use in patients requiring a full supplement of vitamin A.

02.08.01 Danaparoid 
  • For use on advice from haematologists in patients who develop thrombocytopenia with heparins - cross reactivity with heparin antibodies is thiought to be <10%. 
03.04.03 Danazol 
  • For use on the advice of an immunologist in the prophylaxis, treatment hereditary angioedema associated with C1-esterase inhibitor deficiency.
     
06.07.02 Danazol 100mg and 200mg capsules 
10.02.02 Dantrolene 
15.01.08 Dantrolene Sodium Dantrium Intravenous®
  • 20mg injection
16 Dantrolene sodium 
02.15 Dapafliflozin Forxiga®
  • 5mg and 10mg tablets
  • Approved for treating chronic heart failure with reduced ejection fraction in line with NICE
  • Approved for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults in line with NICE
06.01.02.03 Dapagliflozin Forxiga®
  • 5mg and 10mg tablets
    • Approved for treating type 2 diabetes in adults Green  
    • Approved for the treatment of chronic kidney disease in adults in line with NICE and NTAG Green

 

05.01.10 Dapsone 
  • Used in the treatment of leprosy and some skin conditions (e.g. dermatitis herpetiformis, pemphigoid on the advice of dermatologists).
05.01.07 Daptomycin 
08.01.05 Daratumumab Darzalex®
  • Approved in combination with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable in line with NICE
  • Approved as an option for treating relapsed and refractory multiple myeloma in adults who have had a proteasome inhibitor and an immunomodulator, and whose disease progressed on the last treatment in line with NICE
  • Approved with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable in line with NICE and NHSE Specialised Commissioning guidance

 

09.01.03 Darbepoetin Alfa Aranesp®

  • 10, 15, 20, 30, 40, 50, 60, 80, 100, 150 & 300 microgram injections in prefilled syringes 

  • 20, 40, 60, 80, 100 & 300 microgram Sureclick® pens - approved for management of cancer treatment-induced anaemia in women receiving platinum-based chemotherapy for ovarian cancer 



  • Monitoring: monitoring of erythropeoetin (darbepoetin) in adult patients can be undertaken by GPs under a shared care arrangement Amber

04.01.01 Daridorexant Quviviq®
  • 25mg and 50mg tablets
  • Approved for the treatment long-term insomnia in line with NICE via NHS Sleep Clinic at
    • South Tees Hosptials NHS Foundation Trust; and 
    • The Newcastle upon Tyne Hospitals NHS Foundation Trust
  • First 3 months treatment to be provided by secondary care followed by a review and a further 1 month supply if appropriate before prescribing is handed over to primary care
07.04.02 Darifenacin  
  • MR Tablets - 7.5mg, 15mg
08.03.04.02 Darolutamide Nubeqa®
  • 300mg tablets
  • Approved for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease in line with NICE
  • Approved with andorgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer in line with NICE and NHSE Specialised Commissioning guidance

 

05.03.01 Darunavir 
05.03.01 Darunavir and Cobicistat 

To be used in accordance with NHS England Clinical Commissioning Policy (SSC1614).

08.01.05 Dasatinib Sprycel®
  • Approved for use in accordance with NICE and NHS EnglandCommissioning Policy
08.01.02 Daunorubicin 
  • The following formualtions are approved:
    • 20mg injection;
    • 10mg, 15mg, 35mg;
    • 40mg prefilled syringes.

08.01.03 Daunorubicin/cytarabine Vyxeos®

  • Daunorubicin 44mg/cytarabine 100mg powder for solution for infusion

  • Approved for untreated acute myeloid leukaemia in line with NICE

19 DC beads 
18.05 Debrisoft® 

Polyester fibres with bound edges and knitted outer surface coated with polyacrylate

  • Specialist initiation only
13.02.02 Deegan's ointment 
19 Deep Heat® Max Strength 

  • Approved to arterialise earlobe capillary blood to facilitate capillary blood testing

09.01.03 Deferasirox 
  • Approved for iron chelation in patients with myelodysplastic syndromes (MDS) - (as per NECN Haematology Group Guidelines) and recommended for use in patients when treatment with desferrioxamine is no longer considered to be appropriate due to progressive iron overload despite maximally tolerated doses of desferrioxamine. 
  • Approved for the treatment of iron overload for trasnfused and non-tranfused patients with chronic inherited anaemias (all ages) in line with NHSE Specialised Commissioning Policy
09.01.03 Deferiprone Ferriprox®
02.08 Defibrotide 
  • Approved for use in severe veno-occlusive disease following stem cell transplant - in accordance with NHS England commissioning policy. 
08.03.04.02 Degarelix 
  • Approved formulations include 80mg and 120mg vials (with diluent).
  • Approved for the first line treatment of advanced hormone dependant prostate cancer with a PSA > 20ng/l at presentation 
    • -approved as an option for treating advanced hormone-dependent prostate cancer in people with spinal metastases in line with NICE.

04.12 Dehydrated alcohol 100% BP for Injection 
  • Approved for intrathecal neurolysis treatment of intractable pain due to cancer in terminally ill patients
09.06.07 DEKAs® Essentials multivitamins 

  • Approved for adult patients requiring multivitamin and mineral supplementation with Cystic Fibrosis

09.06.07 DEKAs® Plus multivitamins 

  • Approved for adult patients requiring multivitamin and mineral supplementation with Cystic Fibrosis

19 Del Nido Cardioplegia Solution 

  • Approved for use at Newcastle in paediatric and adult congenital cardiac surgery.

05.01.12 Delafloxacin 
  • 450mg tablets
  • 300mg powder for concentrate for solution for infusion

  • approved for the treatment of acute bacterial skin and skin structure infections where other antibiotics are inappropriate either due to resistant organisms or intolerance/allergy
05.01.09 Delamanid 
  • To be used in accordance with NHS England Commissioning Policy 
06.05.02 Demeclocycline 
  • 150mg capsules
    • Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
      Treatment to be intitated by specialist.
06.06.02 Denosumab Xgeva®
  • Denosumab 70mg in 1ml (120mg) vial is approved for the prevention of skeletal-related events in adults with bone metastases from solid tumours in line with NICE 
    • Note: denosumab is not approved for therapy induced bone loss in non- metastatic prostate cancer (NICE).


  • North Cumbria only
    • New patients        Red
    • Exisiting patients  Green plus
06.06.02 Denosumab Prolia®
  • Denosumab 60mg in 1ml solution in prefilled syringe is approved for use in the treatment of postmenopausal osteoporosis in line with NICE. Also approved for male patients who dont tolerate bisphosphonates or strontium ranelate. 

 

18.04.02 Dermatix® 15g Gel 

Silicone gel



  • Burns Team and scar clinic initiation only

13.02.01 Dermol® 
13.02.01 Dermol® 500 Lotion 
16 Desferrioxamine 
  • 500mg vials (for preparing injection & oral solution)
09.01.03 Desferrioxamine Mesilate 
  • Approved for the treatment of iron overload for trasnfused and non-tranfused patients with chronic inherited anaemias (all ages) in line with NHSE Specialised Commissioning Policy
03.04.01 Desloratadine 
06.05.02 Desmopressin 
  • The following desmopressin  formualtions are approved for use:
    • 10 microgram/dose nasal spray.
    •  2.5 & 150 microgram/dose nasal sprays Red Traffic Light(unlicensedunlicensed).
    • 100 microgram & 200 microgram tablets.
    • 120 microgram sublingual tablets.
    •  4 microgram in 1ml injection and 15 microgram in 1ml injectionRed Traffic Light
07.04.02 Desmopressin 
  • The following formulations are approved:
    • 100microgram and  200 microgram tablets;
    • 120 microgram sublingual tablets. 

  • Note: nasal formulations no longer licensed for treating nocturnal
    enuresis (see section 6.5.2 for other formulations).
07.04.02 Desmopressin Noqdirna®
  • Oral lyophilisates: 25microgram, 50 microgram
13.05.03 Deucravacitinib Sotyktu
  • 6mg tablets
  • Approved for the treatment of moderate to severe plaque psoriasis in line with NICE
06.03.02 Dexamethasone  
  • 500microgram & 2mg tablets
  • 500microgram soluble tablets
  • 2mg in 5ml oral solution and 5mg in 5ml oral solution  is also approved. unlicensedunlicensed
  • 20mg/5ml oral solution Red
  • Approved for use in patients requiring high dose to reduce pill burden
12.01.01 Dexamethasone 0.05% with framycetin 0.5% ear drops Sofradex®
  • Alternative choice compound antibacterial/corticosteroid ear drop.
11.04.01 Dexamethasone 0.05%, framycetin sulf. 0.5%, gramicidin 0.005% eye drops Sofradex
11.04.01 Dexamethasone 0.1% eye drops Maxidex®
  • Preservative-free eye drops are also approved.
    • 0.1% Minims® - first choice.
    • 0.1% preservative free eye drops unlicensedunlicensed - approved only for patients who are unable to use Minims®due to dexterity problems.

11.04.01 Dexamethasone 0.1% Preservative-free 

First choice

Unit dose vials (Minims®)

Alternative

Eye drops (unlicensed) - only for patients who are unable to use Minims® due to dexterity problems

12.01.01 Dexamethasone 0.1% with neomycin 0.5% spray Otomize®
  • Alternative choice compound antibacterial/corticosteroid ear drop.
06.03.02 Dexamethasone 3.3mg in 1ml and 6.6mg in 2ml 
  • Note: there are two different strength preparations of dexamethasone injection available in the UK (3.8mg/ml and 3.3mg/ml) where traditionaly a 4mg/ml preparation was available and prescribed as such. To avoid confusion the 3.3mg/ml strength is the preparation of choice in the acute Trusts. Where previously a 4mg dose would have prescribed it is appropriate to prescribe a 3.3mg dose (or multiples thereof). This is because the range of doses given in clinical practice varies widely and subsequent doses tend to be adjusted to reflect clinical response. If 4mg is required please ensure that the appropriate volume of 3.3mg/ml is (e.g. 1.2ml) prescribed (or mulitples thereof).
11.04.01 Dexamethasone 700 microgram intravitreal implant Ozurdex®
  • Approved for macular oedema following central retinal vein occlusion
    in line with NICE.
  • Approved for treating diabetic macular oedema in line with NICE.
  • Approved for the treatment of non-infectious uveitis in line with NICE and NHS England Commissioning Policy

 

Note: The Northern (NHS) Treatment Advisory Group recommends the sequential pharmacological management of MO secondary to RVO as per the North East Retina Group (NERG) RVO treatment pathway.

10.01.02.02 Dexamethasone Phosphate 

Injection: 3.3 mg/1 mL, 4 mg/1 mL, 6.6 mg/2 mL, 8 mg/2 mL 

11.04.01 Dexamethasone with Neomycin and Polymyxin B sulphate Maxitrol®
  • Eye drops and eye ointment
04.04 Dexamfetamine 
  • 5mg, 10mg and 20mg tablets
    • ADHD
    • Narcolepsy
    • Doses up to 60mg daily 

 

06.01.06 Dexcom One® 
  • Recommended for use only as per NTAG advice and NHS England Guidance.

 

15.01.04.04 Dexmedetomidine  Dexdor®

  • 100 micrograms in 1ml injection approved for use in patients:


    • with traumatic brain injury, have no respiratory problems but require prolonged ventilatory support due to severe agitation, confusion and requirement for propofol/midazolam; and

    • who are difficult to sedate e.g. with overdose of MDMA/PMA/”legal highs” or who have pre-existing drug or alcohol dependence or who have failed conventional methods of treatment.

    • Paediatric patients undergoing cardiac surgery with a high risk of post-operative Junctional Ectopic Tachyarrhythmia (JET) or those suitable for fast-track surgery.



  • 100 micgrograms in 1ml injection (intranasal) unlicensedunlicensed route


    • approved for pre-operative sedation in anxious children at risk of respiratory depression in whom midazolam is contraindicated or those who have failed pre-operative sedation with other agents.



08.01 Dexrazoxane  Savene®
  • For use in line with NECN extravasation.
09.02.02.02 Dextran 40/Sodium Chloride 
  • 10%/0.9% 
04.07.02 Diamorphine 

 

    • unlicensed Unlicensed intranasal diamorphine is approved for use in children for the relief of severe pain due to clinically suspected limb fractures, burns and significant fingertip injuries. Appropriate risk assessments are to be conducted by each organisation in order to determine formulation of choice (e.g. ampoules or intranasal spray).

 

    • Note: intranasal diamorhine Red Traffic Light  

 

04.01.02 Diazepam 
  • Diazepam 2mg tablets: are the preferred strength in primary care. 
  • Diazepam 10mg tablets: should no longer be used. 
  • Diazepam 10mg in 2ml injection: only approved for use in epilepsy (see section 4.8.2).
  • Diazepam 2 mg/5ml oral solution: swallowing difficulties
04.08.02 Diazepam 
10.02.02 Diazepam 
  • Note: diazepam 10mg tablets are no longer on the formulary. 
15.01.04.01 Diazepam 
  • 2mg, 5mg tablets – 10mg tablets should no longer be used.
  • 2mg in 5ml oral solution.
  • 10mg in 2ml injection (plain & emulsion) Red Traffic Light.
    • For use in epilepsy see section 4.8.2 and use in anxiety see
      section 4.1.2.

16 Diazepam (emulsion) 
02.05.01 Diazoxide 
06.01.04 Diazoxide 
  • Diazoxide suspensions can be obtained/prepared if needed. unlicensedunlicensed
19 Dibotermin Alfa Inductos®
04.07.01 Diclofenac 
  • Oral diclofenac is restricted to short-term use for post operative pain.
  • If long-term use is required diclofenac is only approved for 4th line treatment (see below):
    • Ibuprofen low dose – first line treatment.
    • Naproxen low dose – second line treatment.
    • Naproxen high dose – third line treatment.
    • Diclofenac – fourth line treatment.
04.07.04.01 Diclofenac 
10.01.01 Diclofenac 

Tablets: 25mg, 50mg

The use of oral diclofenac is restricted. It can be used short-term for post operative pain, or as a fourth line choice for long-term use.

  • Topical formulations are NOT on the formulary
11.08.02 Diclofenac 
  • 0.1% eye drops and unit dose eye drops.
  • For post-operative inflammation limited to patients where corticosteroids are unsuitable.
13.08.01 Diclofenac 3% in sodium hyaluronate (Solaraze) 
15.01.04.02 Diclofenac 75mg/1ml injection 

  • Mainly for use in post-operative analgesia - see section 10.01.01 for other formulations

10.01.01 Diclofenac Sodium 

Injection: 75 mg/3 ml

10.01.01 Diclofenac Suppositories 

Diclofenac: new contraindications and warnings - GOV.UK (www.gov.uk)

16 Dicobalt edetate 
  • 300mg in 20ml injection
01.02 Dicycloverine 
05.03.01 Didanosine 
08.03.01 Diethylstilbestrol 
  • Should be initiated with specialist advice.
13.14.07 Difelikefalin Kapruvia®
  • 50mcg/1ml solution for injection
  • Approved for pruritus in adults with chronic kidney disease having haemodialysis in line with NICE
02.01.01 Digoxin 
  • 62.5, 125 & 250 microgram tablets Green Traffic Light.
  • 50 microgram per ml elixir Green Traffic Light.
  • 500 microgram in 2ml injection Red Traffic Light.
  • 100 microgram in 1ml injection unlicensedunlicensed Red Traffic Light.
02.01.01 Digoxin specific antibody fragments Digifab®

For the treatment of life threatening digoxin toxicity only, requests must be cleared by an appropriate clinician.

 

 

05.04.01 Dihydroartemisinin / piperaquine phosphate Eurartesim®
  • 160mg/20mg & 320mg/40mg tablets
    • Approved for the treatment for plasmodium falciparum malaria in line with current UK and WHO guidelines.
    • Only available from Newcastle Hospitals (RVI)
04.07.02 Dihydrocodeine 
  • Note: the use of dihydrocodeine 30mg tablets & 10mg in 5ml oral solution is no longer recommended for regular use. Codeine is the preferred weak opioid analgesic.
  • Dihydrocodeine is only approved for use in breast feeding mothers immediately postdelivery/ c-section where adequate pain relief has not been achieved using paracetamol and NSAIDs. Patients requiring contunation of dihydrocodeine following discharge (post delivery/c-section) can have dihydrocodeine prescribed in primary care (for short-term use only).
05.04.02 Diloxanide 
02.06.02 Diltiazem 
  • Preferred calcium channel blocker for angina.
  • Zemtard® is the formulary brand of choice for starting new patients on long acting diltiazem.
01.07.04 Diltiazem 2% 
  • The most effective formulation is to be prescribed
16 Dimercaprol 
  • 100mg in 2ml injection
08.02.04 Dimethyl fumarate Tecfidera®

  • Approved as a option for treating adults with active relapsing-remitting multiple sclerosis that isn’t highly active or rapidly evolving severe relapsing-remitting multiple sclerosis NICE and NHS England Commissioning Policy. 

13.05.03 Dimethyl fumarate Skilarence®
  • 120mg tablets
  • Approved for the treatment of moderate to severe plaque psoriasis in line with NICE
13.02.02 Dimeticone Siopel®
13.10.04 Dimeticone 4% lotion Hedrin®
07.01.01 Dinoprostone 
  • The following formulations are approved:
    • 0.75mg in 0.75ml injections;
    • 3mg vaginal tablets;
    • 10mg pessaries.

08.01.05 Dinutuximab beta Qarziba®
  • 20mg/4.5mL concentrate for solution for infusion 
  • Approved for the treatment of high-risk neuroblastoma in people aged 12 months and over in line with NICE
09.02.01.02 Dioralyte® Oral Rehydration Salts 
19 Diphencyprone in acetone 
13.05.02 Diprosalic ointment 

  • 0.05%/3%

02.09 Dipyridamole 
  • Only approved for use in accordance with NICE guidance.
  • 50mg in 5ml sugar free suspension alos avialable unlicensedunlicensed.
08.02.04 Diroximel fumarate Vumerity®
  • 231mg capsules
    • Approved for treating relapsing-remitting multiple sclerosis in line with NICE
11.08.02.04 Disodium edetate 0.37% solution  
09.05.01.02 Disodium Pamidronate  
  • 30mg injection
06.06.02 Disodium Pamidronate 30mg injection 
02.03.02 Disopyramide 
04.10.01 Disulfiram 
  • COUNTY DURHAM Red acamprosate, chlordioazepoxide, disulfiram & nalmefene prescribing should be retained within the commissioned service within County Durham.
13.05.02 Dithranol in Full Strength Lassar's Paste BP 

  • 0.1%, 0.2%, 0.4%, 0.6%, 0.8%, 1%, 2%, 4%, 6% & 8%.

13.05.02 Dithranol pomade 

  • 0.2%, 0.4% & 0.6% unlicensedunlicensed

13.05.02 Dithranol with salycyclic acid 0.5% 

  • 0.1%, 0.2%, 0.4%, 0.6%, 0.8%, 1%, 2%, 4%, 6%, 8% & 16%in emulsifying base.

02.07.01 Dobutamine 
08.01.05 Docetaxel  
  • Approved for early node-positive breast cancer in line with NICE. 
  • Approved for hormone refractory metastatic prostate cancer in line with NICE.
01.06.02 Docusate sodium 
05.03.01 Dolutegravir 
05.03.01 Dolutegravir Sodium & Lamivudine Dovato®
  • Film-coated tablet containing dolutegravir sodium equivalent to 50 mg dolutegravir and 300 mg lamivudine
05.03.01 Dolutegravir Sodium & Rilpivirine Hydrochloride Juluca®
  • Film-coated tablets containing dolutegravir sodium (equivalent to 50 mg dolutegravir) and rilpivirine hydrochloride (equivalent to 25 mg rilpivirine)
01.02 Domperidone 

Tablets - 10mg Suspension - 5mg/5ml

MHRA Drug Safety Alert (May 2014): Domperidone: risk of cardiac side effects
MHRA Drug Safety Update (Dec 2019): Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents

04.06 Domperidone 
  • Approved for use as a galactagogue to re-establish breastfeeding on specialist advice and following a cardiovascular risk assessment in light of MHRA advice.
04.11 Donepezil 
  • Only approved for use in accordance with NICE guidance. 
02.07.01 Dopamine 
03.07 Dornase Alfa 
11.06 Dorzolamide 
  • 2% eye drops.
  • 2% unit dose eye drops.
11.06 Dorzolomide 2% with Timolol 0.5%  
  • Eye drops and unit dose eye drops
  • Approved for use in patients with confirmed allergy presenting as
    conjunctival changes or skin allergy. To be initiated by ophthalmologists
    only. The ophthalmologists must clearly document that signs and
    symptoms of preservative allergy have been demonstrated in their
    patient prior to initiation.
08.01.05 Dostarlimab  Jemperli

Vial: concentrate for infusion 500 mg/10 mL

 
Link  NICE TA 779: Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
13.02.01 DoubleBase®gel 
03.05.01 Doxapram 
15.01.07 Doxapram 
  • 100mg in 5ml injection
  • 2mg/ml 500ml intravenous infusion in glucose 5%
    see section 03.05.01
02.05.04 Doxazosin 
  • 1mg, 2mg & 4mg tablets
07.04.01 Doxazosin 1mg, 2mg and 4mg tablets 

 

    • 1mg, 2mg and 4mg tablets

 

    • MR formulations are not approved

 

08.01.02 Doxorubicin 
  • Doxorubicin 50mg injection - includes use with DC Beads for use in transcatheter arterial chemoembolisation (TACE) therapy in patients with hepatocellular cancer. 
  • Doxorubicin 20mg & 50mg pegylated liposomal injection - approved for second-line (or subsequent) treatment in advanced ovarian cancer in line with NICE. 
  • Approved for the treatment of recurrent ovarian cancer in line with NICE.
05.01.03 Doxycycline 

  • 50mg and 100mg capsules Green

  • 100mg/5ml injection Red unlicensed unlicensed

    • approved as sclerosing agent for lymphatic malformations in children




 

11.03.01 Doxycycline 

SR capsules 40 mg

Specialist indication: drug of choice for ocular rosacea

13.06.02 Doxycycline 
12.03.01 Doxycycline 20mg tablets 
  • Treatment of periodontitis.
13.02.02 Drapolene® 
13.10.05 Drapolene® cream 
18.02.07 DrawTex® 

Super absorbent hydroconductive dressing with absorbent, cross-action structures of viscose, polyester and cotton

18.07.01 Dressit® 

Contains vitrex gloves, large apron, disposable bag, paper towel, soft swabs, absorbent pad and sterile field.

  • Second choice on FP10. 
02.03.02 Dronedarone 
  • Approved for patients who are unsuitable for or not tolerant of amiodarone. Treatment should be initiated by a cardiologist.
04.06 Droperidol 
06.01.02.03 Dulaglutide Trulicity®
  • 0.75mg, 1.5mg, 3mg and 4.5mg prefilled syringes
    • Approved for use in patients who require once-weekly GLP-1 receptor agonist therapy. 
    • This has replaced once-weekly exenatide. Existing patients can continue to receive exenatide until reviewed by a specialist

 

04.03.04 Duloxetine 
  • For use on advice of psychiatrists as a third-line antidepressant - but only for use in patients who cannot tolerate high-dose (>150mg daily) venlafaxine, or patients with hypertension, established CHD or other cardiovascular risk factors which would make the use of high-dose venlafaxine undesirable.
  • Also approved for third-line use (after drugs such as the tricyclic antidepressants and gabapentin) in the treatment of neuropathic pain on the advice of pain specialists.
04.07.03 Duloxetine 

  • For third-line use (after drugs such as the tricyclic antidepressants and gabapentin) in the treatment of neuropathic pain on the advice of pain specialists.

07.04.02 Duloxetine 
  • Capsules: 20mg, 40mg
  • Moderate to severe stress incontinence in combination with supervised pelvic floor excercises only
06.01.05 Duloxetine 30mg and 60mg capsules 
A2.04.01.02 Duocal® Super Soluble 
18.02.04 DuoDERM® Extra Thin 

Semi-permeable hydrocolloid dressing

11.08.01 Duolube® eye ointment 

UNDER REVIEW

    • Please note
      The brand name will soon change to Sooth Night-time and Duolube will be unable to be ordered

 

11.08.02 Duovisc® Injection 
  • Injection for use in cataract surgery containing VisCoat (1% sodium hyaluronate) and ProVisc (3% sodium hyaluronate, 4% chondroitin sulphate).
03.04.02 Dupilumab Dupixent®
  • 200mg/1.14ml & 300mg/2ml solution for injection
  • Approved for or treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over in line with NICE
13.05.03 Dupilumab Dupixent®
  • 200mg/1.14ml & 300mg/2ml solution for injection
  • Approved for treating moderate to severe atopic dermatitis in adults in line with NICE
08.01.05 Durvalumab Imfinzi®
  • Approved for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults in line with NICE.
  • Approved in combination with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer in line with NICE and NHS England Specialised Commissioning Policy.
06.04.02 Dutasteride 
  • 500mcg capsules
07.04.01.02 Dutasteride 
  • Capsules: 500micrograms
13.02.01 E45® 
18.05 Eakin® Wound Pouches 
18.01.02 Eclyspe® adherent 

Soft silicone wound contact layer with absorbent pad and film-backing

  • Specialist initiation only
09.01.03 Eculizumab  
  • 300mg/30ml solution for infusion
  • Approved treating atypical haemolytic uraemic syndrome in adults and children in line with NICE

Paroxysmal nocturnal haemoglobinuria treatment is only commissioned from:

  • King’s College Hospital NHS Foundation Trust, London - London and South East
  • Leeds Teaching Hospitals NHS Trust - Rest of United Kingdom
02.08.02 Edoxaban 
  • Only approved for use in accordance with NICE guidance. 
15.01.06 Edrophonium 
  • 10mg in 1ml injection
10.02.01 Edrophonium Chloride 
05.03.01 Efavirenz Sustiva®
13.09 Eflornithine 11.5% cream Vaniqa®
  • **UNDER REVIEW**
  • Approved for use as a second-line treatment of facial hirsutism in patients where co-cyprindiol is ineffective, contra-indicated or considered inappropriate. Treatment should be initiated by or on the specific advice of an appropriate specialist - endocrinologist (or gynaecologist).
18.08.03 Elasticated Tubular Bandages BP 1993 Comfigrip®
18.08.03 Elasticated Viscose Stockinette Comfifast® range
18.08.03 Elasticated Viscose Stockinette Clinifast® range
05.03.03.02 Elbasvir & grazoprevir Zepatier®

  • Approved for the treatment of chronic hepatitis C in line with NICE and NHS England Commissioning Policy.

A2.01.01.02 Elemental 028® Extra 
09.08.01 Elosulfase alfa 
  • 5mg/5ml concentrate for solution for infusion:
    • treating mucopolysaccharidosis type 4A in people of all ages
09.01.04 Eltrombopag 
  • For the treatment of adults with chronic immune (idiopathic) thrombocytopenia purpura in line with NICE.
02.15 Empagliflozin Jardiance®
  • 10mg and 25mg tablets
  • Approved for the treatment of chronic heart failure with reduced ejection fraction in adults in line with NICE
  • Approved for the treatment of chronic heart failure with preserved or mildly reduced ejection fraction in line with NICE
06.01.02.03 Empagliflozin 
  • Approved in combination therapy for treating type 2 diabetes in line with NICE 
  • Approved for the treatment of type 2 diabetes in line with NICE 
  • Approved for treating chronic kidney disease in line with NICE
05.03.01 Emtricitabine 
05.03.01 Emtricitabine & Elvitegravir & Cobicistat & Tenofovir alafenamide Genvoya®
  • Tablet: 200mg / 150 mg / 150 mg / 10 mg
  • To be used in accordance with NHS England Clinical Commissioning Policy.
05.03.01 Emtricitabine & Rilpivirine & Tenofovir alafenamide Odefsey®
  • Film coated tablets containing rilpivirine 25mg, emtricitabine 200mg & tenofovir alafenamide (as fumarate) 25mg
  • To be used in accordance with NHS England Clinical Commissioning Policy.
05.03.01 Emtricitabine & Rilpivirine & Tenofovir disoproxil Eviplera®
  • Tablets: 200 mg / 25 mg / 245 mg
05.03.01 Emtricitabine & Tenofovir alafenamide Descovy®
  • Film coated tablets containing:
    • emtricitabine 200mg & tenofovir alafenamide (as fumarate) 10mg
    • emtricitabine 200mg & tenofovir alafenamide (as fumarate) 25mg
  • To be used in accordance with NHS England Clinical Commissioning Policy.
05.03.01 Emtricitabine & Tenofovir Disoproxil 
  • Tablets: Emtricitabine 200 mg and Tenofovir disoproxil (as fumarate) 245 mg

 

  • Use generic preparation in preference to the branded product (Truvada®)
13.02.01 Emulsifying Ointment BP 
02.05.05.01 Enalapril  
  • For use in breastfeeding mothers only. Breastfeeding mothers should be converted to ramipril when they are no longer breastfeeding. 
13.10.05 Enbucrilate 
  • See 13.10.05 skin tissue adhesives (Liquiband®, Liquiband Optima®, IndermilX-Fine, Histoacryl Blue®)
08.01.05 Encorafenib Braftovi®

  • Approved in combination with binimetinib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults in line with NICE

  • Approved in combination with cetuximab (Erbitux) for treating BRAF V600E mutation-positive metastatic colorectal cancer in adults who have had previous systemic treatment

05.03.01 Enfuvirtide 
02.08.01 Enoxaparin Inhixa®
  • approved for use in the treatment of acute coronary syndromes
  • VTE prophylaxis 

 

02.01.02 Enoximone 
  • As per licensed indication
  • Injection given orally. Approved for the treatment of severe heart failure in adults and children to wean from IV milrinone as a bridge to transplant and to reduce the need for ventricular assist devices (VADs) unlicensedunlicensed
04.09.01 Entacapone 
05.03.03.01 Entecavir 
15.01.02 Entonox® 

50% nitrous oxide and 50% oxygen mixture used for analgesia

08.01.05 Entrectinib Rozlytrek®
  • Approved for ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors in line with NICE
08.03.04.02 Enzalutamide 
  • Approved for use in adults with metastatic hormone-relapsed prostate cancer, who have not had chemotherapy in line with NICE.
  • Approved for treating hormone-sensitive metastatic prostate cancer in line with NICE
13.02.01 Epaderm® emollient 
  • Hydromol® Ointment is made to the same formula and is more cost effective.
02.07.02 Ephedrine 
  • 30mg in 1ml injection 
  • 30mg in 10ml syringe unlicensedunlicensed.
  • 15mg tablets.
12.02.02 Ephedrine 
  • 0.5% and 1% nasal drops.
03.01.01.02 Ephedrine Hydrochloride 
13.02.01 Epimax® 
08.01.02 Epirubicin  
  • Note: epirubicin 100mg injection is unlicensedunlicensed.
02.02.03 Eplerenone 
  • For use in post-acute myocardial infarction patients with left ventricular dysfunction and heart failure. Only to be used in patients who are unable to tolerate the estrogenic side effects of spironolactone. Treatment should only be on advice from a cardiologist.
09.01.03 Epoetin alfa Eprex®
  • Prefilled syringes (various strengths)
    • Approved for management of cancer treatment-induced anaemia in
      women receiving platinum-based chemotherapy for ovarian cancer
    • No longer regularly used in NUTH
09.01.03 Epoetin beta NeoRecormon®

  • Cartridges for use in RecopensPrefilled syringes


    • Approved for management of cancer treatment-induced anaemia
      in women receiving platinum-based chemotherapy for ovarian cancer.

    • No longer regularly used in NUTH.



  • Monitoring: monitoring of erythropeoetin (epoetin beta) in adult patients can be undertaken by GPs under a shared care arrangement Amber

09.01.03 Epoetin delta 
09.01.03 Epoetin theta 
09.01.03 Epoetin zeta 
02.05.01 Epoprostenol 
  • Approved for pulmonary hypertension - in accordance with NHS England Commissioning policy. 
02.08.01 Epoprostenol 
  • For pulmonary hypertension see section 2.5.1 
04.07.04.02 Eptinezumab Vyepti®
  • 100mg/1ml concentrate for solution for infusion
    • Approved for the prevention of chronic migraine in adults in line with NICE only if
      • they have 4 or more migraine days a month
      • at least 3 preventative drug treatments have failed
19 Eptotermin alfa Osigraft®
04.07.04.02 Erenumab Aimovig®
  • 70mg/1ml and 140mg/1ml solution for injection (pre-filled pens)
    • Approved for the prevention of chronic migraine in adults in line with NICE only if
      • they have 4 or more migraine days a month
      • at least 3 preventative drug treatments have failed

 

09.06.04 Ergocalciferol 
  • 250 microg. (10,000 units) & 1.25mg (50,000 units) tablets.
    • A 3000 units in 1ml suspension (unlicensedunlicensed) may be supplied if colecalciferol oral solution is not available.

  • 7.5mg (300,000 units) in 1ml injection.
07.01.01 Ergometrine Maleate 
  • Injection: 500 micrograms in 1ml
07.01.01 Ergometrine Maleate and Oxytocin Syntometrine®
  • Injection: ergometrine maleate 500micrograms and oxytocin 5 units
08.01.05 Eribulin Halaven®
  • Approved for the treatment of locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens  in accordance with NICE and NHS England Commissioning Policy
08.01.05 Erlotinib 
  • Also approved for second line use, as an alternative to docetaxel, in NSCLC in line with NICE.
  • Monotherapy not approved for maintenance after platinum chemotherapy in advanced or metastatic NSCLC NICE.
  • Approved for the treatment of locally advanced or metastatic nonsmall-cell lung cancer that has already been treated with non-targetted chemotherapy because of delayed confirmation of epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation status if; their cancer tests positive for EGFR-TK mutation; it is not know if the cancer is EGFR-TK mutation- positive because of problems with the test, and the cancer is very likely to be EGFR-TK mutation-positive and it responds to the first 2 cycles of treatment with erlotinib - in line with NICE.
05.01.02.02 Ertapenem 
06.01.02.03 Ertugliflozin 
  • Approved as monotherapy or with metformin for the treatment of type 2 diabetes in line with NICE

 

11.03.01 Erythromycin 0.5% Eye ointment 
13.06.01 Erythromycin 40mg with Zinc Acetate 1.2% topical solution Zineryt®
05.01.05 Erythromycin Injection 
  • Injection for infusion: 1g vial*
05.01.05 Erythromycin Oral Preparations 
  • Tablets: 250mg, 500mg
  • Oral suspension (sugar-free available): 125mg/5ml, 250mg/5ml, 500mg/5ml 
04.03.03 Escitalopram 
04.08.01 Eslicarbazepine 
  • Approved for use by specialists only in those patients for whom intolerance of carbamazepine is a major concern and when use of this agent is more cost effective than alternatives available.
02.04 Esmolol 
01.03.05 Esomeprazole 
06.04.04 Estradiol 1mg and 2mg tablets 
06.04.01.01 Estradiol patches/gel/spray 
  • Twice weekly matrix patches releasing approximately 25, 37.5 (Estradot® only), 50, 75 & 100 microgram/24 hours (Estradot®,Evorel®, Estraderm® MX);
  • Weekly matrix patches releasing approximately 25, 50, 75 & 100 microgram/24 hours (Femseven®);
  • Once weekly matrix patches releasing approx. 50 & 100 microgram estradiol/24 hours (Progynova TS®)
  • Estradiol 0.1% gel (Sandrena®)
  • Estradiol 0.06% gel (Oestrogel®) 
    • Approved for use in gender dysphoria therapy Green plus
    • Approved for use as hormone replacement therapy
  • Estradiol 1.53mg/spray transdermal spray (Lenzetto®)
    • Approved as an alternative to patches and gels for patients who have issues with absorption, find patch adhesive irritating or the gel messy

 

06.04.01.01 Estradiol tablets 
  • 1mg and 2mg tablets
06.04.01.01 Estradiol vaginal tablet 
  • 10mg vaginal tablet
    • Vagifem® 10mg vaginal tablets
    • Vagirux® 10mg vaginal tablets (alternative)


07.03.01 Estradiol valerate plus dienogest  Qlaira®
  • Each wallet (28 film-coated tablets) contains in the following order:
    2 dark yellow tablets each containing 3 mg estradiol valerate
    5 medium red tablets each containing 2 mg estradiol valerate and 2 mg dienogest
    17 light yellow tablets each containing 2 mg estradiol valerate and 3 mg dienogest
    2 dark red tablets each containing 1 mg estradiol valerate

  • Approved for
    • women who need HRT as well as contraceptive pill, and
    • for heavy menstrual bleeding (HMB)
08.01.01 Estramustine Phosphate  
07.02.01 Estriol  
  • The following topical estriol formulations are approved:
  • 0.01% cream (Gynest®) 80g;
  • 0.1% cream (Ovestin®)
10.01.03 Etanercept 

Prescribe by brand name.

  • Approved formulations include 10mg (Enbrel®) 25mg injection (Enbrel®, Benepali® & Erelzi®), 50mg injection (Enbrel®, Benepali® & Erelzi®). 
  • Approved for:
    • Treatment in adults with severe rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed in line with NICE.
    • Rheumatoid arthritis after the failure of a TNF inhibitor in line with NICE.
    • Psoriatic arthritis in accordance with NICE.
    • Treatment of severe active ankylosing spondylitis in adults whose disease has responded inadequately to, or who cannot tolerate, non-steroidal anti-inflammatory drugs in accordance with NICE.
    • The treatment of juvenile idiopathic arthritis (JIA) in people 2 years or older whose disease has responded inadequately to, or who are intolerant of methotrexate in line with NICE.
    • Treatment of Juvenile Scleroderma (Its use will be subject to informed consent and specialists using etanercept in this indication should collect data on patient outcomes. If after a six month trial, treatment were found to be beneficial, it would be continued for two years. If unsuccessful after six months, treatment should be discontinued).
    • People aged 2 years and older to treat polyarticular juvenile idiopathic arthritis (JIA) whose diease has responded inadequately to, or who are intolerant of methotrexate in line with NICE.
    • Treating moderate rheumatoid arthritis after conventional DMARDs have failed in line with NICE


13.05.03 Etanercept Enbrel®, Benapali® & Erelzi®
  • Approved for psoriasis in line with NICE
  • Approved for the treatment of plaque psoriasis in children and young people in line with NICE

 

Biosimilars are available – note that indications can differ between different products – prescribe by brand. Consult with individual trust pharmacy department for details of
preferred biosimilar brand.

09.05.01.02 Etelcalcetide Parsabiv®
  • 2.5mg/0.5ml, 5mg/1ml & 10mg/2ml solution for injection
  • Approved for the treatment of secondary hyperparathyroidism in line with NICE and NHS England Commissioning Policy
05.01.09 Ethambutol  
11.08.02 Ethanol 20% eye drops. 
  • For use in the debridement of the corneal epithelium in patients with
    recurrent corneal erosion syndrome.
02.13 Ethanolamine Oleate 
06.04.01.01 Ethinylestradiol 
  • Note: ethinylestradiol 2microgram tablets are unlicensedunlicensed.
07.03.01 Ethinylestradiol and drospirenone Eloine®
  • 20mcg ethinylestradiol and 3mg drospirenone
04.08.01 Ethosuximide 
15.02 Ethyl Chloride Spray 
10.01.01 Etodolac 
  • Capsules: 300mg
  • MR tablets: 600mg
15.01.01 Etomidate 20mg/10ml injection 
07.03.02.02 Etonorgestrel 68mg implant Nexplanon®
  • Replaces Implanon® and differs in that it is impregnated with radio opaque material.
08.01.04 Etoposide 
  • The following formulations are approved for use:
    • 50mg capsules & 100mg capsules;
    • 100mg in 5ml injections;
    • 500mg in 25ml injections.

10.01.01 Etoricoxib 
  • Tablets: 30mg, 60mg, 90mg, 120mg
01.05.03 Etrasimod Velsipity®
  • 2mg tablet
  • Approved for treating moderately to severely active ulcerative colitis in people aged 16 and over in line with NICE
05.03.01 Etravirine Intelence®
13.09 Eucerin 5% Dry Scalp Shampoo 
08.01.05 Everolimus Afinitor®, Votubia®
  • 2.5mg, 5mg & 10mg tablets (Votubia®)
    • Approved for the treatment of angiomyolipomas associated with tuberous sclerosis in accordnace with NHS England Commissioning Policy.
    • Approved for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in accordnace line with NHS England Commissioning Policy.
  • 5mg & 10mg tablets (Afinitor®)
    • Approved, in combination with exemestane, for the treatment of advanced human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor-positive breast cancer in postmenopausal women in accordance with NICE.
    • Approved for the treatment of advanced breast cancer after endocrine therapy in line with NICE.
    • Approved for the treatment of advanced renal cell carcinoma after previous treatment in line with NICE.
    • Approved for the treatment of unresectable or metastatic neuroendocrine tumours in people with progressive disease in line with NICE and NHS England Commissioning Policy
02.12 Evolocumab 
  • Approved for use in accordance with NICE guidance for treating primary hypercholesterolaemia.
  • Approved for the treatment of homozygous familial hypercholesterolaemia in line with NHS England Commissioning policy.
08.03.04.01 Exemestane 
06.01.02.03 Exenatide 
  • 5 microgram and 10 microgram per dose are prefilled injection pens containing a 250microgram/ml solution for subcutaneous injection.
    • Only approved for use in accordance with NICE guidance Treatment must be initiated by a consultant diabetologist and use is limited to overweight patients with type 2 diabetes in line with NICE guidelines.
  • 2.5mg/0.85ml prolonged-release suspension for injection
    • temporarily approved due to supply issues with semaglutide and dulaglutide (please refer to linked advice below)

 

02.12 Ezetimibe 
  • Only approved for use in accordance with NICE guidance.
  • For further information refer to NEELI

 

02.11 Factor IX 
02.11 Factor VIIa 
02.11 Factor VIII  
02.11 Factor VIII  
02.11 Factor XIII 
01.03.01 Famotidine 
11.08.02 Faricimab Vabysmo®
  • 120mg/1ml solution for injection
    • Approved for the treatment of diabetic macular oedema in adults in line with NICE
    • Approved for the treatment of wet age-related macular degeneration in line with NICE
10.01.04 Febuxostat Adenuric®
  • Approved for patients where allopurinol is not tolerated or contraindicated in line with NICE.
08.01.05 Fedratinib 

Capsule: 100 mg

 
Link  NICE TA 756: Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis
02.06.02 Felodipine 
  • M/R tablets: 2.5mg, 5mg, 10mg 
04.08.01 Fenfluramine Fintepla®

Oral solution: 2.2mg/mL

02.12 Fenofibrate 

For initiation in lipid clinic only in patients with combined hyperlipidaemias and severe hypertriglycerideamia.

04.07.02 Fentanyl 
  • 12, 25, 50, 75 & 100 microgram/hour transdermal patches Green Traffic Light
    • Prescribe by brand. Mezolar® has replaced Matrifen® as the first choice brand. Patients who currently use Matrifen® can continue to do so if managing well.
  • Fentanyl sublingual tablets (Abstral®) NoTGhdNC Red only for patients experiencing incident pain during radiotherapy, restricted to palliative care use only 
  • Fentanyl sublingual tablets (Abstral®) CD&TV Green plus for breakthrough / rescue pain relief in palliative care
  • nasal spray Red
    • approved for use in children during diamorphine shortage with appropriate local governance arrangements
15.01.04.03 Fentanyl 
  • 100 microgram in 2ml & 500 microgram in 10ml injections 
  • 2.5mg in 50ml (50 micrograms/ml) syringe unlicensedunlicensed 
09.01.01.02 Ferric Carboxymaltose 100ml in 2ml & 500mg in 10ml injections Ferinject®
  • For use as an alternative to iron dextran or iron sucrose. Approved for
    use by renal physicians, gastroenterologists and haematologists.
  • Unlicensed for use in children under 14 years of age. If used in this age-group, use should only be on the advice of a consultant with the informed consent of the patient and/or his/her parents/carers.
09.01.01.01 Ferric maltol 30mg hard capsules Ferracru®

  • For the treatment of iron deficiency anemia in patients with or without inflammatory bowel disease.

  • To be initiated by specialist in inflammatory bowel disease or iron deficiency anaemia 

19 Ferric Subsulphate (Monsel’s Soln) 50ml 
09.01.01.01 Ferrous Fumarate 
  • First Choice oral liquid iron preparation140mg in 5ml syrup (45mg iron/5ml).
  • 210mg tablets (68mg iron/tablet).
09.01.01.01 Ferrous Gluconate 

300mg tablets (35mg iron)

09.01.01.01 Ferrous Sulphate 
  • 200mg tablets (65mg iron).
07.04.02 Fesoterodine  
  •  MR Tablets - 4mg, 8mg
03.04.01 Fexofenadine 
13.10.05 Fibrin sealant (Artiss®) 
  • 2ml, 4ml & 10ml prefilled syringe.
  • For use in plastic surgery to close dead spaces, adhere skin graft, close simple wounds and stabilise bone grafts.
13.10.05 Fibrin sealant (Bioglue®) 
  • For use in neurosurgery and vascular surgery.
13.10.05 Fibrin sealant (Evicel® Human Fibrin Glue) 

2ml and 5ml kit

13.10.05 Fibrin sealant (Floseal® Matrix sealant) 
13.10.05 Fibrin sealant (Tisseel Lyo® Fibrin Glue) 
  • 2ml, 4ml & 10ml kit
  • Also approved for use in the treatment of mesh fixation in hernia repair.
02.11 Fibrinogen 
05.01.07 Fidaxomicin Dificlir®
  • 200mg tablets
  • Fidaxomicin 40mg/ml granules for oral suspension
    • Approved for use in the treatment of C. difficile. To be initiated on the recommendation of a consultant microbiologist.
01.05.03 Filgotinib Jyseleca®
  • 100mg and 200mg tablets
  • Approved for the treatment of moderate to severe active ulcerative colitis in line with NICE
10.01.03 Filgotinib Jyseleca®
  • Approved for treating moderate to severe rheumatoid arthritis in line with NICE

 

09.01.06 Filgrastim (G-CSF) Neupogen®, Ratiograstim®
  • Available as Neupogen (original brand) and Ratiograstim – a
    biosimilar product.
07.04.01.02 Finasteride 
  • Tablets: 5mg
06.04.02 Finasteride 5mg tablets 
06.04.04 Finasteride 5mg tablets 
02.02.03 Finerenone Kerendia®
  • Approved as an option for treating stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults - in line with NICE TA877:
    • add-on to optimised standard care; this should include, unless they are unsuitable, the highest tolerated licensed doses of:
      • angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) and
      • sodium–glucose cotransporter‑2 (SGLT2) inhibitors and
    • the person has an estimated glomerular filtration rate (eGFR) of 25 ml/min/1.73 m2 or more.
08.02.04 Fingolimod 

  • Approved for the treatment of highly active relapsing–remitting multiple sclerosis in line with NICE and NHS England Commissioning Policy.

  • Approved for patients who have progressed on glatiramer acetate and for those patients who are at high risk of progressive multifocal leukoencephalopathy (PML) in line with NHS EnglandClinical Commissioning Policy.

01.03 First choice regimen - eradication H.Pylori
  • The most current H.Pylori guidance and treatment regimens can be found here

 

 

18.03.04 Flaminal ® Hydro Gel  

Alginate with glucose oxidase and lactoperoxidase, for lightly to moderately exuding wounds                                                                  

18.03.04 Flaminal® Forte Gel 

Alginate with glucose oxidase and lactoperoxidase, for moderately to heavily exuding wounds                                                                  

02.03.02 Flecainide 
  • 50mg & 100mg tablets
  • 5mg in 1ml liquid unlicensedunlicensed. 
02.03.02 Flecainide Injection 
  • Injection: 150ml/15ml 
13.04 Flucinolone Acetonide 0.025% with Neomycin Sulphate 0.5% Synalar N®
05.01.01.02 Flucloxacillin Injection 
  • Injection: 250mg, 500mg, 1g
05.01.01.02 Flucloxacillin Oral Preparations 
07.02.02 Fluconazole 
05.02.01 Fluconazole Infusion 
  • IV infusion: 50mg/25ml, 200mg/100ml
05.02.01 Fluconazole Oral Preparations 
  • Capsules: 50mg, 150mg, 200mg
  • Oral solution: 50mg/5ml, 200mg/5ml 
05.02.05 Flucytosine 
  • 500mg tabletsunlicensedunlicensed.
  • 2.5g in 250ml IV infusion.
08.01.03 Fludarabine Phosphate  
  • Approved for the second line therapy of B-cell CLL in line with NICE.
  • Note: fludarabine is not approved for monotherapy in the first line treatment of CLL - this is in line with NICE.
06.03.01 Fludrocortisone 
13.04 Fludroxycortide  Haelan®
15.01.07 Flumazenil 
  • 500 microgram in 5ml injection
16 Flumazenil 
12.01.01 Flumetasone 0.02% with Clioquinol 1% ear drops 
  • Alternative choice compound antibacterial/corticosteroid ear drop.
11.04.01 Fluocinolone 190 microgram intravitreal implant 
  • Recommended as a possible treatment for people with chronic diabetic macular oedema who have an artificial lens in their eye if the implant is used in the eye with the artificial lens and their diabetic macular oedema has not got better with other treatments - in line with NICE.
  • Approved for the treatment of recurrent non-infectious uveitis in line with NICE
  • Approved for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy in line with NICE
  • Approved for treating chronic diabetic macular oedema in line with NICE

 

13.04 Fluocinolone Acetonide 0.025% Synalar®
  • Cream, ointment & gel
13.04 Fluocinolone acetonide 0.025% with clioquinol 3% Synalar C®
11.08.02 Fluorescein 
  • 2% minims eye drops
  • 1mg ophthalmic strips
  • Fluorets
  • 10% 5ml & 20% 5ml injections unlicensedunlicensed
11.04.01 Fluorometholone 0.1% Eye drops FML®
  • For use in patients who experience ocular hypertension with other corticosteroids – treatment to be initiated with the advice of an ophthalmologist.
08.01.03 Fluorouracil  
  • A fluorouracil 10mg in 0.4ml subconjunctival injection (unlicensedunlicensed) is also approved for use. 
  • FOLFIRINOX is approved for the management of selected patients with inoperable pancreatic cancer in patients with performance status 0-1.
13.08.01 Fluorouracil Efudix®

  • For the treatment of superficial malignant and premalignant skin lesions.

04.03.03 Fluoxetine 
  • 20mg capsules
  • 20mg dispersible tablets
    • first choice for patients unable to use the capsules
  • 20mg/5ml oral solution
04.02.01 Flupentixol 
04.02.02 Flupentixol Decanoate 
  • Green plus CNTW
  • Amber TEWV
10.01.01 Flurbiprofen 
08.03.04.02 Flutamide 
03.02.03 Fluticasone furoate & vilanterol Relvar Ellipta®
  • Fluticasone 22 microgram/dose & vilanterol 92 microgram/dose dry powder inhaler (DPI): Licensed for COPD and asthma.
  • Fluticasone 22 microgram/dose & vilanterol 184 microgram/dose dry powder inhaler (DPI): Licensed for asthma only.



 

12.02.01 Fluticasone furoate 27.5microgram/dose nasal spray Avamys®
  • Note: take care to avoid confusion with fluticasone propionate.
03.02 Fluticasone propionate Flixotide®
  • 50mcg/inhalation
  • Approved for asthma in children only
12.02.01 Fluticasone Propionate 400microgram/dose nasal drops Flixonase Nasule®
  • Note: take care to avoid confusion with fluticasone furoate.
12.02.01 Fluticasone Propionate 50microgram/dose nasal spray Nasofan®
  • Note: take care to avoid confusion with fluticasone furoate.
03.02 Fluticasone propionate and formoterol Flutiform®
  • 50/5mcg per puff
  • 125/5mcg per puff
  • 250/10mcg per puff



 

03.02 Fluticasone propionate and salmeterol Sereflo®
03.02 Fluticasone propionate and salmeterol Combisal®
  • Fluticasone 50microgram & salmeterol 25 microgram; fluticasone 125microgram & salmeterol 25 microgram; & fluticasone 250microgram & salmeterol 25 microgram (pMDI)
  • Approved for asthma in children only
03.02 Fluticasone propionate and salmeterol Seretide®
03.02 Fluticasone propionate and salmeterol Sirdupla®
03.02.03 Fluticasone, umeclidinium & vilanterol Trelegy Ellipta®
  • Fluticasone 92 microgram/dose, umeclinidium 65 microgram/dose & vilanterol 22 microgram/dose dry powder inhaler (DPI)

 

09.01.02 Folic Acid 
  • 400 microgram and 5mg tablets
  • 2.5mg in 5ml sugar-free syrup
  • 15mg in 1ml injection unlicensedunlicensed
  • 30mg in 2ml injection
06.05.01 Follitropin Alfa  
06.05.01 Follitropin delta Rekovelle®
  • Approved for patients at risk of ovarian hyper stimulation syndrome (OHSS).

 

16 Fomepizole 
  • 100mg in 20ml injection unlicensedunlicensed
02.08.01 Fondaparinux 
  • Approved for high risk orthopaedic surgery pateints and as an alternative to enoxaparin in accordance with NICE guidance.
09.06.07 Forceval® 
  • Capsules
    • For limited use as a vitamin and mineral supplement in patients with phenylketonuria The capsules are also approved as an oral supplement in burns patients with malnutrition or alcohol dependency and patients with major burns after discontinuation of IV therapy, and have also been approved for use in patients with severe anorexia nervosa. Treatment initiated with specialist advice.
  • Soluble
    • Approved for short term use in patients who are unable to swallow
      Forceval capsules.
13.07 Formaldehyde  
03.01.01.01 Formoterol  

 

    • 6 mcg & 12 mcg/puff breath actuated dry powder inhaler (DPI) - Turbohaler®



 

A2.02.01.02 Fortijuce®  
A2.01.03.03 Fortini 
A2.02.02.03 Fortisip  
05.03.01 Fosamprenavir 
04.06 Fosaprepitant 
  • For the prevention of chemotherapy induced nausea and vomiting (CINV) in high risk patients in accordance with North of England Cancer Network: CINV Guidelines in adult oncology and haematology patients
05.03.02.02 Foscarnet Sodium 
05.01.07 Fosfomycin 
  • 500mg capsules unlicensedunlicensed Red Traffic Light
  • 4g injections Red Traffic Light
  • 3g sachets: sachets can be initiated in primary care for the treatment of UTIs caused by multi-resistant organisms following advice from microbiology only. Most cost effective option to be used Green
04.09.01 Foslevidopa/foscarbidopa  Produodopa®
  • foslevidopa 240mg/foscarbidopa 12mg in 1ml solution for infusion
  • Approved for the treatment advanced Parkinson’s with motor symptoms in adults in line with NICE and NHSE Specialised Commissioning Policy
08.01.05 Fostamatinib 

100mg and 150mg film-coated tablets

Approved for use in accordance with the following NICE TAs or if the indication is funded from the Cancer Drugs Fund:

• NICE TA835: Fostamatinib for treating refractory chronic immune thrombocytopenia

Commissioner: NHS England

Only to be used in line with a current chemotherapy protocol from the North of England Cancer Alliance in line with the appropriate Network Site Specific Group’s clinical guidelines or chemotherapy algorithm

05.03.01 Fostemsavir Rukobia®
  • 600mg MR tablets
  • Approved for the treatment of multi-drug resistant HIV-1 infection in adults
18.08.08 Four layer systems  
  • Profore® Kit
  • Profore® Lite Kit
06.01.06 Freestyle Libre 2®  
  • Flash Blood Glucose Monitoring System 
  • Recommended for use only as per NTAG advice and NHS England Guidance.

 

06.01.06 Freestyle Libre 3®  
  • Flash Blood Glucose Monitoring System 
  • Use is limited to patients with a compantible insulin pump
    • To be prescribed/supplied by secondary care diabetes teams only

 

04.07.04.02 Fremanezumab Ajovy®
  • 225mg/1.5ml solution for injection (Pre-filled pens/syringes)
    • Approved for the prevention of chronic migraine in adults in line with NICE only if
      • they have 4 or more migraine days a month
      • at least 3 preventative drug treatments have failed


04.07.04.01 Frovatriptan 
08.03.04.01 Fulvestrant Faslodex®
13.05.02 Fumaric acid esters 
  • 30mg & 120mg tablets
02.02.02 Furosemide 
11.03.01 Fusidic Acid Fucithalmic®
13.10.01.02 Fusidic Acid 2% 
  • Cream and ointment
04.07.03 Gabapentin 
  • For use in the treatment of neuropathic pain
  • Gabapentin is also approved for hospital use  as an adjunct to other treatment in the management of peri/post-operative pain. Red Traffic Light unlicensedunlicensed
  • GPs should not be asked to prescribe gabapentin for this unlicensed indication.
  • Approved for intractable itch with severe burns Green plus

 

04.08.01 Gabapentin 
  • Note: gabapentin 250mg in 5ml is also approved unlicensedunlicensed.
06.01.05 Gabapentin 
  • Also approved for hospital use as an adjunct to other treatment in
    the management of peri/post-operative pain. Red
  • GPs should not be asked to prescribe gabapentin for this unlicensedunlicensed indication.
19 Gadobenate dimeglumine Multihance ®
  • for use in the differential diagnosis of liver disease
19 Gadobutrol Gadovist®
  • Gadolinium based MRI Contrast medium for use as an alternative to Magnevist®. One of the safer gadolinium contrast media with regard to the potential risk of nephrogenic systemic fibrosis.
17 Gadobutrol Gadovist® 
19 Gadofosveset Vasovist®
  • Gadolinium (MRI) contrast agent that binds to albumin for use
    in MRI angiograms
17 Gadoxetate Primovist® 
19 Gadoxetic acid Primovist®
  • Gadolinium based MRI Contrast medium for use in:
     The assessment of hepatic vascular structures and biliary system of potential living, related liver donors.
     The detection and characterisation of focal liver lesions using MRI, when standard imaging with other agents has been inconclusive.
  • The detection and characterisation of focal liver lesions which
    potentially communicate with the biliary system e.g. large liver
    cysts.
04.11 Galantamine 
  • Only approved for use in accordance with NICE guidance. 
  • The oral solution is only approved for limited short-term use in the management of hospital patients who are unable to swallow tablets/ capsules. It is not for use in patients whose dementia is so severe that they can no longer swallow tablets.
04.07.04.02 Galcanezumab Emgality®
  • 120mg/1ml injection
    • Approved for the prevention of chronic migraine in adults in line with NICE only if
      • they have 4 or more migraine days a month
      • at least 3 preventative drug treatments have failed



09.08.01 Galsulfase Naglazyme®
05.03.02.02 Ganciclovir 
11.03.03 Ganciclovir  Virgan®
  • 0.15% ophthalmic gel
19 Gastrografin 
  • A contrast medium for the radiological examination of the gastrointestinal tract
01.01.02 Gaviscon Infant 
  • Note: each half of the dual-sachet is identified as ‘one dose'.
    To avoid errors prescribe as ‘dual-sachet' with directions in
    terms of ‘dose'
08.01.05 Gefitinib  
  • Approved for first line use in locally advanced or metastatic NSCLC in line with NICE.
09.02.02.02 Gelatin Isoplex®
  • 4%succinylated gelatin infusion in a balanced electrolyte solution containing Na+ 145 mmol, K+ 4 mmol, Mg2+ 0.9 mmol, Cl- 105 mmol, lactate 25 mmol/litre.
    • Mainly for use in critical care areas and other situations where the perceived advantages of a balanced electrolyte plasma substitute are likely to be clinically important. Note Not yet cleared for use in NUTH.

09.02.02.02 Gelatin Volplex® or Gelofusine®
  • 4% succinylated gelatin infusion in sodium chloride 0.9% (500ml bags)
12.03.01 Gelclair® 
  • Trusts encouraged to prescribe enough between chemotherapy and radiotherapy appointments in secondary care in anticipation of mucositis developing.
08.01.03 Gemcitabine 

  • Approved in combination with paclitaxel for metastatic breast cancer in line with NICE. 

  • NECDAG approved for the second line treatment of women with partially platinum – sensitive, platinum resistant or platinum refractory advanced ovarian cancer (To be used when liposomal doxorubicin [Caelyx] is unavailable). 

  • Approved for pancreatic cancer in line with NICE. 

  • Approved for the treatment of recurrent ovarian cancer in line with NICE.

  • Approved in combination with capecitabine following surgery for pancreatic cancer in line with NHS England Clinical Commissioning Policy

07.01.01 Gemeprost 1mg pessaries 
08.01.05 Gemtuzumab ozogamicin Mylotarg®
  •  Approved for untreated acute myeloid leukaemia in line with NICE
19 Gentafleece®  
05.01.04 Gentamicin 
  • Approved for
    • For long term therapy in non-cystic fibrosis bronchiectasis usually in patients having > 3 exacerbations per annum with an organism identified as being sensitive to gentamicin.
    • Nebulised therapy for patients on assisted ventilation, patients with tracheostomies and those with persistant bacterial bronchitis 
05.01.04 Gentamicin 
  • 80mg in 2ml & 20mg in 2ml IV/IM injections
  • 5mg in 1ml intrathecal injection
  • bone cement & beads (for use in orthopaedic surgery) unlicensedunlicensed.
11.03.01 Gentamicin 0.3% ear/eye drops 
  • 1.5% eye drops with and with out preservative are also approved -  unlicensedunlicensed and Red Traffic Light
12.01.01 Gentamicin 0.3% ear/eye drops 
11.03.01 Gentamicin 15mg/ml 
13.11 Gigasept PA 
08.01.05 Gilteritinib Xospata®
  • Approved for relapsed or refractory FLT3-mutation-positive acute myeloid leukaemia in adults in line with NICE
09.08.02 Givosiran Givlaari®

  • Approved for treating acute hepatic porphyria (AHP) in adults and young people aged 12 and older in line with NICE, only if:

    • they have clinically confirmed severe recurrent attacks (4 attacks or more within 12 months) and

    • the company provides it according to the commercial arrangement.



08.02.04 Glatiramer Acetate 

  • Approved for treating multiple sclerosis in line with NICE and NHS Engand commissioning policy.

05.03.03.02 Glecaprevir & Pibrentasvir Maviret®

  • Approved for the treatment of chronic hepatitis C in line with NICE and NHS England Commissioning Policy.

06.01.02.01 Gliclazide 
  • 40mg & 80mg tablets

  • 30mg MR tablets
    • *Not to be prescribed for new patients*
    • Exisiting patients can continue until clinically appropriate to change in line with switch policy
06.01.02.01 Glimepiride 
06.01.02.01 Glipizide 
08.01.05 Glofitamab Columvi®
  • 2.5mg and 10mg concentrate for solution for infusion
  • Approved for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments in line with NICE and NHSE Specialised Commissioning guidance
06.01.04 Glucagon 
  • GlucaGen® Hypokit - 1mg powder and solvent for solution for injection Green

 

  • Ogluo® - 500mcg/0.1ml & 1mg/0.2ml solution for injection (pre-filled pens) Green plus
    • To be used in accordance with Medicine Supply Notification (MSN/2023/051U) due to supply issues with GlucaGen® Hypokit
16 Glucagon GlucaGen® Hypokit
08.01 Glucarpidase  
  • Approved for the urgent treatment of methotrexate-induced renal
    dysfunction.
09.02.02.01 Glucose  
  • 5% IV infusion (100ml, 250ml, 500ml & 1000ml)
  • 10% IV infusion (500ml & 1000ml)
  • 20% IV infusion (500ml)
  • 50% Injection (50ml)
A2.07 Glucose 
06.01.04 Glucose 5%, 10%, 25% & 50% 
06.01.04 Glucose 40% Oral Gel GlucoGel®
13.07 Glutaraldehyde 10% paint Glutarol®
A2.06.01 Gluten Free Products 
01.06.02 Glycerol (Glycerin) 
02.06.01 Glyceryl Trinitrate 

 

    • 400 microgram/metered dose spray Green Traffic Light.   
      5mg & 10mg/day patches - for use in cardiothoracic critical care unit.Red Traffic Light.

 

07.01.04 Glyceryl trinitrate 
  • Spray: 400micrograms/dose
16 Glyceryl Trinitrate 
01.07.04 Glyceryl Trinitrate 0.4% ointment  Rectogesic®
  • 0.2% also available unlicensedunlicensed.
02.06.01 Glyceryl Trinitrate Injection 
  • 5mg in 5ml , 50mg in 10ml & 50mg in 50ml injections 

 

07.04.04 Glycine 1.5% solution 
  • 1.5% large volume solutions (up to 3 litres).
19 Glycopyrrolate 0.5% in Cetomacrogol A 
13.12 Glycopyrrolate 1% cream 
  •  To be initiated by specialist.
03.01.02 Glycopyrronium Seebri Breezhaler®

 

    • 44microgram (equivalent to 55 micrograms of glycopyrronium bromide) powder capsule with device (DPI)



 

03.01.04 Glycopyrronium & formoterol Bevespi Aerosphere®

 

    • Glycopyrronium 7.2 microgram/dose & formoterol 5 microgram/dose (equivalent to Glycopyrronium (as Glycopyrronium bromide) 7.2 microgram /dose & formoterol fumarate dihydrate 5 microgram/dose) pressurised metered dose inhaler - (pMDI)



 

01.02 Glycopyrronium bromide 
  •  1mg/5mL oral solution sugar free
    • Approved for the first line treatment of uncontrolled oral/respiratory secretions/sialorrhoea in Motor Neurone Disease/Home Ventilation patients who have cognitive impairment.
    • Approved for second line treatment of uncontrolled oral/respiratory secretions/sialorrhoea in Motor Neurone Disease/Home Ventilation  patients who have failed other treatment options such as hyoscine patches or who have intolerance to other agents.
  • 2mg/5ml oral solution (Sialanar®)
    • approved for the treatment of severe sialorrhoea in children and adolescents with chronic neurological disorders.
15.01.03 Glycopyrronium injection 
03.01.04 Glycopyyronium & indacaterol  Ultibro Breezhaler®

 

    • Glycopyrronium 43 microgram/dose & indacaterol 85 microgram/dose (equivalent to glycopyrronium bromide 54 microgram/dose & indacaterol maleate 85 microgram/dose) inhalation powder capsules (DPI)



 

01.05.03 Golimumab 
  • Only approved for use in accordance with NICE guidance. 
10.01.03 Golimumab Simponi®
  • Approved for:
    • Rheumatoid arthritis in accordance with NICE.
    • Psoriatic arthritis in accordance with NICE.
    • The treatment of severe active ankylosing spondylitis in adults whose disease has responded inadequately to, or who cannot tolerate, non-steroidal anti-inflammatory drugs in accordance with NICE.
    • Treatment in adults with severe rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed in accordance with NICE.
    • The treatment of non-radiographic axial spondyloarthritis in accordance with NICE

 

06.05.01 Gonadorelin 100microgram in 1ml 
06.07.02 Goserelin 
  • The following goserelin formulations are approved for use 3.6mg & 10.8mg injections (also see section 8.3.4.2). 
  • Note: leuprorelin is now substantially less expensive than goserelin
08.03.04.02 Goserelin 
  • Approved formulations include 3.6mg and 10.8mg implants.
06.04.04 Goserelin 3.6mg injection 
04.06 Granisetron 
03.04.02 Grass and Tree Pollen Extract Pollinex Quattro®
  • For use in adults and children by adult and paediatric immunologists only.
  • Less injections than with conventional Pollinex®
03.04.02 Grass and Tree Pollen Extract Pollinex®
  • For use in adults and children by adult and paediatric immunologists only.
03.04.02 Grass pollen extract Grazax®
05.02.05 Griseofulvin 
  • For very limited use where terbinafine is contraindicated.
09.04 Growth Faltering in Primary Care 
04.04 Guanfacine Intuniv®
  • 1mg, 2mg, 3mg & 4mg prolonged release tablets
    • Approved for use in children and adolescents when 1st line stimulants and atomoxetine are contraindicated or ineffective.
    • Can also be prescribed in primary care by GPs in adults who started treatment in childhood and wish to continue, for whom stimulants are not suitable, not tolerated or have been shown to be ineffective under specialist supervision

 

10.01.03 Guselkumab  Tremfya
  • 100 mg/1 mL as a pre-filled syringe
  • Approved (alone or with methotrexate) for treating active psoriatic arthritis after inadequate response to DMARDs in line with NICE

Overview | Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs | Guidance | NICE

13.05.03 Guselkumab Tremfya®
  • 100mg/1mL solution for injection
  • Approved for the treatment of moderate to severe plaque psoriasis in line with NICE

 

13.12 Haem-agglutinin complex 
  • For limited use as an alternative to surgery in some patients.
14.04 Haemophilus influenzae type B 
14.04 Haemophilus Influenzae type b & Meningococcal Group C Conjugate vaccine 
01.07.01 Haemorrhoid relief ointment 
  • Self Care Self Care Medicine: Advise that a prescription for treatment of haemorrhoids should not routinely be offered in primary care as the condition is self-limiting and will clear up on its own without the need for treatment.
04.02.01 Haloperidol 
  • Green Palliative Care
04.02.02 Haloperidol Decanoate 
  • Green plus CNTW
  • Amber TEWV
09.02.02.01 Hartmann’s solution (compound sodium lactate) 

Infusion: 500ml, 1000ml

15.01.02 Heliox21® 
02.08.01 Heparin 
02.08.01 Heparin 
  • 50 units in 5ml & 200 units in 2ml – for flushing cannulae
14.04 Hepatitis A vaccine 
14.04 Hepatitis A vaccine with Hepatitis B vaccine  Twinrix®
14.05.02 Hepatitis B immunoglobulin Hepatect CP®
14.05.02 Hepatitis B immunoglobulin HBIG
  • 200 international units - for infant use 
14.04 Hepatitis B vaccine 
11.03.01 Hexamidine 

UNLICENSED

12.03.04 Hexetidine 0.1% mouthwash 
13.10.05 Histoacryl Blue® 
11.08.02.04 Holoclar® 
  • Approved for treating limbal stem cell deficiency after eye burns in line with NICE and NHS England Commissioning Policy as of 14 November 2017
18.08.02 Hospilite® 

Cotton, Polyamide and Elastane Bandage

03.04.02 House dust mite allergen immunotherapy Acarizax®

  • 12 SQ-HDM oral lyophilisates

    • Approved for the treatment of house dust mite allergy.

    • Licensed alternative to Oralvac®



09.02.02.02 Human Albumin Solution 
  • 4.5% (50ml, 100ml & 500ml)
  • 20% (50ml & 100ml)
09.08.02 Human Arginate 
14.04 Human papilloma virus (HPV) vaccine 

 

 

07.02.01 Hyalofemme® water-based intimate lubricant 

  • For restricted use for the relief of symptoms of atrophic vaginitis, in women who have had treatment for gynaecological malignancyand where topical estriol is not a treatment option

12.03.01 Hyaluronan 
  • 0.2% gel and 0.025% mouthwash.
  • For limited second-line use on specialist advice in the treatment of
    orofacial granulomatosis, severe oral ulceration and mucositis secondary
    to immunosuppression where conventional treatments are unsuitable or
    have failed.
19 Hyaluronic Acid Hydrafil Softline Max®
19 Hyaluronic Acid - Perlane Restylane Perlane®
19 Hyaluronic Acid - Sub Q Restylane Sub Q ®
10.03.01 Hyaluronidase Hyalase®
02.05.01 Hydralazine 
  • Tablets - 25mg, 50mg
02.05.01 Hydralazine Injection 
  • Ampoules: 20mg
06.03.02 Hydrocortisone 

  • 10mg/5ml oral solution

06.03.02 Hydrocortisone 
  • 10mg and 20mg tablets Green
  • 2.5mg buccal tablets Green
  • 10mg in 5ml suspension unlicensedunlicensed.Green


10.01.02.02 Hydrocortisone acetate 25mg in 1ml injection 
06.03.02 Hydrocortisone sodium phosphate Efcortesol®
  • 100mg/ml solution for injection
  • As an additional option to hydrocortisone sodium succinate for patients who are steroid dependent (pituitary or adrenal cause and occasionally non-endocrine reasons for long term steroid use) to manage sick day rules to avoid an Addisonian crisis.
  • Paraesthesia and pain may follow intravenous injection.
06.03.01 Hydrocortisone sodium succinate 
13.04 Hydrocortisone 0.5%, 1% & 2.5% 
  • Cream and ointment
12.01.01 Hydrocortisone 1% Neomycin 0.439% & Polymixin B sulphate 10,000iu/ml ear drops Otosporin®
  • Alternative choice compound antibacterial/corticosteroid ear drop.
13.04 Hydrocortisone 1% with Clotrimazole 1% Canesten HC®
  • Cream 30g
  • 15g available Over the Counter.
13.04 Hydrocortisone 1% with Miconazole Nitrate 2% Daktacort®
  • Cream 30g (15g available Over the Counter) and Ointment 30g
13.04 Hydrocortisone 1%, Oxytetracycline 3%  Terra-Cortril ®
06.03.01 Hydrocortisone 10 mg, and 20mg tablets 
  • Hydrocortisone 10mg in 5ml suspension is also approved for use. unlicensed unlicensed
12.03.01 Hydrocortisone 2.5mg Lozenges 
13.04 Hydrocortisone Acetate 1% with Fusidic Acid 2% Fucidin H®
12.01.01 Hydrocortisone Acetate 1% with Gentamicin 0.3% Gentisone® HC
  • First choice compound antibacterial/corticosteroid ear drop.
13.04 Hydrocortisone Butyrate 0.1% cream Locoid®
06.03.02 Hydrocortisone Granules Alkindi®

0.5mg, 1mg, 2mg & 5mg

  • approved for treatment of adrenal insufficiency in infants, children and adolescents 
  • patients should be transitioned onto tablets once they are able to take them

 

18.02.02 Hydrofilm® Plus 
  • Primary care only
13.11.06 Hydrogen Peroxide Solution BP 
  • 10 volume (3%) & 20 volume (6%) solutions.
13.02.01.01 Hydromol® bath and shower 
  • For inpatient use only as per Trust Moisture-Associated Tissue Damage (MASD) guidelines
13.02.01 Hydromol® ointment 
  • This product is also known locally as ‘Emulsifying Ointment RVI
    Formula’. It is softer than emulsifying ointment BP. Epaderm ointment is
    made to the same formula, but is more expensive.
04.07.02 Hydromorphone 
13.02.01 Hydrous® ointment 
16 Hydroxocobalamin Cyanokit®
09.01.02 Hydroxocobalamin 1mg in 1ml injection 
08.01.05 Hydroxycarbamide  
10.01.03 Hydroxychloroquine 

 

 

13.05.03 Hydroxychloroquine 
03.04.01 Hydroxyzine 
11.08.01 Hylo Night® 
  • Eye ointment (containing retinol palmitate (vitamin A) 250iu/g, white soft paraffin, light liquid paraffin, liquid paraffin and wool fat)
01.02 Hyoscine Butylbromide Buscopan®

  • First choice for respiratory secretions

04.06 Hyoscine Hydrobromide 
  • For the management of excessive secretions where tablets are unsuitable.
15.01.03 Hyoscine Hydrobromide 400microgram injection 
18.07.03 Hypafix® 

Permeable, Apertured Non-Woven Synthetic Adhesive Tape, BP 1988

03.07 Hypertonic sodium chloride 7% Nebusal®
11.08.01 Hypromellose 
  • 0.3% eye drops
  • 0.3% preservative-free eye drops:
    • 1st line Tear-Lac®;
    • 2nd line PF Drops® 
      • treatment to be initiated on the advice of ophthalmologist only
06.06.02 Ibandronic Acid  

  • Ibandronic acid 50mg tablets are approved for use in the reduction of bone damage in patients with metastatic breast cancer. Not approved for use in the treatment of patients with other forms of cancer (e.g. prostate). Green plus  

  • Ibandronic acid 150mg tablets are approved for the treatment of osteoporosis in line with NICE Green

  • Ibandronic acid 3mg in 3ml injection is approved for use where oral bisphosphonates are not appropriate (not tolerated, contra-indicated because of upper gastro-intestinal problems or insufficiently effective) Red

08.01.05 Ibrutinib Imbruvica®
  • Approved for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation in line with NICE and NHS Commissioning Policy.
  • Approved for treating relapsed or refractory mantle cell lymphoma in line with NICE and NHS England Commissioning Policy if:
    • they have had only 1 previous line of therapy
  • Approved for untreated chronic lymphocytic leukaemia in line with NICE
04.07.01 Ibuprofen 
04.07.04.01 Ibuprofen 
10.01.01 Ibuprofen 

Tablets: 200mg, 400mg, 600mg
Suspension (sugar-free available): 100mg/5mL 

02.14 Ibuprofen 10mg injection Pedea®
  • Approved only for use when there is a supply problem with indometacin.
10.03.02 Ibuprofen gel 
07.01.01.01 Ibuprofen Injection Pedea®
  • 10mg/2ml ampoule
03.04.03 Icatibant Firazyr®

  • For use on the advice of immunologist in the treatment hereditary angioedema associated with C1-esterase inhibitor.

13.05.01 Ichthammol 
02.12 Icosapent ethyl Vazkepa®
  • 998mg capsules
  • Icosapent ethyl is recommended as an option for reducing the risk of cardiovascular events in adults. It is recommended if they have a high risk of cardiovascular events and raised fasting triglycerides (1.7 mmol/litre or above) and are taking statins, but only if they have:
    • established cardiovascular disease (secondary prevention), defined as a history of any of the following:
      • acute coronary syndrome (such as myocardial infarction or unstable angina needing hospitalisation)
      • coronary or other arterial revascularisation procedures
      • coronary heart disease
      • ischaemic stroke
      • peripheral arterial disease, and
    • low-density lipoprotein cholesterol (LDL‑C) levels above 1.04 mmol/litre and below or equal to 2.60 mmol/litre
08.01.02 Idarubicin 
  • Approved formulations include:
    • 5mg and 10mg capsules;
    • 10mg injection.

02.08 Idarucizumab 
  • Approved for use as a rapid reversal agent for dabigatran.
08.01.05 Idelalisib  
  • Approved in combination with rituximab for the treatment of:
    • Untreated chronic lymphocytic leukaemia in adults with a 17p deletion or TP53 mutation; NICE or
    • Chronic lympocytic leukaemia in adults when the disease has been treated but has relapsed within 24 months NICE.

 

09.08.01 Idursulfase 
08.01.01 Ifosfamide  
02.05.01 Iloprost  
  • Approved for pulmonary hypertension - in accordance with NHS England Commissioning policy. 
02.08.01 Iloprost 
  • Mainly for use in treating pulmonary hypertension - see secton 2.5.1 
08.01.05 Imatinib  
  • Approved for the first-line management of people with KIT (CD117)- positive unresectable and/or KIT (CD117)-positive metastatic gastrointestinal stromal tumours (GISTs) in line with NICE. 
  • Approved for the adjuvant treatment of gastrointestinal stromal tumours (GISTs) after surgery when there is a high risk relapse of tumour NICE. 
  • Approved for Philadelphia-chromosome-positive CML in the accelerated phase or with blast crisis in line with NICE.
  • A standard-dose imatinib is recommended as an option for the first-line treatment of adults with chronic phase Philadelphia-chromosomepositive CML in line with NICE.
09.08.01 Imiglucerase Cerezyme®
  • 400iu injection
05.01.02.02 Imipenem with Cilastatin & Relebactam Recarbrio®

  • Imipenem 500 mg,  Cilastatin 500 mg & Relebactam 250 mg powder for solution for infusion

    • Approved for the treatment of multi-resistant gram-negative infections ONLY on the advice of microbiologists



04.03.01 Imipramine 
04.07.04.02 Imipramine 
07.04.02 Imipramine  
  • 10mg and 25mg tablets
  • 25mg in 5ml syrup is also approved. unlicensedunlicensed.
13.08.01 Imiquimod  Zyclara®
13.07 Imiquimod 5% cream Aldara®
  • Second line specialist use for treatment of ano-genital warts (mainly in genitourinary medicine [GUM] clinics).
  • Green For the management of actinic keratosis.
13.07 Imiquimod  
08.01.05 Imlifidase Idefirix®
  • 11mg powder for concentrate for solution for infusion
  • Approved for desensitisation treatment before kidney transplant in people with chronic kidney disease in line with NICE and NHSE Commissioning Policy
18.03.02 Inadine® 

Knitted viscose primary dressing impregnated with povidone-iodine ointment

 

02.12 Inclisiran Leqvio®

  • 284mg/1.5ml solution for injection pre-filled syringes

    • Approved for the treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet in adults in line with NICE. 




02.02.01 Indapamide 2.5mg tablets 
  • First choice for new patients
  • Modified release (MR) indapamide tablets are NON FORMULARY.
13.10.05 Indermil X-Fine® 
19 Indigo Carmine 
05.03.01 Indinavir 
11.08.02 Indocyanine green 

25mg injection.

10.01.01 Indometacin 
  • Capsules: 25 mg, 50 mg
  • SR Capsules: 75 mg
  • Suppositories: 100 mg
02.14 Indometacin 1mg injection 

unlicensedunlicensed

13.11.01 Industrial Methylated Spirit BP 

70% liquid & 70% spray

13.11.03 Infacare Baby Bath Additive 
  • Secondary care use only
01.05.03 Infliximab Remicade®, Inflectra®, Remsima®
  • Only approved for use in accordance with NICE guidance.
  • Prescribe by brand only.  

 

10.01.03 Infliximab Remsima®, Inflectra®, Remicade®
  • Approved for:
    • Treatment in adults with severe rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs have failed in accordance with NICE.
    • Rheumatoid arthritis after the failure of a TNF inhibitor in line with NICE.
    • Psoriatic arthritis in accordance with NICE.
    • JIA in patients who have not responded to etanercept.
    • Juvenile dermatomyositis and paediatric onset Behcet’s disease where there has been intolerance or lack of response to 1st and 2nd line therapies.
    • The treatment of severe active ankylosing spondylitis in adults whose disease has responded inadequately to, or who cannot tolerate, non-steroidal anti-inflammatory drugs in accordance with NICE.
    • Treating moderate rheumatoid arthritis after conventional DMARDs have failed in line with NICE
    • Refractory sarcoidosis (excluding neurosarcoidosis) in adults in line with NHSE Specialised Commissioing Policy 


  • Prescribe by brand name; Remsima®, Inflectra®, Remicade®. 

 

13.05.03 Infliximab Remsima®, Inflectra®, Remicade®

  • Approved for psoriasis in line with NICE.

19 Infloran® 
14.04 Influenza vaccine  
04.12 Inotersen  Tegsedi®

  • Approved as an option for treating stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis in line with NICE

08.01.05 Inotuzumab ozogamicin Besponsa®

  • Approved for treating relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia in adults in line with NICE

06.01.01.01 Insulin Humulin® S
  • Approved formulations of Humulin® S include:
    • 10ml vials;
    • 5x3ml cartridges.

06.01.01.01 Insulin Actrapid®
  • Human Actrapid® 10ml vial approved. 
06.01.01.01 Insulin Aspart  NovoRapid® Trurapi®
  • Approved formulations for Novorapid® include:
    • 10ml vial;
    • 5x3ml cartridge (for use with Novopen and Novopenmate devices);
    • 5x3ml Flexpen®.
  • Approved formulations for Trurapi® include:
    • 100 units/ml 10ml vial
    • 100 units/ml cartridge
    • 100 units/ml pre-filled pen

Trurapi = BLACK TRIANGLE

06.01.01.01 Insulin Aspart Fiasp®

  • Approved formulations for Fiasp® include:


    • 10ml vial;

    • 5x3ml cartridge;

    • 5x3ml FlexpTouch pen®.



06.01.01.02 Insulin degludec  Tresiba®

  • 100 units/mL only

  • Pre-filled pen and cartridges

  • Approved for use in patients with Type 1 diabetes with


    • Nocturnal/Severe Hypogycaemia (with or without hypoglycaemic unawareness) in patients who would otherwsie progress to insuling pump treatment as per NICE TA151); or

    • Recurrent DKA episodes despite good compliance and who would otherwise progress to insulin pump therapy

    • Paediatric patients who cannot tolerate glargine sting

    • Paediatric patients with poor control on the high HbA1c pathway

    • Patients or Parents/Carers with unpredictable lifestyles such as students or shift workers.



06.01.01.02 Insulin Detemir Levemir®
  • Alternative choice long acting basal insulin.
  • Approved Levemir® formualtions include:
    • 5x3ml cartridges;
    • 5x3ml pens. 

06.01.01.02 Insulin Glargine Lantus®
  • Alternative choice long acting basal insulin. 
  • Approved Lantus® formulations include:
    • 10ml vials;
    • 5x3ml cartridges;
    • 5x3ml pens (Solostar® - in line with NICE). 
06.01.01.02 Insulin Glargine  Toujeo®
  • Alternative choice long acting basal insulin.
  • Approved Toujeo® formulations include:
    • 3x1.5ml pen (Solostar®).

06.01.01.02 Insulin Glargine biosimilar Abasaglar® 
  • First choice long acting basal insulin in patients eligible for treatment in line with NICE and NTAG
  • Approved Abasaglar® formulations include:
    • 5x3ml cartridge
    • 5x3ml Kwikpen®.

06.01.01.01 Insulin Glulisine Apidra®
  • Approved Apidra® formulations include:
    • 10ml vials;
    • 5x3ml cartridges
    • 5x3ml Solostar® pens.

06.01.01.01 Insulin Human 500 units in 1mL Humulin R®

  • Humulin R 500units in 1ml (10ml vial) approved for a very small number of insulin resistant patients that require very high doses of insulin. 

06.01.01.01 Insulin Lispro 100 units/ml Humalog®
  • Approved formulations for Humalog 100 ® include:
    • 10ml vial;
    • 5x3ml cartridge;
    • 5x3ml Kwiikpen®.
  • Prescriptions need to be written as Insulin Lispro Sanofi® or Humalog® to avoid prescribing/dispensing errors.
  • Note that there are two strengths of Humalog® (insulin lispro). Caution should be exercised when prescribing and dispensing
06.01.01.01 Insulin Lispro 200 units/ml Humalog®
  • 200 units per ml
  • Approved formulations for Humalog 200® include the 5x3ml Kwikpen®.
  • Note that there are two strengths of Humalog® (insulin lispro). Caution should be exercised when prescribing and dispensing
06.01.01.01 Insulin Lispro Sanofi 
  • 100units /ml
  • 10ml vial 3ml cartridges (for AllStar Pro and JuniorSTAR pen), 3ml SoloStar prefilled pen
  • Prescriptions need to be written as Insulin Lispro Sanofi® or Humalog® to avoid prescribing/dispensing errors. Insulin lispro biosimilar
19 Integuseal® IS 100 
08.02.04 Interferon Alfa-2b 
08.02.04 Interferon Alfa-2b Roferon-A®
08.02.04 Interferon Beta Avonex®
08.02.04 Interferon Beta Rebif®
08.02.04 Interferon Beta Betaferon®
08.02.04 Interferon beta Extavia®
16 Intralipid 
07.03.04 Intra-uterine Contraceptive Devices 

First choice

  • TT380 Slimline® Intrauterine device – replacement every 10 years.
  • Mini TT380 Slimline® Intrauterine device – replacement every 5 years.
  • T-Safe Cu380A® Intrauterine device – replacement every 10 years.

Alternatives

  • Nova T 380® Intrauterine device – replacement every 5 years.
07.03.02.03 Intra-uterine Progestogen Only System Mirena®
  • Levonorgestrel 52mg in a T-shaped intra-uterine system. 
  • For idiopathic menorrhagia. Especially in women requiring (reversible) contraception. Also used for protection from endometrial hyperplasia during oestrogen replacement therapy. Lasts for up to 5 years - for use in accordance with agreed guidelines.
07.03.02.03 Intra-uterine Progestogen Only System Levosert®
  • Levonorgestrel 52mg in a T-shaped intra-uterine system. 
  • For idiopathic menorrhagia. Especially in women requiring (reversible) contraception. Also used for protection from endometrial hyperplasia during oestrogen replacement therapy. Lasts for up to 6 years - for use in accordance with agreed guidelines.



 

07.03.02.03 Intra-uterine Progestogen Only System Jaydess®
  • Levonorgestrel 13.5mg in a T-shaped intra-uterine system. 
    Low dose long acting reversible contraceptive. Lasts for up to 3 years - not recommended as first line for nulliparous women.
07.03.02.03 Intra-uterine Progestogen Only System Kyleena®

  • Levonorgestrel 19.5mg intra-uterine system. 
    Low dose long acting reversible contraceptive. Lasts for up to 5 years 

06.02.02 Iodine Lugol's® Iodine
  • Oral solution containing 130mg total iodine/ml (5% iodine & 10% potassium iodide).
18.03.02 Iodoflex® 

Iodine 0.9% as cadexomer-iodine in a paste basis with gauze backing

  • Specialist use only
18.03.02 Iodosorb® Ointment 

Iodine 0.9% as cadexomer-iodine in an ointment basis

  • Specialist use only
17 Iohexol Omnipaque® 
17 Iopamidol (Niopam®) 
17 Iopamidol Gastromiro® 
06.02.02 Iopanoic acid 
  • Approved for use in rapid blockade of thyrotoxicosis in otherwise medically resistant patients prior to surgery/thyroidectomy.
08.01.05 Ipilimumab Yervoy®
  • Approved for previously treated advanced melanoma in line with NICE.
  • Approved for previously untreated advanced melanoma in line with NICE.
  • Approved in combination with nivolumab for untreated renal cell carcinoma in line with NICE.
06.01.06 i-Port Advance®  
  • Recommended for use only as per NTAG advice and NHS England Guidance.

 

12.02.02 Ipratropium Bromide 21 microgram/puff nasal spray Rinatec®
03.01.02 Ipratropium Nebules 
  • 250 microgram/1ml & 500 microgram/1ml nebuliser liquid



 

02.05.05.02 Irbesartan 
  • Only to be used in the treatment of exisiting patients. 
08.01.05 Irinotecan Hydrochloride  
09.01.01.02 Iron Dextran 100ml in 2ml and 500mg in 10ml injections 
09.01.01.02 Iron Isomaltoside 1000mg in 10ml injection Monofer®
09.01.01.02 Iron Sucrose 100mg in 5ml injection Venofer®
08.01.05 Isatuximab 

20mg/mL concentrate for solution for infusion.

Approved for use in accordance with the following NICE TAs or if the indication is funded from the Cancer Drugs Fund:

• NICE TA658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma

Not approved in accordance with the following NICE TAs:

• NICE TA727: Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)

Commissioner: NHS England

Only to be used in line with a current chemotherapy protocol from the North of England Cancer Alliance in line with the appropriate Network Site Specific Group’s clinical guidelines or chemotherapy algorithm.

05.02.01 Isavuconazole Cresemba®
  • Approved for use in line with licensed indications and specifically in solid organ transplant and bone marrow transplant recipients.
15.01.02 Isoflurane 
05.01.09 Isoniazid Injection 
  • 50mg in 2ml injection
05.01.09 Isoniazid Oral Preparations 
  • 50mg & 100mg tablets
  • 50mg in 5ml elixir unlicensedunlicensed
06.01.01.02 Isophane Insulin Insulatard®
  • Approved Insulatard® formulations include:
    • 10ml vial;
    • 5x3ml cartridges (for use with Novopen® and Novopenmate® devices);
    • 5x3ml Innolet® pens. 

06.01.01.02 Isophane Insulin Humulin® I
  • Approved Humulin® I formulations include:
    • 10ml vials;
    • 5x3ml cartridges;
    • 5x3ml pens. 

02.07.01 Isoprenaline 
13.11.01 Isopropyl alcohol 70% Skin Preparation Swabs Sterets®
16 Isosorbide dinitrate 
02.06.01 Isosorbide Dinitrate 10mg in 10ml injection 
02.06.01 Isosorbide Mononitrate 10mg, 20mg and 40mg tablets, and 60mg MR tablets 
  • 10mg, 20mg and 40mg tablets
  • 60mg MR tablets - should only be used in patients when the non-modified release tablets are unsuitable Restricted Item
13.06.02 Isotretinoin capsules 
  • 5mg, 10mg, 20mg & 40mg capsules
  • Isotretinoin is a toxic drug only to be prescribed by or under the supervision of a consultant dermatologist – see BNF and product literature.
  • Drug Safety Updates can be found via the following link:
01.06.01 Ispaghula Husk 
05.02.01 Itraconazole Infusion 
  • 250mg in 25ml injection for IV infusion 
05.02.01 Itraconazole Oral Preparations 
  • 100mg capsules 
  • 50mg in 5ml oral solution 
02.06.03 Ivabradine 
  • Angina - for intiation on advice from a consultant cariologist in patients with contra-indications to or intolerance of beta-blockers.
  • Heart failure  - approved for use in accordance with NICE guidelines.
03.07 Ivacaftor 
  • Approved for the treatment of cystic fibrosis in patients who have a faulty mutation in the CFTR gene in line with NHS England Clinical Commissioning Policy. 
  • Only available from:
    • South Tees Hopsitals NHS Foundation Trust
    • The Newcastle upon Tyne Hospitals NHS Foundation Trust
05.05 Ivermectin 
  • Unlicensed Oral formulations - 3mg tablets
  • Chronic strongyloides infection; cutaneous larva migrans;
13.10.04 Ivermectin 
  • 3mg tablets 
    • Approved for the treatment of scabies in accordance with DHSC Medicine Supply Notification
    • Note: The licensed preparation is currenly only avialable from Alliance.   
13.06.01 Ivermectin 1% cream Soolantra®
  • For the treatment of papulopustular rosacea in patients as second line treatment in patient who have failed topical metronidazole.
08.01.05 Ivosidenib Tibsovo®
  • 250mg tablets
  • Approved for for treating locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in adults after 1 or more systemic treatments in line with NICE and NHSE Specialised Commissioning Policy.
08.01.05 Ixazomib 
  • Capsules: 2.3mg, 3mg, 4mg

 

10.01.03 Ixekizumab Taltz®
  • 80mg/ml pre-filled syringe or pen
  • Approved for the treatment of axial spondyloarthritis in line with NICE
  • Approved for the treatment of active psoriatic arthritis after inadequate response to DMARDS

13.05.03 Ixekizumab Taltz®
  • Approved for the treatment of moderate to severe plaque psoriasis in adults in line with NICE

 

14.04 Japanese Encephalitis Vaccine Ixiaro®
19 Juvederm® Ultra 3 
19 Juvederm® Ultra 4 
18.08.08 Juxta CURES® 
  • Specialist use only
18.08.02 K-Band® 

Knitted Polyamide and Cellulose Contour Bandage, BP 1988

18.04.02 Kelo-Cote® 15g Gel 

Silicone gel



  • Burns Team and scar clinic initiation only


 


 

18.02.03 Kendall Telfa Clear® 

Clear non-adherent wound contact layer

18.03.04 Kendall® AMD Antimicrobial Foam 
  • 5cm x 5cm and 8.8cm x 7.5cm only 
18.03.04 Kendall® AMD Foam Discs 
18.01.02 KerraMax® Care 

Super absorbent cellulose primary dressing

18.10 Kerraped® 
18.10 Kerrapro® Pressure Reducing Pads 
04.07.02 Ketamine 
15.01.01 Ketamine  

 



 

15.01.01 Ketamine  
  • 200mg in 20ml (10mg/ml), 500mg in 10ml (50mg/ml) & 1g in 10ml (100mg/ml) injections
  • 50mg in 5ml oral solution unlicensedunlicensed

 

  • Often used as an analgesic in the management of neuropathic pain by specialist pain teams 

 



 

06.07 Ketoconazole Ketoconazole HRA

Tablets: 200mg

Indication: Cushing's Syndrome 

13.10.02 Ketoconazole 
  • 2% cream
  • shampoo
13.09 Ketoconazole 2% shampoo Nizoral®
11.08.02 Ketorolac Acular®
  • 0.5% eye drops.
15.01.04.02 Ketorolac injection 
  • 10mg/1ml & 30mg/1ml injection
    • the use of this is no longer recommended, other parenteral analgesics are now preferred

11.04.02 Ketotifen Zaditen®

Ophthalmology advice - atopic keratoconjunctivitis

09.06.07 Ketovite® 
18.08.04 Knitted Elastomer and Viscose Bandage K- Lite®
02.04 Labetalol 
  • Tablets: 50mg, 100mg, 200mg, 400mg
02.04 Labetalol Injection 
  • 50mg/10ml and 100mg/20ml
04.08.01 Lacosamide  
  • Only approved on advice from consultant neurologists, in patients that are refractory to treatment with other drugs.
01.06.04 Lactulose 
  • Not for PRN use - not effective.
05.03.01 Lamivudine 
  • 150 mg and 300 mg tablets
  • 50 mg/5ml oral solution
05.03.03.01 Lamivudine 
04.02.03 Lamotrigine 
04.08.01 Lamotrigine 
03.04.03 Lanadelumab Takhzyro®

  • 300mg/2mL solution for injection

    • Approved for preventing recurrent attacks of hereditary angioedema in line with NICE



13.10.05 Lanolin Cream 
08.03.04.03 Lanreotide 

  • Approved formulation include lanreotide 30mg long-acting injection and lanreotide 60mg, 90mg, and 120mg autogel injections.

    Existing patients 
    Green Traffic Light  for acromegaly, neuroendocrine tumour and carcinoid. 
    New patients (commenced treatment after July 2019)
    Red Traffic Light  for acromegaly, neuroendocrine tumour and carcinoid.


 

01.03.05 Lansoprazole 

  • 15mg and 30mg capsules

  • Orodispersible tablets should only be used in patients who cannot swallow capsules or tablets and for NG/PEG/PEJ use. Omeprazole capsules are currently cheaper than lansoprazole capsules in primary care.

09.05.02.02 Lanthanum Carbonate 
08.01.05 Lapatinib Tyverb®
09.08.01 Laronidase Aldurazyme®
08.01.05 Larotrectinib 

20 mg/mL oral solution

19 LAT Gel 
11.06 Latanoprost 0.005% with Timolol 0.5% eye drops 
  • For use as a second/third-line agent in patients insufficiently responsive
    to monotherapy with a prostaglandin analogue or beta blocker.
11.06 Latanoprost eye drops 

  • 50 microgram/ml drops

  • 50 microgram/ml preservative free SDU (Monopost)

10.01.03 Leflunomide 
08.02.04 Lenalidomide 
  • Approved for multiple myeloma in line with NICE - approved for myelodysplastic syndrome with 5q deletion in line with NICE. 
  • Approved in combination with dexamethasone for previously untreated multiple myeloma in line with NICE 
  • Approved in combination with dexamethasone for multiple myeloma after one treatment with bortezomib
  • Approved for maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults in line with NICE
  • Approved with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults in line with NICE

 



09.01.06 Lenograstim (rHuG-CSF) Granocyte®
  • 263 microgram (33.6 million units) injection vials
08.01.05 Lenvatinib Kisplyx®
  • 4mg & 10mg capsules
  • Approved with everolimus for previously treated advanced renal cell carcinoma in line with NICE
  • Approved to the treatment of differentiated thyroid cancer after radioactive iodine in line with NICE
  • Approved for untreated advanced hepatocellular carcinoma in line with NICE
02.06.02 Lercanidipine 
  • For use as a second line calcium channel blocker where amlodipine is not tolerated. 
05.03.02.02 Letermovir Prevymis®

  • Approved for the prevention of cytomegalovirus disease after a stem cell transplant in line with NICE

08.03.04.01 Letrozole 
06.07.02 Leuprorelin 
  • Approved formualtions include 3.75mg and 11.25mg pre filled syringes (also see section 8.3.4.2).
06.04.04 Leuprorelin 11.25mg injection 
08.03.04.02 Leuprorelin Acetate 
  • Approved formulations include leuprorelin 3.75mg & 11.25mg prefilled syringes.
05.05 Levamisole 
  • 50mg tablets
  • For roundworm infections.
04.08.01 Levetiracetam 
04.09.01 Levidopa/carbidopa Intestinal Gel Duodopa®
  • levidopa 20mg/carbidopa 5mg intestinal gel
  • Approved for the treatment of Parkinson's disease
11.06 Levobunolol 

Eye drops: 0.5%
Unit dose eye drops: 0.5%

15.02 Levobupivacaine Chirocaine®
  • 0.25%, 25mg in 10ml & 0.5%, 50mg in 10ml & 0.75%, 75mg in 10ml injections 
  • 0.625mg/ml & 1.25mg/ml infusion bags Red Traffic Light
    - for local infiltration in hip and knee replacement surgery.
15.01.04.03 Levobupivacaine with Fentanyl 
  • 2 micrograms/ml with levobupivacaine 0.1% in sodium chloride 0.9% infusion, 100ml, 250ml & 500ml unlicensedunlicensed
  • 4 micrograms/ml with levobupivacaine 0.125% in sodium chloride 0.9% infusion, 500ml (RVI) unlicensedunlicensed
11.03.01 Levofloxacin 
05.01.12 Levofloxacin Infusion 
  • 500mg/100ml infusion 
05.01.12 Levofloxacin Nebuliser Solution Quinsair®
  • 240mg/2.4ml nebuliser solution in line with NHS England Commissioning Policy
05.01.12 Levofloxacin Oral Preparations 
  • 250mg & 500mg tablets 

 

04.02.01 Levomepromazine 
  • Green For use in palliative care.
    • Levomepromazine 25mg in 1ml injection is approved for use in palliative care. 
  • Note: Methotrimeprazine / Levomepromazine 6mg tablets are unlicensedunlicense
06.04.01.02 Levonorgestrel Mirena®
  • Levonorgestrel 52mg in a T-shaped intra-uterine system. 
  • For idiopathic menorrhagia. Especially in women requiring (reversible) contraception. Also used for protection with endometrial hyperplasia during oestrogen replacement therapy. Lasts for up to 5 years - for use in accordance with agreed guidelines.
07.03.05 Levonorgestrel 1.5mg tablet Levonelle 1500 ®
  • Levonorgestrel is recommended for patients who present at up to 72 hours following unprotected intercourse, and the use of ulipristal should be second-line to the use of a copper containing IUCD.
02.07.01 Levosimendan 
  • Approved for use in weaning paediatric and adult patients off extracorporeal membrane oxygenation (ECMO).
  • Approved for use in paediatrics and adults where additional intravenous inotropic support is considered appropriate.
06.02.01 Levothyroxine 
  • 25microgram, 50microgram, 75microgram & 100 microgram tablets
  • 25microgram in 5ml, 50microgram in 5ml & 100microgram in 5ml sugar-free oral solution
02.03.02 Lidocaine 
  • 100mg injection, pre-filled syringes
  • 1mg/ml (0.1%) & 2mg/ml (0.2%) IV infusions 500ml
15.02 Lidocaine 
  • Injections (plain)
  • 0.5% 10ml
  • 1% 2ml, 5ml, & 10ml (10mg/ml)
    • approved for use in post-operative pain management subject to local protocols with a review of adverse events to be submitted by October 2018
  • 2% 2ml, 5ml & 20ml injection (20mg/ml)
  • 5% 2ml Heavy injection (50mg/ml)
  • 5% 10ml injection (50mg/ml) unlicensedunlicensed
  • Topical preparations
  • 1% & 2% gel with chlorhexidine 0.25%
  • 4% topical solution (some packs unlicensed)
  • 5% ointment
  • 2% spray unlicensedunlicensed
  • 100mg lollipops unlicensedunlicensed
  • Lidocaine 4%, adrenaline 0.1% & tetracaine 0.5% (LAT gel®) unlicensedunlicensed
    - approved for use in anaesthetising lacerations particularly in the paediatric population – not to be used in children
    weighing under 15kg.
15.02 Lidocaine 2.5% with Prilocaine 2.5% EMLA®
15.02 Lidocaine 4% cream LMX4®
11.07 Lidocaine 4% with Fluorescein 0.25% Minims® 
15.02 Lidocaine 5% and Phenylephrine 0.5% 
  • 5% lidocaine & 0.5% phenylephrine solution with
    applicator
04.07.03 Lidocaine 5% medicated plasters (700mg lidocaine/plaster) 

  • For use in the treatment of post-herpetic neuralgia only, on the advice of pain specialists and subject to an appropriate trial of efficacy in each individual patient.

01.07.01 Lidocaine 5% ointment 
  • Topical preparations containing local anaesthetics should only be used for a few days as they may cause sensitisation of the anal skin.
13.03 Lidocaine 5% ointment 
12.02.03 Lidocaine and Phenylephrine Nasal spray 
13.03 Lidocaine and prilocaine EMLA®
15.02 Lidocaine Spray 
  • Metered dose spray (10mg/spray)
15.02 Lidocaine with Adrenaline Injections 
06.01.04 LIFT Juice Shot 
  • Carbohydrate drink
  • Approved for the treatment of mild to moderate hypoglycaemia in children and young people 
    • First choice ahead of Glucogel® Green plus
18.10 Limbo® Waterproof Protector 
01.06.07 Linaclotide 
  • Approved for specialist initiation for the symptomatic treatment of moderate-to-severe irritable bowel syndrome with constipation (IBS-C).
06.01.02.03 Linagliptin 
05.01.07 Linezolid Infusion 
  • IV infusion: 600mg/300ml

 

  • Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
05.01.07 Linezolid Oral Preparations 
  • 600mg tablets
  • 100mg in 5ml suspension

 

To be used only on the advice of a Consultant Microbiologist for resistant Gram-positive infections.

Patients must have weekly bloods taken to monitor for haematological side effects if receiving treatment for more than 10 to 14 days. In those receiving treatment for more than 4 weeks a pre-treatment eye assessment is recommended followed by monthly assessments. Patients should be warned to report any visual symptoms promptly (see BNF for CSM warning).

Linezolid is a MAO inhibitor and so potentially life threatening interactions can occur. Check before prescribing.

05.01.07 Linezolid Oral Preparations 
  • 600mg tablets
  • 100mg in 5ml suspension

 

To be used only on the advice of a Consultant Microbiologist for resistant Gram-positive infections.

RED drug for courses greater than 14 days  Red Traffic Light

Patients must have weekly bloods taken to monitor for haematological side effects if receiving treatment for more than 10 to 14 days. In those receiving treatment for more than 4 weeks a pre-treatment eye assessment is recommended followed by monthly assessments. Patients should be warned to report any visual symptoms promptly (see BNF for CSM warning).

Linezolid is a MAO inhibitor and so potentially life threatening interactions can occur. Check before prescribing.

06.02.01 Liothyronine Injection 

 

20mcg injection

 

 

06.02.01 Liothyronine Tablets 

Note: Liothyronine tablets should only be prescribed as per the following guidance:

  • In line with British Thyroid Association (BTA) guidance, where levothyoroxine has failed, liothyronine may be recommended for individual patients after a carefully audited trial of at least 3 months duration of liothyronine.
  • Existing patients should be reveiwed, as appropriate, by an endocrinologist to ensure the continuing need for liothyronine. Patients shouldn't have treatment stopped without review by an endocrinologist. 

 

 

09.01.06 Lipegfilgrastim (G-CSF) 
15.02 Liposomal Bupivacaine Exparel®
  • 133mg/10ml & 266mg/20ml prolonged-release dispersion for injection.
  • Alternative to local anaesthetic infusion via an indwelling brachial plexus nerve catheter for major shoulder/upper limb surgery.
  • Audit of outcomes to be presented to trust Drug and therapeutic Committee's and Formulary Working Group within 12 months (from April 2024).
13.10.05 LiquiBand Optima® 
13.10.05 LiquiBand® 
04.05.01 Liraglutide Saxenda®

 Saxenda®Red

  • Approved as an option for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults in line with NICE and providing: 
    • it is prescribed in secondary care by a specialist multidisciplinary tier 3 weight management service; and
    • the company provides it according to the commercial arrangement 
06.01.02.03 Liraglutide 
  • Victoza® Green
    • Approved for the treatment of type 2 diabetes mellitus in accordance with NICE guidance   
  •  Saxenda®Red
    • Approved as an option for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults in line with NICE and providing: 
      • it is prescribed in secondary care by a specialist multidisciplinary tier 3 weight management service; and
      • the company provides it according to the commercial arrangement 


04.04 Lisdexamfetamine 
  • 20mg, 30mg, 40mg, 50mg, 60mg & 70mg capsules
    • For third line use and specialist initiation. Should only transferred to GPs after at least three month stable symptom control
    • Approved for the treatment of ADHD in adults



 

02.05.05.01 Lisinopril 
11.08.02 Lissamine Green  1.5mg ophthalmic strips
04.02.03 Lithium Carbonate 
  • Prescribe by brand name.
04.07.04.03 Lithium carbonate 
  • Lithium should be prescribed by brand name.
04.02.03 Lithium Citrate 
  • Prescribe by brand name.
04.07.04.03 Lithium citrate 
  • Lithium should be prescribed by brand name.
06.01.02.03 Lixisenatide 
19 l-lysine 2.5%, l-arginine 2.5%  
18.03.01 L-Mesitran® Ointment 

Medical grade honey



  • Specialist tissue viability nurse use or recommendation only

18.03.01 L-Mesitran® Ointment S 

Medical grade honey



  • Specialist tissue viability nurse use or recommendation only

04.03.01 Lofepramine 
  • Safer than amitriptyline in overdosage, but not as effective.
04.10.03 Lofexidine BritLofex®
  • Green plus South Tyneside and Sunderland only 
08.01.01 Lomustine  
  • Note: 10mg capsules are unlicensedunlicensed.
08.01.05 Loncastuximab tesirine Zynlonta®
  • 10mg powder for concentrate for solution for infusion
  • Approved or treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma in adults after 2 or more systemic treatments in line with NICE and NHSE Specialised Commissioning Policy
01.04.02 Loperamide 
  • 2mg tablets and capsules
  • 2mg orodispersible tablets: approved for use in patients with high output stoma only when crushing tablets or opening capsules has failed. Also apporved for oral cancer patients struggling to take capsules Restricted Item Green plus
05.03.01 Lopinavir and Ritonavir Kaletra®
03.04.01 Loratadine 
04.01.02 Lorazepam 
04.08.02 Lorazepam 

  • For initiation by neurologists only.

  • Lorazepam  2mg/ml suspension & 4mg/ml suspension are also approved but are unlicensedunlicensed.

  • Buccal administration of lorazepam suspensions are only approved for use in paediatrics in children with status epilepticus in whom buccal midazolam, rectal paraldehyde or rectal diazepam are ineffective.Red Traffic Light

15.01.04.01 Lorazepam 
  • See section 04.01.02.
16 Lorazepam 
08.01.05 Lorlatinib Lorviqua®
  • Approved for previously treated ALK-positive advanced non-small-cell lung cancer in adults in line with NICE
02.05.05.02 Losartan 
  • To be used as first line treatment in all new patients.
11.04.01 Loteprednol Eye drops 
  • Approved as a second line agent to conventional corticosteroid eye drops, treatment to be imitated with the advice of an ophthalmologist only.
19 Low dose Naltrexone 
13.11 Lubricating jelly 
03.07 Lumacaftor and Ivacaftor Orkambi®
  • Ivacaftor 125mg/lumacaftor 100mg & ivacaftor 200mg/lumacaftor tablets
  • Ivacaftor 95mg/lumacaftor 75mg, ivacaftor 125mg/lumacaftor 100mg &
    ivacaftor 188mg/lumacaftor 188mg granules in sachet
  • Approved for the treatment of cystic fibrosis in patients 1 year and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene in line with NHS England Specialised Commissioning Policy (SSC2538)
  • Only available from:
    • South Tees Hopsitals NHS Foundation Trust
    • The Newcastle upon Tyne Hospitals NHS Foundation Trust
04.02.01 Lurasidone Latuda®

  • 18.5mg, 37mg and 74mg tablets

  • Approved for the treatment of schizophrenia in adults and adolescents aged 13 years and over 

09.01.04 Lusutrombopag 

  • 3mg film-coated tablets

  • Approved as an option for treating severe thrombocytopenia in adults with chronic liver disease having planned invasive procedures in line with NICE

08.01.05 Lutetium (177Lu)  
  • Lutetium (177Lu) oxodotreotide (Lutathera)
    • Approved for treating unresectable or metastatic neuroendocrine tumours in adults in line with NICE
  • Lutetium-177 vipivotide tetraxetan (Pluvicto)
    • Approved for treating prostate-specific membrane antigen-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments in adults in line with NICE 
06.05.01 Lutropin Alfa 
05.01.03 Lymecycline 
13.06.02 Lymecycline 
02.05.01 Macitentan 
  • Approved for pulmonary hypertension - in accordance with NHS England Commissioning policy. 
01.06.04 Macrogol Movicol liquid®

Approved as a second line macrogol laxative for care home residents only.

16 Macrogol '3350' Klean-Prep®
01.06.04 Macrogol oral powder 
01.06.04 Macrogol oral powder, Compound 
  • Macrogol Compound oral powder
  • Macrogol Compound oral powder, Half-Strength
  • Macrogol Compound oral powder,  Paediatric

Use the product with the lowest acquisition cost.

01.06.05 Macrogols Klean-Prep®
01.06.05 Macrogols Moviprep®
13.11.06 Magenta Paint BPC Castellani's paint

Paint containing magenta 0.4%, boric acid 0.8%, phenol 0.004%, resorcinol 8%, acetone and alcohol (or industrial methylated spirit).

09.05.01.03 Magnesium Aspartate 
  • 6.5g (10 mmol) sachets - first line for the treatment and prevention of magnesium deficiency.
  • 614.8mg (2.5mmol) tablets unlicensedunlicensed - for second line treatment in patients with short bowel syndrome.
09.05.01.03 Magnesium chloride  
  • 10 mmol magnesium in 1 litre sodium chloride 0.9% with potassium chloride 0.15% (20 mmol) unlicensedunlicensed
  • 64mg sustained release tablets (2.6mmol magnesium) unlicensedunlicensed
09.05.01.03 Magnesium Glycerophosphate 
  • 1g (4mmol) chewable tablets 
    • Use preparation with cheapest acquisition cost.
    • Yourmag®
    • Magnaphate® unlicensedunlicensed

  • 1mmol/ml suspension -available if supply problems with tablets unlicensedunlicensed.
03.01 Magnesium Sulphate 
07.01.04 Magnesium Sulphate 
  • Ampoules: 20% in 10ml
09.05.01.03 Magnesium Sulphate 
  • 50% 2ml (4 mmol), 50% 10ml (20 mmol) & 10% 10ml (4mmol) injections 
  • 60 mmol in 500ml sodium chloride 0.9% infusion unlicensedunlicensed
19 Magnesium sulphate 10% solution for injection pre-filled syringe 
02.03 Magnesium Sulphate Injection 
13.10.05 Magnesium Sulphate Paste BP 
13.10.04 Malathion 0.5% solution (aqueous) 
02.02.05 Mannitol 
03.07 Mannitol inhalation 
  • Approved for bronchial provocation testing in patients unable to tolerate the taste of methacholine.
03.07 Mannitol inhalation Bronchitol ®
  • Only approved for use in accordance with NICE guidance. 
05.03.01 Maraviroc 
  • Approved for use in the treatment of patients with HIV infections that are resistant to standard therapy in accordance with British HIV Association and EACS guidelines.
05.03.02.02 Maribavir Livtencity®
  • 200mg film coated tablets
02.16 Mavacamten Camzyos®
  • Approved as an option for treating symptomatic obstructive hypertrophic cardiomyopathy in adults who have a New York Heart Association class of 2 to 3 in line with NICE and NHSE Specialised Commissioning guidance.
  • It is recommended only if:
    • it is an add‑on to individually optimised standard care that includes beta‑blockers, non-dihydropyridine calcium-channel blockers or disopyramide, unless these are contraindicated.


The following providers are commissioned to provide this service:

  • North Cumbria Integrated Care NHS Foundation Trust
  • South Tees Hospitals NHS Foundation Trust
  • The Newcastle upon Tyne Hospitals NHS Foundation Trust

 

14.04 Measles, Mumps and Rubella Vaccine, Live (MMR) 
05.05.01 Mebendazole 
01.02 Mebeverine 
06.07.04 Mecasermin Increlex®
18.10 Medi Derma® S  
  • 1ml applicator
  • 3ml applicator
  • 50ml aerosol
  • 30ml pump spray
18.10 Medi Derma® S  
  • sachet
  • 28g
  • 90g 

 

13.02.02 Medi Derma-Pro Foam & Spray Skin Cleanser And Skin Protectant Ointment  Medi Derma-Pro Foam & Spray Skin Cleanser®
13.02.02 Medi Derma-S barrier film  Medi Derma-S ®barrier film
18.09.01 Medi® hosiery 
13.11.03 Mediscrub®  
06.04.01.02 Medroxyprogesterone Acetate 

Approved Medroxyprogesterone formulations include:

  • 2.5mg, 5mg, and 10mg tablets (sometimes used as a progestogen component of HRT).
  • 100mg & 200mg tablets (for use in malignant disease see section 8.3.2).
  • 50mg in ml injection - see sections 7.3.2.2 for use of  medroxyprogesterone acetate injection in contraception.
08.03.02 Medroxyprogesterone Acetate 
  • Approved formualtion include 100mg, 200mg, and 400mg tablets. 
  • Medroxyprogesterone acetate 500mg in 2.5ml injection is also approved. 
07.03.02.02 Medroxyprogesterone Acetate injection 
  • Approved formulations include:
    • Depo-Provera® - 150mg in 1ml depot injection;
    • Sayana Press® - 104mg/0.65ml S/C injection.

10.01.01 Mefenamic Acid 
  • Capsules: 250 mg
  • Tablets: 500 mg
  • Suspension: 50 mg/5 mL
18.07.03 Mefix® 

Permeable, Apertured Non-Woven Synthetic Adhesive Tape, BP 1988

 

05.04.01 Mefloquine 

Note: not approved on the NHS for prophylaxis. Not NHS 

08.03.02 Megestrol Acetate 
18.02.06 Meglisorb®  

Calcium sodium alginate fibre, highly absorbent, gelling dressing, non-woven 

19 Meglumine gadoterate Dotarem®
  • Gadolinium MRI contrast medium that is licensed for use in children. Gadoterate is considered to be much less likely to cause nephrogenic systemic fibrosis than dimeglumine gadopentetate (Magnevist®), which has previously been used in children.
04.01.01 Melatonin  
  • First line: melatonin 1mg and 5mg modified release tablets in line with licensed indications only.
  • Second line: melatonin 1mg, 2mg, 3mg, 4mg and 5mg tablets (crushed if necessary).
  • Third line: melatonin 1mg/1ml oral solution - 1st choice for patients unable to tolerate solid dose formulations. Consilient Health formulation to be used as it is alcohol and propylene glycol free

Approved Indications

Melatonin can be used to facilitate the induction of sleep, and increase the duration of sleep on the advice of an appropriate secondary care specialist, in the following situations:

1) Visually impaired or blind people with disturbed sleep wake cycles. Green plus
2) Delayed sleep phase syndrome and other circadian rhythm disorders.Green plus
3) Children with neurological or behavioural disorders including: Amber

  • Attention deficit hyperactivity disorder (ADHD).*
  • Chronic sleep onset insomnia.*
  • Neurodevelopmental disabilities (e.g. involving delayed brain maturation, sensory dysfunction - especially visual and dysfunction of sleep centres).*

4) Treatment of children and young adults with chronic fatigue syndrome / myalgic encephalomyelitis who have sleep difficulties (as recommended in NICE clinical guideline no. 53).* Amber
5) Prior to examinations such as a sleep encephalogram (EEG) in children and sedation prior to scans in paediatric oncology. Green plus
6) Patients with REM sleep behaviour disorder (RBD) - e.g. associated with degenerative conditions such as Parkinson’s disease or dementia, as a second line treatment to clonazepam. Green plus
7) To improve nocturnal sleep in critically ill patients (to aid weaning from mechanical ventilation) Green plus

*Note that for indications 3 and 4 in children and young people melatonin is classified as an ‘amber’ drug and therefore subject to formal shared care guidance.  Please follow relevant link below for the most recent guideline.

18.01.02 Melolin® 

Absorbent, Perforated Plastic Film Faced, Dressing

  • Podiatry use only
08.01.01 Melphalan 
04.09.03 Memantine  
  • Approved for use as last line drug after other alternatives have been considered, in the treatment of congenital and acquired nystagmus.
04.11 Memantine 
  • Only approved for use in accordance with NICE guidance. 
09.06.06 Menadiol Sodium Phosphate 
  • 10mg tablets - water soluble derivative of vitamin K for use in patients with fat malabsorption, especially in hepatic disease or biliary obstruction including cystic fibrosis patients.
06.05.01 Menotrophin (75 units FSH & 75 units LH activity) injection  
13.03 Menthol and aqueous cream  

- available as Dermacool

05.04.04 Mepacrine Hydrochloride 
18.04.02 Mepiform® 

Silicone gel sheet

  • Burns Team and scar clinic initiation only

 

18.02.03 Mepilex® Border  

Absorbent soft silicone dressing with polyurethane foam and adhesive border

18.02.03 Mepilex® Border lite  

Thin absorbent soft silicone dressing with polyurethane foam and adhesive border

  • Paediatrics only 
18.02.03 Mepilex® Border Post-op 
18.02.03 Mepilex® ST 

Absorbent soft silicone dressing with polyurethane foam film backing 

15.02 Mepivacaine 
  • 3% 2.2 ml cartridges
15.02 Mepivacaine IV 
03.04.02 Mepolizumab Nucala®
  • 100mg/1ml solution for injection (pre-filled devices)
  • Approved for the treatment of severe refractory eosinophilic asthma in line with NICE and NHS England Commissioning Policy.
09.08.01 Mercaptamine  
11.08 Mercaptamine hydrocholride 

  • Viscous eyedrops

    • Approved for the treatment of corneal cystine deposits in people aged 2 years and over in line with NHS England Clinical Commissioning Policy 



01.05.03 Mercaptopurine 
08.01.03 Mercaptopurine  
  • A mercaptopurine 20mg in 1ml suspension (unlicensedunlicensed) is also approved for use. 
  • Note: when prescribed for inflammatory bowel disease. Amber Traffic Light
05.01.02.02 Meropenem 
  • Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
05.01.02.02 Meropenem & vaborbactam Vaborem®

 

    • Meropenem 1 gram / vaborbactam 1 gram. To be used only on advice of microbiology/infectious disease physician



 

01.05.01 Mesalazine Rectal Preparations
  • 500mg & 1g suppositories
  • 1g in 100ml retention enema, 2g in 59ml enema
  • 1g foam enema

 

01.05.01 Mesalazine 

First Choice

  • Octasa MR® (400mg e/c m/r tablets): approved as first choice 400mg e/c m/r preparation for all new patients. Patients receiving Asacol® and Mesren® should be switched to Octasa® when appropriate. 800mg & 1600mg e/c m/r tablets also approved for suitable patients - to reduce tablet burden.
  • Pentasa® (500mg & 1000mg m/r tablets).
  • Mezavant® XL (1.2g e/c m/r tablets).
  • Salofalk® (500mg, 1000mg, 1500mg & 3000mg m/r granules/sachet) - only to be used in patients with difficulty in swallowing.
08.01 Mesna 
  • Approved formulations include 1gram in 10ml injection and 400mg tablets.
16 MESNA (sodium 2-mercapto-ethanesulphonate) 
02.07.02 Metaraminol 
06.01.02.02 Metformin 
  • Metformin 500mg tablets
  • Metformin 500mg oral powder sachets
  • Metformin MR (once daily - Glucophage® SR) are only approved for use in patients who have failed to tolerate the conventional tablets despite careful dose titration.
  • Note: metformin is also approved for use in Polycystic Ovary Syndrome.

 

07.05.01.01 Metformin 
  • 500mg tablets
  • For fertility indications
  • Also approved for polycystic ovarian syndrome (PCOS)
04.07.02 Methadone 

The following preparations are approved:

  • 5mg tablets;
  • 5mg in 5ml mixture DTF & 5mg in 5ml sugar free solution
  • 20mg in 1ml concentrated oral solution (unlicensedunlicensed)
  • 10mg in 1ml injection



04.10.03 Methadone 
  • Methadone 5mg in 5ml oral solution and 5mg in 5ml sugar free solution are both approved for the management of opioid dependence in line with NICE.
  • Red CD&TV and ST&S
05.01.13 Methenamine Hippurate 
  • Approved as second line agent for prophylaxis in patients with recurrent UTI’s who have failed long-term antibiotic prophylaxis, have contraindications to antibiotics or breakthrough infection with resistant organisms.
16 Methionine 250mg and 500mg tablets 

Paracetamol overdose

 

01.05.03 Methotrexate 
  • See section 8.1.3
  • NOTE: Subcutaneous injection for chronic inflammatory conditions in Tees SICBL Red

 

08.01.03 Methotrexate  
  •  Approved formulations:
    • Methotrexate 2.5mg tablets
    • Methotrexate 10mg in 5ml oral solution. unlicensedunlicensed
    • Methotrexate injections (various strengths) – including prefilled syringes.
    • Methotrexate 5mg in 2ml intrathecal injection.
  • NOTE: when used in chronic inflammatory conditions, e.g. Crohn’s disease, rheumatoid arthritis.Amber Traffic Light
  • NOTE: Subcutaneous injection for chronic inflammatory conditions in Tees SICBL Red
10.01.03 Methotrexate 
13.05.03 Methotrexate 

 

09.01.03 Methoxy Polyethylene Glycol-Epoetin Beta Mircera®, Pegzerepoetin® alfa
  • 30, 50, 100, 120, 150, 200 & 250 microgram in 0.3ml and 360 microgram in 0.6ml injections in prefilled syringes.
  • Approved for use as a longer-acting alternative to darbepoetin in a
    small number of patients receiving peritoneal dialysis.
15.01.02 Methoxyflurane Penthrox®
  • 99.9% inhalation vapour
    • Approved for use in trauma related pain in Emergency Departments, in adults only
    • Approved for procedural analgesia in procedures such as VAC dressing change/stent change/brachytherapy rod change, in adults only
13.05.02 Methoxypsoralen 1.2% bath additive 
02.05.02 Methyldopa 
04.04 Methylphenidate 
  • Please prescribe by brand name
  • Approved for ADHD and the treatment of narcolepsy in adult and paediatrics.
  • Approved for improving working memory and processing speed following neurocognitive damage secondary to brain injury from; a brain tumour and its associated treatment (e.g. hydrocephalus and radiotherapy) or neurotoxic chemotherapy.
    • 5mg & 10mg tablets
    • 5mg, 10mg, 20mg, 30mg and 40mg m/r capsules (Medikinet® XL)
    • 10mg, 20mg & 30mg m/r capsules (Equasym® XL)18mg, 27mg & 36mg m/r tablets (Xaggitin® XL)
        • Existing patients who are prescribed Concerta® XL should be reviewed and switched to Xaggitin® XL as appropriate
        • Xaggitin® XL is bioequivalent to Concerta® XL
07.04.02 Methylphenidate 
  • Methylphenidate is approved for use as a third line option (after e.g. antimuscarinics, imipramine, and pelvic floor exercises) in the treatment of giggle incontinence in children. Its use should be subject to a therapeutic trial to be reviewed after two months and considered for Shared Care if patients have been shown to respond after the trial period.
  • The following methylphenidate formulations are approved for giggle incontinence:
    • 5mg & 10mg tablets.
    • 10mg, 20mg & 30mg m/r capsules (Equasym XL®).
    • 18mg, 27mg & 36mg m/r tablets (Xaggitin® XL)
  • Existing patients who are prescribed Concerta® XL should be reviewed and switched to Xaggitin® XL as appropriate
  • Xaggitin® XL is bioequivalent to Concerta® XL
  • The effects of Equasym® XL last for about 8 hours compared with about 12 hours for Xaggitin® XL. 
10.01.02.02 Methylprednisolone Acetate 40mg in 1ml injection 
10.01.02.02 Methylprednisolone Acetate 40mg with lidocaine 1% injection 
06.03.02 Methylprednisolone Acetate 40mgin 1ml and 120mg in 3ml (depot) 
06.03.02 Methylprednisolone sodium succinate 2mg, 4mg, and 16mg tablets
06.03.02 Methylprednisolone sodium succinate 40mg, 125mg, 500mg & 1000mg injection
19 Methylthioninium Chloride 
01.02 Metoclopramide 

Tablets - 10mg Oral Solution - 5mg/5ml
Caution in elderly, young adults and children Do not use in people under 20 years

MHRA Drug Safety Update Alert (Aug 2013): Metoclopramide: risk of neurological adverse effects

04.06 Metoclopramide 

  • Please refer to MHRA advice 

04.07.04.01 Metoclopramide 
  • Used to help promote absorption of analgesics.
04.06 Metoclopramide INJECTION 
  • Palliative care use
02.02.01 Metolazone Xaqua®
02.04 Metoprolol 
  • Tablets: 50mg, 100mg
  • SR Tablets: 200mg 
04.07.04.02 Metoprolol 
02.04 Metoprolol Injection 
  • Injection: 5mg/5ml 
06.08 Metreleptin 

  • 3mg, 5.5mg and 11.3mg powder for solution for injection



  • Approved for treating lipodystrophy in children and adults in line with NICE

05.01.11 Metronidazole 
  • 200mg & 400mg tablets 
  • 200mg in 5ml suspension 
  • 500mg & 1g suppositories 
05.04.02 Metronidazole 
05.04.04 Metronidazole 
13.10.01.02 Metronidazole 0.75%  

Cream & gel

07.02.02 Metronidazole 0.75% vaginal gel 
05.01.11 Metronidazole Infusion 
  • 50mg in 10ml injection & 500mg in 100ml IV infusion 
06.07.03 Metyrapone Metopirone®
  • 250mg capsules
02.03.02 Mexiletine 

  • unlicensed unlicensed

  • ECG monitoring is required to be carried out by as part of the initiation process of mexiletine.

10.02 Mexiletine Namuscla®

  • Approved for the treatment of myotonia in patients with non-dystrophic myotonic disorders in line with NICE and NHSE commissioning policy (SSC2001). 


 

05.02.04 Micafungin 
13.10.02 Miconazole 2% cream 
12.03.02 Miconazole 24mg/ml sugar-free oral gel Daktarin®
12.03.02 Miconazole 50mg muco-adhesive buccal tablets Loramyc®
  • Restricted to use in immunocompromised patients with severe oropharyngeal candidiasis, where the use of other antifungal agents e. g. nystatin, fluconazole is not appropriate and for use on the advice of microbiologists.
06.04.01.02 Micronised progesterone Utrogestan®
  • 100mg oral capsules Green
  • Approved for:
    • adjunctive use with estrogen in post-menopausal women with an intact uterus, as hormone replacement therapy (HRT)
    • Perimenopause (off-label)
    • Premature ovarian insufficiency (off-label)
    • Adolescents undergoing pubertal induction following chemotherapy (off-label)


04.08.02 Midazolam 
  • Buccolam® 5mg in 1ml alcohol-free buccal solution, and Buccolam® 2.5mg, 5mg, 7.5mg and 10mg prefilled oral syringes are approved as first choice for status epilepticus in children aged 3 months to 18 years. 
  • Epistatus® 10mg in 1ml oromucosal solution pre-filled oral syringes is approved for use in the treatment of epileptic seizures in infants under 3 months and adults over 18 years of age. This use is off-label Injection solutions (section 15.1.4) can also be given buccally



 

15.01.04.01 Midazolam 
  • 5mg in 5ml, 10mg in 2ml injections
  • 50mg in 50ml prefilled syringes - ITU use only 
  • Intranasal midazolam 40mg/ml + lidocaine 20mg/ml 
    • approved for use prior to cannulation for adult patients with
      special needs receiving dental treatment under IV sedation.
  • Miprosed® 5mg in 1ml (7.5ml) oral solution is approved for use as a sedative and pre-medication in children 

Palliative care

  • 10mg/2ml injection Green

 

02.07.02 Midodrine 
  • For specialist initiation in treating symptomatic hypotension that has not responsed to conventional therapies. 
08.01.05 Midostaurin Rydapt®
  • Approved for the treatment of advanced systemic mastocytosis in line with NICE

 

08.02.04 Mifamurtide 
  • Approved for high-grade resectable non-metastatic osteosarcoma in line with NICE.
07.01.02 Mifepristone 200mg tablets 
09.08.01 Migalastat Galafold ®
  • Approved for the treatment of Fabry's disease in line with NICE 
02.01.02 Milrinone 
05.01.03 Minocycline 

  • Note: not be prescribed for the treatment of acne in new patients (July 2019). 

10.01.03 Minocycline 
  • Only approved for use in patients with rheumatoid arthritis who are unable to tolerate biologics and other DMARDs.
02.05.01 Minoxidil 
  • Treatment should only be on the advice of a cardiologist/nephrologist.
07.04.02 Mirabegron 

  • Approved for use when antimuscarinics don’t work, are not suitable or side effects are unacceptable, in line with NICE guidance. 

11.09 Miraflow® daily cleaner 
01.05.03 Mirikizumab Omvoh®
  • 100mg/1ml solution for injection pre-filled pens & 300mg/15ml concentrate for solution for infusion
  • Approved for treating moderately to severely active ulcerative colitis in adults in line with NICE 
04.03.04 Mirtazapine 
  • Orodispersible mirtazapine tablets should only be prescribed for use when other formulations are unsuitable (more expensive).
01.03.04 Misoprostol 
  • Note: 100 microgram tablets (unlicensedunlicensed) are also on formulary - mainly for use in paediatric nephrology at the RVI.
07.01.01 Misoprostol 
  • Tablets: 200 micrograms

 

08.01.02 Mitomycin  
  • Also approved for treatment in combination with 5-Fluorouracil for bladder cancer concurrent with radiotherapy.
  •  Mitomycin 0.04% preservative free eye drops  are also approved for useGreen Traffic Light - this is unlicensedunlicensed.
08.01.05 Mitotane 
08.01.02 Mitoxantrone  
15.01.05 Mivacurium Mivacron®
  • 10mg in 5ml injection
  • 20mg in 10ml injection
08.01.05 Mobocertinib 
04.03.02 Moclobemide 
  • For use on advice from psychiatrists only.
04.04 Modafinil 
  • Approved for:
    • treatment of patients with narcolepsy
    • treatment of idiopathic hypersomnia


 

08.01.05 Mogamulizumab  Poteligeo®
  • Approved for previously treated mycosis fungoides and Sézary syndrome in line with NICE

 

05.03.06 Molnupiravir Lagevrio®
03.02.03 Mometasone and indacaterol  Atectura®
  • Mometasone furoate 127.5 microgram/dose & indacaterol 125 microcram/dose inhalation powder capsules (DPI)
  • Mometasone furoate 260 microgram/dose & indacaterol 125 microcram/dose inhalation powder capsules (DPI)
    • Both strengths approved for asthma only


13.04 Mometasone Furoate 0.1% Elocon®
12.02.01 Mometasone Furoate 50microgram/metered dose nasal spray 
03.02.02 Mometasone, Indacaterol & glycopyrronium  Enerzair Breezhaler®
  • Mometasone 136 microgram/dose, indacaterol 114 microcram/dose & glycopyrronium 46 microgram/dose inhalation powder capsules (DPI)
    • Approved for asthma only


 

03.03.02 Montelukast 
  • Review treatment after 6 weeks of initiation and discontinue if no evidence of improvement. Should typically only be initiated by hospital specialist.
  • Montelukast is 2nd line after an inhaled corticosteroid for asthmatic children < 5 years old.
04.07.02 Morphine 
  • Tablets - 10mg, 20mg, 50mg (Sevredol®)
  • MR capsules - 10mg, 30mg, 60mg, 100mg, 200mg (Zomorph®)
  • MR tablets -  5mg, 10mg, 15mg, 30mg, 60mg, 100mg, 200mg (MST®)
  • Oral solution - 10mg in 5ml
  • Injection - 10mg/ml, 15mg/ml, 20mg/ml, 30mg/ml
  • Zomorph® is the preferred M/R formulation. 
  • Red Note: the following preparations are also approved for use:
    • morphine 5mg in 1ml injection   unlicensedunlicensed 
    • 10mg in 1ml preservative free injection   unlicensedunlicensed 
    • 2mg in 5ml epidural   unlicensedunlicensed 
    • 100 micrograms/1 ml oral solution. For use in neonates.   unlicensedunlicensed 
    • 50mg in 50ml PCA injection  
05.01.12 Moxifloxacin 
11.03.01 Moxifloxacin 
02.05.02 Moxonidine 
12.02.03 Mupirocin 2% Bactroban Nasal®
  • First choice the treatment of MRSA
13.10.01.01 Mupirocin 2% Ointment Bactroban®
09.06.07 Mutivitamins BPC 
  • Capsules containing ascorbic acid 15mg, nicotinamide 7.5mg, riboflavin 500 micrograms, thiamine HCl 1mg, vitamin A 2,500 units, & vitamin D 300 units
10.01.03 Mycophenolate 
08.02.01 Mycophenolate Mofetil 
  • For Transplant indications Red unless from a Trust/speciality that hasn't formaly repatriated it's patients or for patients who require weekly scripts for MDS boxes Amber
08.02.01 Mycophenolate Sodium Myfortic®
  • Approved as second-line therapy in patients who do not tolerate mycophenolate mofetil.
  • For Transplant indications Red unless from a Trust/speciality that hasn't formaly repatriated it's patients or for patients who require weekly scripts for MDS boxes Amber
11.08.02.04 Mydrane 

Intracameral injection: tropicamide 0.2 mg/mL, phenylephrine 3.1 mg/mL, lidocaine 10 mg/mL; 0.6 mL ampoules

18.01.01 N/A Ultra® (Silicone-coated) 
04.06 Nabilone 
10.01.01 Nabumetone 
  • 500mg tablets
02.04 Nadolol 
  • Limited to use by cardiologists in patients with long QT syndrome/idiopathic ventricular fibrillation.
  • Liquid formulations (unlicensedunlicensed) can be obtained for use in children if necessary. Treatment should only be on the advice of a cardiologist.
06.07.02 Nafarelin 
02.06.04 Naftidrofuryl 
  • Approved for the treatment of intermittent claudication in people with peripheral arterial disease. 
01.06.06 Naldemedine Rizmoic®
  • 200microgram tablet
  • Approved for the treatment of opioid-induced constipation in line with NICE

 

04.10.01 Nalmefene 
  • Only approved for use in accordance with NICE guidance.
  • COUNTY DURHAM Red acamprosate, chlordioazepoxide, disulfiram & nalmefene prescribing should be retained within the commissioned service within County Durham.
01.06.06 Naloxegol 
  • 12.5mg and 25mg tablets
  • Approved for the treatment of opioid-induced constipation in line with NICE
15.01.07 Naloxone 
  • 400 microgram in 1ml injection (ampoules).
  • 2mg/2ml pre-filled syringes (as per ACMD guidance).
16 Naloxone 
  • 400 microgram injection – ampoules and prefilled syringes Green
  • 1.8mg/0.1ml nasal spray (single use)  Red
    • approved to offer a more convenient method of administration by non-healthcare professionals from Drug and Alcohol Services in accordance with local written protocols.
04.10.01 Naltrexone 
04.10.03 Naltrexone 50 mg tablets Nalorex®
  • Approved for the management of opioid dependence in detoxified formerly opioid-dependent people in line with NICE.
  • Also approved NoTGhdNC for use in reducing agitation and/ or selfinjurious behaviour in patients with learning disabilities or autism (unlicensedunlicensed indication). Treatment must be initiated by an appropriate hospital specialist.
04.07.01 Naproxen tablets 
04.07.04.01 Naproxen tablets 
10.01.01 Naproxen tablets 

Tablets: 250mg, 500mg 

Note: a naproxen 125mg in 5ml suspension (unlicensedunlicensed) is also approved. 

08.02.04 Natalizumab 

  • Approved for rapidly evolving severe relapsing remitting multiple sclerosis in line with NICE and NHS England commissioning policy.

02.04 Nebivolol 
  • For specialist use in the treatment of patients who cannot tolerate other beta-blockers. Treatment should only be on the advice of a cardiologist.
08.01.03 Nelarabine Atriance®
05.03.01 Nelfinavir 
A2.03.01 Neocate LCP 
05.01.04 Neomycin 
  • 500mg tablets
  • 1g in 10ml syrup unlicensedunlicensed.
10.02.01 Neostigmine 
  • 2.5mg in 1ml injection
15.01.06 Neostigmine 
  • 2.5mg in 1ml injection
15.01.06 Neostigmine with Glycopyrronium 
  • Glycopyrronium 500 microgram & neostigmine 2.5mg in 1ml injection (Robinul – neostigmine)
11.08.02 Nepafenac 
  • 1 mg/1mL eye drops
08.01.05 Neratinib Nerlynx®
  • Approved for the treatment of early hormone receptor-positive HER2-positive breast cancer after adjuvant trastuzumab in line with NHS England Commissioning Policy and NICE
04.06 Netupitant & Palonosetron Akynzeo®

  • To be used in accordance with Northern England Strategic Clincial Cancer Network (NCCN) Guidelines

05.03.01 Nevirapine 
19 Nexobrid 

  • Enzyme-based debriding agent for the removal of eschar in adults with deep partial and full thickness thermal burns

02.06.02 Nicardipine 1mg in 1ml injection 
  • Approved as a second line agent for the treatment of aortic dissection and pre-eclampsia.
02.06.03 Nicorandil 
04.10.02 Nicotine 
  • The following nicotine replacement treatments are approved:
    • Nicotine gum -  2mg & 4mg sugar-free chewing gum (Nicorette® is the gum of choice).
    • Nicotine 16 hour patch - 10mg, 15mg, and 25mg/16 hour patches (Nicorette® Invisi). 
    • Nicotine 24 hour patch - 7mg & 14mg, and 21mg /24 hour patches (Nicotinell® is the patch of choice as potential savings to be made).
    • Nicotine lozenges - 2mg and 4mg lozenges (Niquitin® is the lozenge of choice), 1.5mg and 4mg mini lozenges (NiQuitin® Minis Lozenges).
    • Nicotine 2mg sublingual tablets.
    • Nicotine inhalator -  15mg cartridges for use in inhalator.
    • Nicotine oromucosal spray - Nicorette® Quickmist 1mg per dose.

  • North Cumbria - Smoking Cessation is commissioned separately through community pharmacies and should not be prescribed on FP10's
  • Newcastle/Gateshead - Local Authority smoking cessation programme should be used. NRT should not routinely be prescribed on FP10

 

02.06.02 Nifedipine 
  • Once daily formualtions are preferred
  • 20mg controlled release tablets (Adalat LA), 30mg & 60mg m/r capsules (Coracten XL)
  • 5mg & 10mg capsules
  • 10mg & 20mg retard tablets
  • 20mg in 1ml (1mg/drop) nifedipine oral solution is also approved for use unlicensedunlicensed.
07.01.04 Nifedipine 
  • Capsules: 5mg, 10mg
08.01.05 Nilotinib Tasigna®
  • Approved for the first-line treatment of adults with chronic phase Philadelphia-chromosome-positive CML in line with NICE and NHS Commissioning Policy
02.06.02 Nimodipine 
  • 30mg tablets - treatment should be on the advice of the stroke team or a cardiologist.
02.06.02 Nimodipine Injection 
  • 10mg in 50ml for IV infusion 
03.11 Nintedanib Ofev®

  • Approved for treating idiopathic pulmonary fibrosis

  • Approved for treating progressive fibrosing interstitial lung diseases in line with NICE

08.01.05 Nintedanib  
  • Approved for the treatment of locally advanced, metastatic or locally recurrent non-small-cell lung cancer who have previously been treated been with first-line chemotherapy in accordance with NICE.
  • Approved for treating idiopathic pumonary fibrosis in line with NICE
08.01.05 Niraparib Zejula®
  • Approved for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults in line with NICE
05.03.06 Nirmatrelvir and Ritonavir Paxlovid®
  • Nirmatrelvir 150mg tablets and Ritonavir 100mg tablets (Paxlovid®)
  • As per NICE TA 878
09.08.01 Nitisinone 
15.01.02 Nitric Oxide 
05.01.13 Nitrofurantoin 
  • Note: Liquid presentations of nitrofurantoin are very expensive compared to
    other solid dosage formulation. Please consider whether capsules can be used.
13.10.01.01 Nitrofurazone 0.2% Ointment 
  • For limited use in burns/plastic surgery patients only.
15.01.02 Nitrous oxide 
08.01.05 Nivolumab  Opdivo®
  • For the treatment of locally advanced or metastatic squamous nonsmall cell lung cancer (NSCLC) after prior chemotherapy in adults.
  • Approved for the treatment of advanced (unresectable or metastatic) melanoma in adults in line with NICE.
  • Approved in combination with ipilimumab for treating advanced melanoma in line with NICE and NHS England Commissioning Policy (SSC1664)
  • Approved for the treatment of advanced renal cell carcinoma in adults in line with NICE and NHS England Commissioning Policy
  • Approved for the treatment of relapsed of refractory classical Hodgkin lymphoma in line with NICE and NHS England Commissioning Policy 
  • Approved for the treatment of  locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy in line with NICE
  • Approved for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease in adults
  • Approved for use in patients with previously untreated unresectable advanced or recurrent oesophageal cancer in line with NICE
  • Approved in combination ipilimumab for use in patients with previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in line with NICE
  • Approved for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy in adults in line with NICE
  • Approved adjuvant treatment of completely resected oesophageal or gastro‑oesophageal junction cancer in adults who have residual disease after previous neoadjuvant chemoradiotherapy in line with NICE
  • Approved in combination with ipilimumab for untreated advanced renal cell carcinoma in line with NICE
  • Approved for adjuvant treatment of invasive urothelial cancer at high risk of recurrence in line with NICE
  • Approved with ipilimumab or untreated unresectable malignant pleural mesothelioma in adults in line with NICE
  • Approved for treating locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy in line with NICE
  • Approved (with fluoropyrimidine-based and platinum-based combination chemotherapy) for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma in adults whose tumours express PD‑L1 at a level of 1% or more.
  • Approved as an option for the neoadjuvant treatment of resectable (tumours at least 4 cm or node positive) non-small-cell lung cancer (NSCLC) in adults - in line with NICE TA876.
01.03.01 Nizatidine 
18.07.02 Non-woven Fabric Swab 

Non-woven fabric folded 4-ply

07.03.03 Nonxynol ’9’ - 2% gel Gygel®
02.07.02 Noradrenaline / Norepinephrine 
08.03.02 Norethisterone 
06.04.01.02 Norethisterone 5mg tablets 
14.05.01 Normal Immunoglobulin Kiovig®
  • 10% - 1g, 2.5g, 5g, 10g, 20g & 30g
14.05.01 Normal Immunoglobulin Subcuvia®
  • 16% - 0.8g & 1.6g
14.05.01 Normal Immunoglobulin Privigen®
  • 10% - 2.5g, 5g, 10g & 20g
14.05.01 Normal Immunoglobulin Octagam®
  • 5% - 5g & 10g
  • 10% - 2g, 5g, 10g & 20g
14.05.01 Normal Immunoglobulin Flebogamma®DIF
  • 5% - 2.5g, 5g, 10g & 20g
14.05.01 Normal Immunoglobulin Gammunex®
  • 10% - 5g, 10g & 20g
14.05.01 Normal Immunoglobulin Iqymune®
  • 10% - 2g, 5g, 10g & 20g
14.05.01 Normal Immunoglobulin Intratect®
  • 5% - 1g, 2.5g, 5g & 10g
  • 10% - 1g, 5g, 10g & 20g
14.05.01 Normal Immunoglobulin Cuvitru®
  • 20% - 1g, 2g, 4g & 8g
14.05.01 Normal Immunoglobulin Gammanorm®
  • 16.5% - 1g, 1.65g, 2g, 3.3g, 4g & 8g
14.05.01 Normal immunoglobulin for Intramuscular use 
04.07.03 Nortriptyline 
18.07.01 Nurse It® Dressing Pack 

Contains latex-free, powder-free nitrile gloves, sterile laminated paper sheet, large apron, non-woven swabs, paper towel, disposable bag, compartmented tray, disposable forceps, paper measuring tape

10.02 Nusinersen Spinraza®
  • 12mg solution for injection
  • Approved as an option for treating 5q spinal muscular atrophy (SMA) types 1, 2 or 3 in line with NICE.

 

A2.05.02 Nutilis Clear Nutilis®
A2.03.01 Nutramigen Puramino 
A2.01.03.02 Nutrini® 
A2.01.01.01 Nutrison®  
13.04 Nystaform-HC® 
  • Cream and ointment
05.02.03 Nystatin 
  • 100,000 units/ml suspension Green Traffic Light.
  • 100,000 unit pessaries unlicensedunlicensed Red Traffic Light
    • Second line treatment for vaginal non albicans infection, for patients who have not responded to standard treatments such as azoles. Prescribing is restricted to the GUM clinics.

12.03.02 Nystatin 1000,000units/ml suspension Nystan®
07.02.02 Nystatin Pessaries 
  • Nystatin 100,000 Pessaries (unlicensed)

 

  • As per BASHH guidelines for non-albicans vulvovaginal candida or in azole resistance.
01.09.01 Obeticholic acid 
  • 5mg & 10mg tablets
    • Approved for the treatment of primary biliary cholangitis in line with NICE and NHS England Commissioning Policy.

08.02.03 Obinutuzumab 
  • Approved for use in chronic lymphocytic leukaemia in combination with chlorambucil in patients who have co-morbitities that make full‑dose fludarabine‑based therapy unsuitable for them, only if bendamustine‑based therapy is not suitable and the company provides obinutuzumab with the discount agreed in the patient access scheme in line with NICE (subject to NHS England funding).
  • Approved for the treatment of rituximab-refractory follicular lymphoma in combination bendamustine in line with NICE and NHS England Commissioning Policy
  • Approved with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months after treatment with rituximab or a rituximab-containing regimen in adults in line with NICE
  • Approved to prevent immune immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant
    to rituximab (adults) in line with NHSE Commissioning Policy
    • Only available at The Newcastle upon Tyne Hospitals NHS Trust
08.02.03 Ocrelizumab Ocrevus®
  • Approved for the treatment of relapsing-remitting multiple sclerosis in line with NICE

     

11.08.02 Ocriplasmin Jetrea®
  • Approved for use in patients with vitreomacular traction who also have no epiretinal membrane and a hole (up to 400 micrometres) in the centre of their retina or severe sight problems in line with NICE.
02.11 Octanate 
  • Approved for patients with severe Haemophilia A and an inhibitor and in whom there is agreement to undertake immune tolerance induction with a plasma derived product. 
02.11 Octaplas and Octaplas LG 
  • Solution for infusion containing 45-75mg/ml human plasma proteins.
13.11.03 Octenisan® wash 

  • Used in some trusts as an alternative to chlorhexidine scrub and Triclosan skin cleanser in MRSA prophylaxis/eradication on secondary care advice.

08.03.04.03 Octreotide 

  • Approved formulations include octreotide 50microgram, 100microgram, and 500 microgram in 1ml, and 1mg in 5ml injections, and octreotide 10mg, 20mg and 30mg long-acting injections.
    Existing patients 
    Green Traffic Light  for acromegaly, neuroendocrine tumour and carcinoid. 
    New patients (commenced treatment after July 2019)
    Red Traffic Light  for acromegaly, neuroendocrine tumour and carcinoid.



  • Green Traffic Light Approved for the management of GI secretions in end of life care


 

16 Octreotide 
01.09.01 Odevixibat Bylvay®

  • Approved for the treatment of progressive familial intrahepatic cholestasis in line with NICE

06.04.01.01 Oestrogen conjugated tablets 625microgram and 1.2mg Premarin®
08.02.03 Ofatumumab  Kesimpta®
  • 20mg/0.4ml solution for injection (pre-filled pens)
    • Approved for the treatment of relapsing-remitting multiple sclerosis in adults with active diseases defined by clinical or imaging features in line with NICE

 

11.03.01 Ofloxacin 0.3% Eye drops 
05.01.12 Ofloxacin Infusion 
  • IV infusion: 200mg/100ml 
05.01.12 Ofloxacin Oral Preparations 
  • Tablets: 200mg, 400mg
  • For use in the treatment of pelvic inflammatory disease and chlamydia genital tract infections in accordance with local primary care guidelines.
13.09 Oilatum shampoo 
13.02.01 Oilatum® cream 
13.02.01 Oilatum® Junior cream 
01.07.03 Oily phenol injection BP 
04.02.01 Olanzapine 
  • Olanzapine orodispersible tablets should only be used in situations where the plain tablets are unsuitable. 
  • Olanzapine orodispersible tablets and injection are also approved for 2nd/3rd- line use in the management of delirium in critical care patients unlicensedunlicensed indication. Green plus
  •  10 mg injection Green plus
    • for rapid control of agitation and disturbed behaviours in patients with schizophrenia or manic episode, when oral therapy is not appropriate.
    • for delirium at end of life 
  • 210mg, 300mg & 405mg powder and solvent for suspension for long-acting injection (as olanzapine embonate monohydrate) Red

    • approved for the treatment of schizophrenia in adults within secure psychiatric services


04.02.03 Olanzapine (oral) 
04.02.02 Olanzapine Embonate ZypAdhera®
08.01.05 Olaparib  Lynparza®
  • Approved for the maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based chemotherapy in line with NICE.
  • Approved for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer in adults with a BRCA1 or BRCA2 mutation in line with NICE
  • Approved for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy in adults in line with NICE
  • Approved for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults in line with NICE
  • Approved as maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy in adults in line with NICE and NHSE Specialised Commissioning policy
  • Approved with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults in line with NICE and NHSE Specialised Commissioning policy
12.01.03 Olive Oil Ear Drops 
11.04.02 Olopatadine Opatanol®
03.04.02 Omalizumab Xolair®
  • 75mg/0.5ml & 150mg/1ml solution for injection (pre-filled devices)
  • Only approved for use in accordance with NICE guidance. 
01.03.05 Omeprazole 
  •  10mg, 20mg & 40m capsules
  •  Dispersible tablets (Losec® MUPS) should only be used in patients who cannot swallow capsules or tablets and where lansoprazole orodispersible tablets are unsuitable.
  • 10mg in 5ml oral suspension can be obtained for use in very small children and where a suspension has to be given down a very fine NG tube (below French Size 8) . Green plus Green plus
  • For acute Gastrointestinal bleeding see local guidelines

 

01.03.05 Omeprazole IV 
  • 40mg IV Infusion
  • 40mg Injection (powder for reconstitution)
19 Onasemnogene abeparvovec  Zolgenmsa®

  • Approved for the treatment of spinal muscular atrophy in line with NICE

04.06 Ondansetron 
  • The cheapest available formulation should be used.
  • Ondansetron 4mg and 8mg oro-dispersible tablets/films are approved for the treatment of post-operative nausea and vomiting in patients who do not require IV access or are nil by mouth Red Traffic Light   

04.06 Ondansetron INJECTION 
  • Palliative care use
04.09.01 Opicapone 
18.02.02 Opsite® Post-Op 
09.04 Oral Nutritional Supplements 
07.03.02.01 Oral progestrogen-only contraceptive  

First choice

  • Cerelle® (desogestrel 75 microgram tablets).
  • Cerazette® (desogestrel 75 microgram tablets).
  • Zelleta® (desogestrel 75 microgram tablets).

Alternatives

  • Norgeston® (levonorgestrel 30 microgram tablets).
09.01 Oral Rehydration Salts Dioralyte®
04.05.01 Orlistat 
  • Only approved for use in accordance with NICE guidance. 
04.09.02 Orphenadrine 

 

    • 5mg/5ml Liquid

 

05.03.04 Oseltamivir Tamiflu®

  • 30mg, 45mg and 75mg capsules

  • 6mg/mL oral suspension

  • Only approved for use in accordance with NICE guidance. 

08.02.04 Osimertinib Tagrisso
  • 40mg and 80mg tablet
  • Approved for the treatment of EGFR mutation-positive non-small-cell lung cancer in line with NICE
  • Approved for treating epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults in line with NICE 

 

09.05.02.02 Osvaren® 
  • Tablets containing calcium acetate 435mg & Magnesium carbonate heavy 235mg.
  • For use, after calcium carbonate and calcium acetate, but before the
    much more expensive sevelamer and lanthanum.
08.01.05 Oxaliplatin  
  • Approved for Dukes C colon cancer in combination with 5-fluorouracil
    and folinic acid in line with NICE.
  • Approved for advanced and metastatic colorectal cancer in line with NICE.
03.04.03 Oxandrolone 2.5mg and 10mg capsules 
  • For use on the advice of an immunologist in the prophylaxis treatment hereditary angioedema associated with C1-esterase inhibitor deficiency when danzol and stanozolol are not available.
04.08.01 Oxcarbazepine 
11.07 Oxybuprocaine 0.4% Minims®  
07.04.02 Oxybutynin  
  • 2.5mg and 5mg tablets
  • 2.5mg in 5ml & 1mg/1ml oral solution
  • Immediate release oxybutinin is not appropriate for frail elderly people or those with cognitive impairment.

 

07.04.02 Oxybutynin Hydrochloride - patch 
  • Oxybutinin patch 36mg (releases approximately 3.6mg in 24 hours). 
  • Approved for patients in whom two antimuscarinics have proved to be efficacious but the side effects are intolerable, or for patients who cannot swallow tablets.



 

04.07.02 Oxycodone 
  • Approved only for use in patients who are intolerant of morphine. Green
    • Note: Oxycodone 50mg in 1ml injection  is also approved for use, but is restricted to controlled circumstances in palliative patients following risk assessment by individual organisations.Green Traffic Light
  • Approved for use as part of Enhanced Recovery After Surgery (ERAS) as part of multi-modal enhanced recovery pathway following hip and knee surgery Red
    • The OxyPro® branded generic is preferred (most cost effective option). 
    • The oral solution should be used instead of immediate release tablets. 
15.01.02 Oxygen 
11.09 Oxysept® 1 Step 
05.01.03 Oxytetracycline 
07.01.01 Oxytocin 
  • The following formulations are approved for use:
    • 10 units in 1ml injection
    • 5 units in 50ml syringes unlicensedunlicensed.
01.05.03 Ozanimod Zeposia®
  • Approved for moderately to severely active ulcerative colitis in adults in line with NICE.
08.01.05 Pablociclib Ibrance®
08.01.05 Paclitaxel 
  • The following formulations are approved:
  • 30mg in 5ml, 100mg in 16.7ml, and 150mg in 25ml concentrate for preparing IV infusion.
  • Approved for the treatment of recurrent ovarian cancer in line with NICE.
08.01.05 Paclitaxel - Albumin Bound Formulation Abraxane®
  • Note: Abraxane® 5mg in 1ml powder for suspension for infusion is restricted for use within its current license for metastatic breast cancer patients who cannot tolerate standard taxanes. 
  • Approved in combination with a platinum-based compound or platinum-based therapy alone (cisplatin or carboplatin) for first line therapy in ovarian cancer in line with NICE.
  • Approved in combination with a platinum-based drug (carboplatin or cisplatin) for second-line (or subsequent) therapy in ovarian cancer in line with NICE
  • Approved metastatic breast cancer in line with NICE.
  • Abraxane is not recommended for the adjuvant treatment of women with early node-positive breast cancer NICE.
  • Approved in combination with gemcitabine for untreated metastatic pancreatic cancer in line with NICE and NHS England Commissioning Policy as of 5th December 2017
08.03.04.01 Palbociclib Ibrance®
  • 75mg, 100mg & 125mg capsules
  • Approved for use with an aromatase inhibitor for the treatment of previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in line with NICE
  • Approved with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy in line with NICE
04.02.02 Paliperidone 
  • Green plus CNTW
  • Amber TEWV
  • NTAG approved for the treatment of schizophrenia as per its licensed indication and as outlined in the Guidance on the Use of Antipsychotic Long-acting Injections in the North of England.
05.03.05 Palivizumab 
  • To be used in accordance with NHS England Commissioning Policy.   
04.06 Palonosetron 
  • Only approved for the second line treatment of chemotherapy induced nausea vomiting only.
01.09.04 Pancreatin Creon®
01.09.04 Pancreatin Pancrex® V
01.09.04 Pancreatin Creon® Micro
15.01.05 Pancuronium 
  • 4mg in 2ml injection
08.01.05 Panitumumab Vectibix®

  • Approved for previously untreated metastatic colorectal cancer in line with NICE.

08.01.05 Panobinostat  
  • Approved in combination with bortezomib and dexamethasone as an option for the treatment of multiple myeloma in line with NICE.

 

01.03.05 Pantoprazole IV 
  • 40 mg injection

  • Switich to lansoprazole or omeprazole when an oral preparation is needed

15.01.05 Papaverine 
  • 30mg/2ml injection unlicensedunlicensed
04.07.01 Paracetamol 
  • Paracetamol 500mg tablets / soluble tablets
  • Paracetamol 1gram injection for IV infusion Red 
    • NoTGhdNC: approved for limited short-term use where oral and rectal routes cannot be used and NSAIDs are not appropriate in paediatric areas only, the 50ml formulation should be stocked.
  • Paracetamol suppositories
  • Licensed preparations include 60mg,125mg, 250mg, and 500mg suppositories are available in primary care.
  • unlicensed unlicensed preparations include 15mg, 30mg, 60mg, 120mg, 240mg, and 500mg. These are used in NUTH.
04.07.04.01 Paracetamol 
04.08.03 Paracetamol 

Paracetamol suppositories



  • unlicensedunlicensed preparations include 15mg, 30mg, 60mg, 120mg, 240mg, and 500mg. These are used in NUTH.

  • Licensed preparations include 60mg, 125mg, 250mg, and 500mg suppositories are available in primary care.

18.01.01 Paraffin Gauze Dressing BP Sterile Paranet®
13.02.01 Paraffin sterile liquid 
04.08.02 Paraldehyde rectal liquid 

 

    • For initiation by neurologists only.

 

15.01.04.02 Parecoxib 40mg injection Dynastat®
  • For peri-operative use only.
09.05.01.02 Paricalcitol 
  • Approved for use in patients with PTH levels < 800mcg/l but  whose treatment with alfacalcidol is restricted due to a high calcium level.
05.04 Paromomycin 
  • 250mg tablets and Injection
  • For Leishmaniasis
  • Infectious diseases of microbiology advice only
04.03.03 Paroxetine 
08.03.04.03 Pasireotide Signifor®
  • Approved for the treatment of Cushing’s disease in line with NHS England Policy.
19 Patent Blue V Sodium 
09.02.01.01 Patiromer calcium (as Patiromer sorbitex calcium) 
  • Approved for the treatment of hyperkalaemia in adults in line with NICE Green plus
  • Approved for emergency acute treatment Red

 

04.12 Patisiran Onpattro®

  • 10mg vial 

  • Approved for the treatment of hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuopathy in line with NICE

08.01.05 Pazopanib Votrient®
  • Approved for advanced renal cell carcinoma in line with NICE
03.04.02 Peanut Allergy Palforzia®

  • 0.5mg, 1mg, 10mg, 20mg and 100mg oral powder in capsules for opening

  • 300mg oral powder (sachets)

    • Approved for the treatment of peanut allergy in children and young people in line with NICE



08.01 Pegaspargase 3750iu vial 
09.01.03 Pegcetacoplan Aspaveli®
  • 1080mg/20 solution for infusion
  • Approved for the treatment paroxysmal nocturnal haemoglobinuria in adults who have anaemia after at least 3 months of treatment with a C5 inhibitor in line with NICE and NHSE Commissioning Policy.
  • Paroxysmal nocturnal haemoglobinuria treatment is only commissioned from:
    • King’s College Hospital NHS Foundation Trust, London - London and South East
    • Leeds Teaching Hospitals NHS Trust - Rest of United Kingdom

 

09.01.06 Pegfilgrastim (G-CSF) 
05.03.03.02 Peginterferon Alfa Pegasys®, ViraferonPeg®
  • Approved  for hepatitis B and C in accordance with NICE guidelines and NHS England Commissioning Policies. 

 

  • See Section 08.02.04
08.02.04 Peginterferon Alfa Pegasys®, ViraferonPeg®
  • Approved  for hepatitis B and C in accordance with NICE guidelines and NHS England Commissioning Policies. 
08.02.04 Peginterferon Beta-1a Plegridy®

  • Approved treating relapsing–remitting multiple sclerosis in adults in line with NICE.

09.08.01 Pegunigalsidase alfa Elfabrio®
  • 20mg/10ml concentrate for solution for infusion
  • Approved for treating Fabry disease in line with NICE and NHSE Specialised Commissioning guidance
06.05.01 Pegvisomant Somavert®
08.01.05 Pembrolizumab  Keytruda®
  • Approved for the treatment of advanced melanoma after disease progression with ipilimumab in accordance with NICE.  
  • Approved for the treatment of advanced melanoma not previously treated with ipilimumab in accordance with NICE. 
  • Approved for treating PD-L1-positive non-small-cell lung cancer 
  • Approved for treating PD-L1-positive metastatic non-small-cell lung cancer 
  • Approved for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in adults whose tumours express PD L1 with a combined positive score (CPS) of 1 or more in line with NICE
  • Approved with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations.
  • Approved for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults in line with NICE
  • Approved for untreated metastatic colorectal cancer with high microsatellite instability or mismarhc repair deficiency in line with NICE
  • Approved with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer in adults in line with NICE
  • Approved for adjuvant treatment of completely resected stage 3 melanoma in line with NICE
  • Approved in combination with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung cancer in line with NICE
  • Approved for treating relapsed or refractory classical Hodgkin lymphoma in people aged 3 and older who have had a stem cell transplant or at least 2 previous therapies in line with NICE
  • Approved with paclitaxel or nab‑paclitaxel for triple-negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease in line with NICE
  • Approved for adjuvant treatment of renal cell carcinoma in adults in line with NICE
  • Approved for the adjuvant treatment of resected stage 2B and 2C melanoma in people 12 years and over in line with NICE
  • Approved with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations in line with NICE
  • Approved plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer in adults in line with NICE
  • Approved with lenvatinib for previously treated advanced or recurrent endometrial cancer in line with NICE and NHSE Specialised Commissioning guidance
  • Approved for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency in adults in line with NICE and NHSE Specialised Commissioning guidance
  • Approved plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer in line with NICE
08.01.03 Pemetrexed  
  • Approved for:
    • Mesothelioma in line with NICE (funding has to be agreed on an individual patient basis if treatment is not in line with NICE).
    • Combination with cisplatin for the first line treatment of locally advanced or metastatic NSCLC (non-squamous cell histology) in line with NICE.
    • Maintenance treatment of locally advanced or metastatic NSCLC (non-squamous cell histology) in line with NICE.
    • Maintenance treatment of non-squamous non-small lung cancer after pemetrexed and cisplatin in line with NICE and NHS England Commissioning Policy.

  • Note: pemetrexed is not approved for locally advanced or metastatic NSCLC as per NICE. 
08.01.05 Pemigatinib Pemaryze®
  • 4.5mg, 9mg and 13.5mg tablets
  • Approved for the treatment of relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in line with NICE

 

09.08.01 Penicillamine 
  • 125mg & 250mg tablets - also used for the treatment ofcystinuria and rheumatoid arthritis – section 10.1.3
10.01.03 Penicillamine 
16 Penicillamine 
  • 125mg & 250mg tablets
05.04.08 Pentamidine Isetionate 
07.04.03 Pentosan Polysulphate Sodium  Elmiron®
  • 100mg capsules
  • Approved for treating bladder pain in line with NICE
08.01.05 Pentostatin Nipent®
01.02 Peppermint Oil Colpermin®
01.02 Peppermint water 
01.01.02 Peptac 
  • Preferred antacid for treating reflux. Use instead of Gaviscon®.
04.08.01 Perampanel 
  • NETAG approved for partial (focal) seizure epilepsy only when other treatment  options recommended by NICE have been tried or fully considered.
04.09.01 Pergolide 
02.05.05.01 Perindopril erbumine 

  • Perindopril is third line for all indications including prevention of stroke.

  • Note: Perindopril arginine is Non-Formulary.

13.10.04 Permethrin 1% Lyclear® Creme Rinse
13.10.04 Permethrin 5% Lyclear® Dermal Cream
13.10.04 Permethrin 5% Lyclear® Dermal Cream
04.02.01 Perphenazine 
08.01.05 Pertuzumab Perjeta®

  • Approved for the neoadjuvant treatment of HER2-positive breast cancer in line with NICE and NHS Commissioning Policy

  • Approved with trastuzumab and docetaxel for treating HER2-positive breast cancer in line with NICE and NHS Commissioning Policy

  • Approved for adjuvant treatment of HER2-positive early stage breast cancer in line with NICE

04.07.02 Pethidine 
12.01.02 Phenazone with lidocaine Otigo®
  • Phenazone 40mg/1g & lidocaine hydrochloride 10mg/1g ear drops
    • Approved for the treatment of Acute otitis media & Barotraumatic otitis in line NICE


 

19 Phenazopyridine tablets 
04.03.02 Phenelzine 
  • For use on advice from psychiatrists only.
02.08.02 Phenindione 
04.08.01 Phenobarbital 
04.08.02 Phenobarbital Sodium 
04.08.01 Phenobarbital INJECTION 
19 Phenol (aqueous) Injection 6% 
04.12 Phenol 5% in Glycerol Injection 
  • Approved for intrathecal neurolysis treatment of intractable pain due to cancer in terminally ill patients
02.05.04 Phenoxybenzamine  
05.01.01.01 Phenoxymethylpenicillin 
02.05.04 Phentolamine 
16 Phentolamine 
10.01.01 Phenylbutazone 

Tablets: 100mg

Indication: Ankylosing Spondylitis. 

Used only by a specialist in severe cases where other treatments have been found unsuitable.

02.07.02 Phenylephrine 
11.05 Phenylephrine 
  • 2.5% eye drops unlicensedunlicensed
  • 2.5% single use Minims®
11.05 Phenylephrine Hydrochloride 
  • 2.5% eye drops unlicensedunlicensed.
  • 2.5% single use Minims®.
04.07.03 Phenytoin 
04.08.01 Phenytoin 
  • Note: phenytoin 30mg in 5ml suspension (base) – 90mg (15ml) is equivalent to one 100mg phenytoin sodium capsule 250mg in 5ml injection (sodium salt).
04.08.02 Phenytoin sodium 250mg in 5ml injection 

 

    • For initiation by neurologists only.

 

09.05.02.01 Phosphate  
  • 4.15 mmol phosphate in 10ml oral solution unlicensedunlicensed
09.05.02.01 Phosphate Polyfusor 
  • 500ml intravenous infusion containing 50mmol phosphate
    per 500ml (PO4 3- 100 mmol, K+ 19 mmol, and Na+ 162 mmol/litre).
01.06.04 Phosphates  
  • Phosphates enema (Formula B) 128ml

  • Sodium dihydrogen phosphate dihydrate 18.1% / Disodium hydrogen phosphate dodecahydrate 8% 133ml enema - Cleen® Ready-to-use

09.05.02.01 Phosphate-Sandoz® 
  • Effervescent tablets (phosphate 16.1 mmol, sodium 20.4mmol & potassium 3.1 mmol / tablet)
09.02.02.02 Phoxilium 1.2mmol/l phosphate 
  • A haemofiltration and haemodialysis fluid containing Na+ 140 mmol, K+ 4 mmol, Mg2+ 0.6 mmol, Ca2+ 1.25mmol/l, Cl- 115.9 mmol/l, HCO3 - 30.0mmol/l, HPO4 2- 1.20mmol/l.
    • Approved for use in CRRT in patients not requiring reduced potassium or low bicarbonate.

15.01.06 Physostigmine 
  • 1mg in 1ml injection unlicensedunlicensed
09.06.06 Phytomenadione 
  • 50 microgram in 0.25ml drops (NeoKay®) unlicensedunlicensed
  • 1mg capsule- preferred product for use in neonates
  • 10mg in 1ml injection unlicensedunlicensed
  • 2mg in 0.2ml mixed micelles injection (Konakion® MM
    Paediatric) – may be taken by mouth as well as being given by IM or IV injection
16 Phytomenadione (vitamin K) 
08.01.05 Picibanil  
18.06.01 PICO® Single Use NPWT System 
11.06 Pilocarpine 
  • 2% and 4% eye drops.
  • 1% and 2% unit dose eye drops.
12.03.05 Pilocarpine 5mg tablets 
  • Treatment to be initiated with specialist advice.
13.05.03 Pimecrolimus cream Elidel®
  • Approved for moderate disease on face and neck for those between 2 and 16 years in line NICE.
06.01.02.03 Pioglitazone 
05.01.01.04 Piperacillin and Tazobactam 
  • Restricted for use on microbiology/infectious diseases advice, or as agreed in Trust Guidelines.
04.08.01 Piracetam 
03.11 Pirfenidone 

 

    • Approved for the treatment of idiopathic pulmonary fibrosis in line with NICE and NHS England Commissioning Policy

 

04.04 Pitolisant Wakix®
  • Approved for use in patients with narcolepsy who experience psychomotor side effects with modafinil and dexamfetamine.
  • To be used in line with NTAG

 

05.01.01.05 Pivmecillinam 
08.01.02 Pixantrone  
  • Approved as a possible treatment for adults with multiply relapsed or refractory aggressive non-Hodgkin's B cell lymphoma if they have previously been treated with rituximab and they are having third- or fourth-line treatment in line with NICE. 
04.07.04.02 Pizotifen 
09.02.02.02 Plasma-lyte 148 with Glucose 5% 
  • Infusion in a balanced electrolyte solution containing Na+ 140 mmol, K+ 5 mmol, Mg2+ 1.5 mmol, acetate 27 mmol/litre. Gluconate 23 mmol/litre. Note calcium free.
    • Approved for use in paediatric theatres only.

13.11 Plaster remover 
01.06.05 Plenvu ® 

  • Approved as a second line option to Moviprep for bowel cleansing prior to colonoscopy where large fluid volumes are a problem.

09.01.07 Plerixafor Mozobil®
  • Approved by NHS England Specialist Services for stem cell mobilisation for patients with Hodgkin’s disease, Non-Hodgkins lymphoma or multiple myeloma and meet the policy for Haematopoietic Stem Cell Transplantation.
14.04 Pneumococcal polysaccharide conjugate vaccine  
13.07 Podophyllotoxin 0.15% cream Warticon®
08.01.05 Polatuzumab vedotin Polivy®
  • Approved with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma in adults who cannot have a haematopoietic stem cell transplant in line with NICE
  • Approved with rituximab, cyclophosphamide, doxorubicin and prednisolone (R‑CHP) for untreated diffuse large B-cell lymphoma (DLBCL) in adults - in line with NICE TA874.
11.03.01 Polihexanide 

Unlicensed

14.04 Poliomyelitis Vaccine Inactivated (Salk) 
14.04 Poliomyelitis Vaccine Live (oral)  
18.07.01 Polyfield ® Nitrile Patient Pack 

Contains powder-free nitrile gloves, laminate sheet, non-woven swabs, towel, polythene disposable bag, apron

  • First choice on FP10
11.03.01 Polyhexamethylene biguinide (PHMB) 0.02% Eye drops 
08.01.05 Pomalidomide 

Commissioner: NHS England

Only to be used in line with a current chemotherapy protocol from the North of England Cancer Alliance in line with the appropriate Network Site Specific Group’s clinical guidelines or chemotherapy algorithm

 

 

08.02.04 Pomalidomide Imnovid®
  • For the treatment of multiple myeloma previously treated with lenalidomide and bortezomib in line with NICE and NHS Commissioning Policy
08.01.05 Ponatinib Iclusig®
  • 15mg, 30mg & 45mg film-coated tablets
  • Approved for the treatment of chronic myeloid leukaemia and acute lymphoblastic leukaemia in line with NICE and NHS England Commissioning Policy
08.02.04 Ponesimod Ponvory®
  • 20mg tablets
    • Approved for treating relapsing–remitting multiple sclerosis with active disease defined by clinical or imaging features in adults in line with NICE


 

03.05.02 Poractant Alfa 
08.01.05 Porfimer Sodium Photofrin ®
05.02.01 Posaconazole  Noxafil®
  • Approved for the prevention of invasive fungal infection in immunocompromised patients in whom there is a specific risk of aspergillus infection or where fluconazole and itraconazole are not tolerated or are unlikely to be sufficiently effective (largely for secondary prevention).
  • Approved for patients with invasive fungal infections that are not responding to other treatments or where they are not tolerated (largely in place of liposomal amphotericin/ voriconazole).
09.02.01.01 Potassium Chloride Sando-K®
  • Effervescent tablets (12mmol potassium 8 mmol chloride)
09.02.01.01 Potassium Chloride 

5mmol in 5ml sugar-free syrup (Kay-Cee-L) 

07.04.03 Potassium Citrate Mixture 

 

    • potassium citrate 3g & citric acid 500mg in 10ml



Note: for the treatment of  mild cystitis potassium citrate mixture is suitable for self-care.

06.02.02 Potassium Iodate 85mg tablets 
  • Mainly used by medical physics.
13.10.01.01 Potassium Iodide capsules 
  • Unlicensed Drug Unlicensed
  • Potassium Iodide 60mg and 300mg capsules
  • Approved for neutrophilic dermatoses (Sweet syndrome and pyoderma gangrenosum) and panniculitis (including erythema nodosum and nodular vasculitis)
  • Dermatology only
13.11.06 Potassium Permanganate 
  • 5% solution unlicensedunlicensed
  • 400mg tablets  
  • Potassium permanganate not to be issued on repeat prescription 
09.02.01.01 Potassium Removal Polystyrene Sulphonate Resin Powder (Calcium polystyrene sulphonate) Sorbisterit
11.03.01 Povidone iodine 5% 
11.08.02 Povidone iodine 5% eye drops 
  • For use in eye surgery only. 
13.11.04 Povidone-Iodine 
  • 2.5% dry powder spray
  • 10% alcoholic solution
  • 7.5% surgical scrub
  • 10% antiseptic solution (aqueous)
  • 0.35% sterile aqueous solution Red Traffic Light
    • approved for use in the prevention of surgical site infection in arthroplasty. 

18.03.02 Povitulle® 

Knitted viscose primary dressing impregnated with povidone-iodine ointment

  • First choice in primary care 
15.02 PR Freeze Spray 
16 Pralidoxime Mesylate 
  • 1g in 5ml injection
04.09.01 Pramipexole 
  • Approved for second line use in Parkinson's disease. 
04.09.01 Pramipexole (restless legs) 
02.09 Prasugrel 
  • Only approved for use in accordance with NICE guidance.
02.12 Pravastatin  

  • 10mg, 20mg & 40mg tablets

05.05.05 Praziquatel Biltricide  
07.04.01 Prazosin  
  • 500microgram tablets
01.05.02 Prednisolone 

  • 5mg suppositories only

01.05.02 Prednisolone 

First Choice

See BNF 06:03:02 for formulations

 

06.03.02 Prednisolone  
  • The lowest cost formulation should be used when clinically appropriate.  Formulations approved include:
    • 1mg, 5mg tablets;
    • 5mg soluble tablets;
    • 1mg in 1ml oral solution (Prednisolone Dompé®);
    • 5mg suppositories.
12.01.01 Prednisolone 0.5% ear/eye drops 
  • Second choice corticosteroid ear drops.
11.04.01 Prednisolone 0.5% Single Use Minims® 
11.04.01 Prednisolone eye drops 
  • The following formulations are approved
    • 0.5% eye drops and 1% (Pred-Forte).
    • 0.1% and 0.3% eye drops - both unlicensedunlicensed.

  • Approved preservative free formulations include
    • 0.5% minims.
    • 0.1%, 0.3%, 0.5% and 1% - all unlicensedunlicensed.

04.01.02 Pregabalin 
04.07.03 Pregabalin 
  • Pregabalin is restricted to use in the management neuropathic pain as a second choice where treatment with gabapentin has been unsuccessful or not tolerated.
04.08.01 Pregabalin 
  • Approved for specialist advice in the management of treatment resistant epilepsy. 
  • Also approved as a second line agent for General Anxiety Disorder. Although treatment can be given 2-3 times daily, it is more cost effective to give as a twice daily dose. 
06.01.05 Pregabalin 
09.02.02.01 Premixed potassium infusion bags 

Infusion: 0.15% (10 mmol) potassium chloride & 0.9% sodium chloride 500ml
Infusion: 0.15% (20 mmol) potassium chloride & 0.9% sodium chloride 1000ml
Infusion: 0.15% (10 mmol) potassium chloride & 5% glucose 500ml
Infusion: 0.15% (20 mmol) potassium chloride & 5% glucose 1000ml
Infusion: 0.15% (10 mmol) potassium chloride & 10% glucose 500ml
Infusion:  0.15% (10 mmol) potassium chloride, 0.18% sodium chloride & 4%  glucose 500ml
Infusion:  0.15% (20 mmol) potassium chloride, 0.18% sodium chloride & 4%  glucose 1000ml
Infusion:  0.15% (10 mmol) potassium chloride, 0.9% sodium chloride & 5%  glucose 500ml
Infusion:  0.2% (13.5 mmol) potassium chloride & 0.9% sodium chloride 500ml
Infusion: 0.2% (27 mmol) potassium chloride & 0.9% sodium chloride 1000ml
Infusion:  0.2% (13.5 mmol) potassium chloride & 5% glucose 500ml
Infusion:  0.2% (27 mmol) potassium chloride & 5% glucose 1000ml
Infusion:  0.2% (13.5 mmol) potassium chloride, 0.18% sodium chloride & 4% glucose 500ml
Infusion: 0.2% (27 mmol) potassium chloride, 0.18% sodium chloride & 4% glucose 1000ml
Infusion:  0.3% (20 mmol) potassium chloride & 0.9% sodium chloride 500ml
Infusion: 0.3% (40 mmol) potassium chloride & 0.9% sodium chloride 1000ml
Infusion: 0.3% (20 mmol) potassium chloride & 5% glucose 500ml
Infusion:  0.3% (40 mmol) potassium chloride & 5% glucose 1000ml
Infusion: 0.3% (20 mmol) potassium chloride & 10% glucose 500ml
Infusion:  0.3% (20 mmol) potassium chloride & 20% glucose 500ml
Infusion:  0.3% (20 mmol) potassium chloride, 0.18% sodium chloride & 4% glucose 500ml
Infusion: 0.3% (40 mmol) potassium chloride, 0.18% sodium chloride & 4% glucose 1000ml
Infusion:  0.3% (20 mmol) potassium chloride, 0.45% sodium chloride & 5% glucose 500ml
Infusion:  0.3% (20 mmol) potassium chloride, 0.9% sodium chloride & 5% glucose 500ml
Infusion:  0.6% (40 mmol) potassium chloride & 0.9% sodium chloride 500ml
Infusion:  0.6% (40 mmol) potassium chloride & 5% glucose 500ml

 

09.04 Preterm Infants in Primary Care  
15.02 Prilocaine Hydrochloride 

 

    • 0.5% 10ml injection unlicensedunlicensed, 1% 20ml injection.

 

    • 4% 2ml injection (cartridges).

 

    • 2% 5ml injection (cartridges) 



      • Only to be used in patients undergoing spinal anaesthesia for day surgery where the procedure is anticipated to last less than 90 minutes.





    • 3% & felypressin injection (cartridges).

 

05.04.01 Primaquine 
04.08.01 Primidone  
19 PrimsOcal® B22 
19 Primsocitrate® 18/0 
05.01.07 Pristinamycin 
  • Tablets: 500 mg

 

  • Approved for
    • Pregnant women infected with Mycoplasma Genitalium (MG) infection that is resistant to macrolides
    • Mycoplasma Genitalium (MG) infection that is resistant to macrolides, quinolones and tetracyclines in both men and women
10.01.04 Probenecid 

Tablets: 500mg

11.05 Procaine hydrochloride, atropine sulphate & adrenaline acid tartrate Mydricaine®
  • Mydricaine® No.2 [Contains procaine hydrochloride 6mg, atropine sulphate 1mg, adrenaline 1:1,000; (0.12mg)]
  • Approved for the treatment of anterior uveitis
05.01.01.01 Procaine Penicillin 
08.01.05 Procarbazine  
04.06 Prochlorperazine 
  • Note: Buccastem® 3mg tablets are only approved for the treatment of nausea associated with migraine when the oral route cannot be used due to vomiting.
01.07.02 Proctosedyl® 
  • Cinchocaine 0.5% / Hydrocortisone 0.5% ointment
  • Self Care Self Care Medicine: Advise CCGs that a prescription for treatment of haemorrhoids should not routinely be offered in primary care as the condition is self-limiting and will clear up on its own without the need for treatment.
  • Topical corticosteroids are suitable for occasional short-term use (no more than 7 days) after exclusion of infections
04.09.02 Procyclidine 
16 Procyclidine 
06.04.01.02 Progesterone 
  • Approved formulations include:
    • 200mg & 400mg pessaries (Cyclogest®) Green
    • 25mg SC/IM injection (Lubion®) Red
      • Approved for luteal support in patients who have had a previous failed biochemical pregnancy in a froxen embryo transfer (FET) cycle
  • CD&TV Red for Luteal Phase support following IVF.
    • Full course to be supplied by hospital
  • CD&TV  Green plus to support the pregnancies of women who have a history of miscarriage or premature labour as per NICE NG25: Preterm labour and birth.
03.04.01 Promethazine 
04.01.01 Promethazine Hydrochloride 
04.06 Promethazine Hydrochloride Phenergan
13.11.02 Prontosan 
  • Solution containing Betaine 0.1% (surfactant) and Polyhexanide 0.1% (a chlorhexidine polymer). Mainly for use from 40ml plastic ampoules.
    Also available as a gel. 
  • To be prescribed/used only on the advice of tissue viability specialists.
18.03.04 Prontosan® Wound Gel 30ml 

Hydrogel containing betaine surfactant and polihexanide

  • Specialist use only
18.03.04 Prontosan® Wound Irrigation Solution  

Aqueous solution containing betaine surfactant and polihexanide

  • Specialist use only
02.03.02 Propafenone 
11.03.01 Propamidine Isetionate 
  • For use in the treatment of acanthamoeba keratitis – used with PHMB.
01.02 Propantheline 
07.04.02 Propiverine 
  • Tablets: 15mg
15.01.01 Propofol 
  • 1% (10mg/ml) injections (Propofol Lipuro®) available as 200mg in 20ml ampoules.
  • 500mg in 50ml and 1g in 100ml bottles.
  • 1% (10mg/ml) 50ml (500mg) prefilled syringes for use in Diprifusor pumps (Diprivan®).
  • 2% (20mg/ml) injection - 1g in 50ml bottles for ITU use only.
02.04 Propranolol 
04.07.04.02 Propranolol 
06.02.02 Propranolol 80mg MR capsules 
  • Propranolol 80mg MR capsules is the preferred formulation for relief of thyrotoxic symptoms.
02.04 Propranolol Injection 
19 Pro-Prems® 

  • Approved for the prevention of necrotising enterocolitis (NEC) in pre-term infants.

06.02.02 Propylthiouracil 
02.08.03 Protamine Sulphate 
16 Protamine Sulphate 
02.11 Protein C Concentrate Ceprotin®
05.01.09 Prothionamide 
  • 250mg tablets - Unlicensed

 

  • Infectious diseases, microbiology or respiratory advice only
02.11 Prothrombin Complex Concentrate  Octaplex®
06.05.01 Protirelin (TRH) 
11.07 Proxymetacaine 0.5% Minims® 

Minims® eye drops (preservative free): 0.5%

01.06.07 Prucalopride 
  • Approved for chronic constipation in women in line with NICE guidance.
  • Also approved for use in men with chronic constipation according to the NICE criteria for women.
03.10 Pseudoephedrine Hydrochloride 
05.01.09 Pyrazinamide 
10.02.01 Pyridostigmine Bromide 
09.06.02 Pyridoxal Phosphate 
  • 25mg tablets unlicensedunlicensed
  • 50mg capsules unlicensedunlicensed
16 Pyridoxine (high dose) 
09.06.02 Pyridoxine Hydrochloride 
  • 10mg unlicensedunlicensed
  • 50mg tablets
09.06.02 Pyridoxine Hydrochloride Injection 

Injection: 50 mg/2 mL

05.04.01 Pyrimethamine Darprim®
04.02.01 Quetiapine 

  • 25mg, 100mg, 150mg 200mg & 300mg tablets Green plus

  • 50mg, 200mg, 300mg & 400mg prolonged release tablets Green plus 


    • Prolonged release tablets are approved for use in patients who require an outside carer to administer their medicines, and for short term use when rapid dose titration is considered important e.g. where its use might avoid the need to admit the patient to hospital.



  • Quetiapine 20mg/ml Oral Suspension (Rosemont) - CNTW only Red 


 

04.02.03 Quetiapine 
06.07.01 Quinagolide 
05.04.01 Quinine Dyhydrochloride 
10.02.02 Quinine sulfate 
  • 300mg tablets
  • Approved for nocturnal leg cramps in accordance with MHRA advice
05.04.01 Quinine sulphate 
13.02.01 QV® 
  • Approved for used in radiotherapy only.
14.04 Rabies vaccine 
19 Radiesse Voice® 
08.03.04.02 Radium-223 dichloride 
  • Provided by radiotherapy department in accordance with NICE
08.03.04.01 Raloxifene 

60mg tablets

06.04.01.01 Raloxifene Hydrochloride 
  • For use on the advice of specialists in the prevention and treatment of osteoporosis where alternative treatments are inappropriate.
05.03.01 Raltegravir 
  • Approved for use in the treatment of patients with HIV infections that are resistant to standard therapy in accordance with British HIV Association and EACS guidelines.
08.01.03 Raltitrexed Tomudex®
02.05.05.01 Ramipril 
  • Most cost effective formulation to be prescribed
08.01.05 Ramucirumab Cyramza®
11.08.02 Ranibizumab 10mg/1ml injection Lucentis®
  • Approved for wet age related macular degeneration in line with NICE.
  • Approved for diabetic macular oedema in line with NICE.
  • Approved for visual impairment caused by macular oedema secondary
    to retinal vein occlusion in line with NICE.
  • Approved as a possible treatment for sight problems caused by choroidal neovascularisation in people who also have pathological myopia in line with NICE.

 

 

02.06.03 Ranolazine 
  • For use in the treatment of angina in those patients for whom other treatments have been unsuccesful.
  • Initial prescribing should be by a consultant cardiologist only. 
04.09.01 Rasagiline 
10.01.04 Rasburicase 
  • Only approved for prophylactic use in high risk patients.
09.01.03 Ravulizumab Ultomiris®
  • 300mg/30ml & 1,100mg/11ml concentrate for solution for infusion
  • Approved for the treatment of paroxysmal nocturnal haemoglobinuria in adults in line with NICE
  • Approved for the treatment of atypical haemolytic uraemic syndrome in line with NICE
  • Paroxysmal nocturnal haemoglobinuria treatment is only commissioned from 
    • King’s College Hospital NHS Foundation Trust, London - London and South East
    • Leeds Teaching Hospitals NHS Trust - Rest of United Kingdom
04.03.04 Reboxetine 
  •  Not licensed in the elderly

 

02.03.02 Regadenoson 
  • For radionuclide myocardial perfusion imaging in patients who are unable to undergo adequate exercise stress (e.g. COPD and asthma patients where dobutamine is indicated, and obese patients who require several vials of adenosine).
08.01.05 Regorafenib Stivarga®
  • 40mg tablets
  • Approved for treating unresectable or metastatic gastrointestinal stromal tumours in adults whose disease has progressed on, or who are intolerant to, prior treatment with imatinib and sunitinib in line with NICE and NHS England Commissioning Policy.
  • Approved for treating advanced hepatocellular carcinoma in adults who have had sorafenib in line with NICE
  • Approved as an option for metastatic colorectal cancer in adults who have had previous treatment (including fluoropyrimidine-based chemotherapy, anti‑VEGF therapy and anti‑EGFR therapy) or when these treatments are unsuitable - in line with NICE.
06.07.02 Relugolix–estradiol–norethisterone acetate Ryeqo®
  • Approved as an option for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age - in line with NICE TA832.
15.01.04.03 Remifentanil 
  • 1mg, 2mg & 5mg injections.
18.06.01 Renasys® Go  
09.06.07 Renavit® tablets 
  • Water soluble vitamin supplementation therapy for maintenance haemodialysis patients only.
06.01.02.03 Repaglinide 
03.04.02 Reslizumab Cinquil®
  • 10 mg/mL concentrate for solution for infusion
  • Approved for the treatment of severe eosinophilic asthma in line with NICE and NHS England Commissioning Policy
09.02.01.01 Resonium A® 
  • Powder (Sodium polystyrene sulphonate)
A2.05.02 Resource® Thickened Drink 
A2.05.02 Resource® ThickenUp Clear 
05.03.03.02 Ribavirin 
05.03.05 Ribavirin Virazole®
08.03.04.01 Ribociclib Kisqali®
  • 200mg tablets
  • Approved for use with an aromatase inhibitor for the treatment of previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in line with NICE and NHS England Commissioning Policy
  • Approved for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in adults who have had previous endocrine therapy in line with NICE

 

05.01.09 Rifabutin 
05.01.09 Rifampicin 
  • 150mg & 300mg capsules Green Traffic Light
  • 100mg in 5ml syrup Green Traffic Light
  • 600mg vials for IV infusion Red Traffic Light  
05.01.09 Rifampicin and Isoniazid 
05.01.09 Rifampicin and Isoniazid and Pyrazinamide 
05.01.07 Rifaximin 
  • 550mg Tablets: Only approved for use in accordance with NICE guidance. 

 

05.03.01 Rilpivirine hydrochloride 
  • For patients who, due to renal impairment, require reduced doses that are not able to be accommodated by the fixed combination product.
04.09.03 Riluzole 
  • 50mg tablets; 50mg orodispersible tablets (Emylif); 5mg/1ml oral suspension
  • Approved for motor neurone disease in line with NICE. 
  • Note: riluzole orodispersible film and oral suspension approved only when other preparations (including crushing tablets) are not suitable.

04.07.04.02 Rimegepant  Vydura®
  • 75mg oral lyophilisates
  • Approved for preventing migraine in line with NICE Green plus
    • First three month's supply from secondary care followed by 12 week review and then transfer to primary care with a 4 week prescription to allow for handover
  • Approved for treating migraine in line with NICE Green
11.04.01 Rimexolone 

ophthalmology advice only - second line if flurometholone unsuitable

02.05.01 Riociguat 
  • Approved for Chronic Thromboembolic Pulmonary Hypertension - in accordance with NHS England Commissioning policy. 
01.05.03 Risankizumab Skyrizi®
  • 150mg/1ml solution for injection (pre-filled devices)
  • Approved for previously treated moderately to severely active Crohn's disease in people 16 years and over in line with NICE
13.05.03 Risankizumab Skyrizi®

  • Approved for the treatment of moderate to severe plaque psoriasis in line with NICE

10.02 Risdiplam Evrysdi®
  • 0.75mg/1ml oral solution
  • Approved for treating spinal muscular atrophy in line with NICE
  • To be provided by Newcastle Hospitals homecare service only 
06.06.02 Risedronate 
  • Approved risedronate formulations include:
    • 5mg tablets (taken daily);
    • 35mg tablets (taken once weekly for osteoporosis) -preferred.

  • Risedronate is approved for the primary prevention of osteoporosis in line with NICE, and for for the secondary prevention of osteoporotic fragility fractures in postmenopausal women who are confirmed to have osteoporosis in line with NICE. 
  • Risedronate 30mg tablets are also approved for Paget’s disease.
  • Approved for the treatment of osteoporosis in line with NICE
04.02.01 Risperidone 
  • Note: risperidone orodispersible tablets should only be used in situations where the plain tablets are unsuitable.
04.02.02 Risperidone Risperdal Consta®
  • Green plus CNTW
  • Amber TEWV
  • Only for use by psychiatrists in accordance with NTAG guidelines.

 

04.02.03 Risperidone (oral) 
07.01.03 Ritodrine 
05.03.01 Ritonavir 
08.02.03 Rituximab 

NICE have approved rituximab for the following indications:

  • First line use in NHL in combination with CHOP.
  • Maintenance therapy in follicular NHL that has responded to first line induction therapy with rituximab in combination with chemotherapy.
  • Stage III and IV follicular lymphoma in previously untreated people.
  • Replased or refractory follicular NHL.
  • Post-transplant lymphoproliferative disease.
  • First line use in CLL in combination with fludarabine and cyclophosphamide.
  • Combination with fludarabine and cyclophosphamide for relapsed or refractory CLL.
  • Autoimmune haematological conditions (where conventional treatments have failed)
  • Autoimmune haemolytic anaemia (AIHA), Evans syndrome, pure red cell aplasia (PRCA), & thrombocytopenia purpura (TTP).
  • Combination with bendamustine for first line use in CLL (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate.Vasculitis (including Wegener’s granulomatosis in adults and children) that has not responded adequately to conventional treatment (e.g. corticosteroids, cyclophosphamide) in line with NICE and additional NHS England criteria.

NECDAG have approved rituximab for the following indications:

  • Treatment of NLPHL
  • Newly diagnosed mantle cell NHL in patients aged 
  • In combination with bendamustine for patients with CLL not fit for FCR chemotherapy or for patients who relapse within 2 years of FCR chemotherapy and not fit for alemtuzumab.
  • Salvage chemotherapy for patients relapsing > 12 months post 1st line therapy with R-CHOP.
  • Standard NHL induction regimen in patients who cannot be given an anthracycline. Rituximab with other chemotherapy regimens is an alternative treatment option e.g. DECC, CVP for this group of patients, as part of their first line therapy. Also in addition to the MACOP-B regimen for the small number of young patients with DLBCL, subtype Primary Mediastinal B cell Lymphoma.
  • Treatment of Hairy Cell Leukaemia (HCL) or  HCL varian (HCL-v) who:
    • relapse early after purine analogue therapy (< 2 years post treatment)
    • are refractory to purine analogues.

NTAG have approved rituximab for the following indications:

  • Treatment of immune (idiopathic) thrombocytopenic purpura (ITP) in adults and children.

NHS England have approved rituximab for the following indications:

  • Treatment of immunobullous disease
  • Steroid Sensitive Nephrotic Syndrome in Children
  • Steroid Resistant Nephrotic Syndrome in Children
  • Acquired Haemophilia
  • Cytopenia Complicating Primary Immunodeficiency
  • Maintenance single agent therapy in FL, mantle cell lymphoma, marginal zone lymphoma and lymphoplasmacytic lymphoma in line with (SSC1434) - 1.4g solution for sc injection.
  • Second line treatment for anti-NMDAR auto-immune encephalitis (all ages)
  • Treatment of refractory myasthenia gravis in a specialised neuroscience centre
  • Treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and post-pubescent children
  • Treatment of IgM paraproteinaemic demyelinating peripheral neuropathy in adults
  • Treatment of Thrombotic Thrombocytopenic Purpura (TTP)
  • Treatment of Idiopathic Membranous Nephropathy (IMN)


North of Tyne, Gateshead and North Cumbria APC have approved rituxumab for the following indication:

  • Autoimmune hepatitis in patients who have failed or who are intolerant of therapies such as azathioprine, mycophenolate mofetil, corticosteroids and ta